tribemd-images-cdnconservative-oxygen-therapy-in-unresponsive-patients-after-cardiac-arrest-results-of-the-logical-trial-3803.true!@-aasasat.---p-p-;as.png175677103889834812025-09-01T23:57:18.941Z"b7e5d650a5279fb9fa8b429f8e3bafc7"14564-easd-2026--dados-de-vida-real-no-mostram-aumento-do-risco-de-cncer-pancretico-com-semaglutida-6865.png179094493563883712026-10-02T12:42:15.709Z"f4c8aafe4ca519e67a7fa1c0830ddd64"2463391-esc-2026--acacia-hcm-la-inhibicin-de-la-miosina-llega-a-la-miocardiopata-hipertrfica-no-obstructiva.png178792641179159612026-08-28T14:13:31.860Z"675f2d3f60493ec5824698cecbdca062"3142474-esc-2026--destaques-do-terceiro-dia--1673.jpeg178810631341351712026-08-30T16:11:53.485Z"b938765da725b643375b2b26120f23b3"222892-esc-2026--esc-2026--poet-ii-puede-acortarse-el-tratamiento-antibitico-de-la-endocarditis-infecciosa.png178792595720916912026-08-28T14:05:57.278Z"af0a93e796cb8eb80691d36415961a50"2609058-esc-2026--premium-o-papel-da-monoterapia-com-prasugrel-aps-icp-primria-no-stemi-9934.jpeg178801794447501212026-08-29T15:39:04.554Z"bfa9b90c62a5a373b8d191b59d9f7984"300221-esc-2026--time-hf-cuidado-coordenado-e-sade-digital-na-insuficincia-cardaca-9113.png178809557037113412026-08-30T13:12:50.439Z"464b20ae9ed7a60bab35d41d31daeae9"2574149-esc®-2025-–-beta-bloqueadores-após-infarto-em-fração-de-ejeção-levemente-reduzida.png175657190267736012025-08-30T16:38:22.720Z"942a092d59954542bfc315b619f8d203"946688-esc®️-2025-–-beta-blockers-after-infarction-in-slightly-reduced-ejection-fraction.png175659907953944412025-08-31T00:11:19.583Z"9563ac2a4998ab989972dc4ea2831792"1178665-fda-amplia-indicao-de-mounjaro-para-reduo-de-risco-cardiovascular-no-diabetes-tipo-2-3819.png178827112944835512026-09-01T13:58:49.534Z"9cb1709a7f6eafba6205f7b2d2516728"2682096-hero-banner-mobile.jpeg177342957734465112026-03-13T19:19:37.387Z"eeceea6e70a05923782c6a3ee1f4f659"330708-hero-banner-mobile.null177342716199202112026-03-13T18:39:22.025Z"7a3fc90c40655acf10b9b47241fe6b5a"696740-hero-banner-mobile.png177393038235191112026-03-19T14:26:22.460Z"0935acaf673f2600ae64c0171b24432f"1851328-infecções-respiratórias-e-síndrome-gripal--o-papel-do-otorrino--.png175640832368248312025-08-28T19:12:03.728Z"1857191cc4734adbf35f8184b602c339"1602324-kdigo-2026-e-anemia-na-drc-o-que-muda-na-investigao-no-uso-do-ferro-e-na-tomada-de-deciso-clnica.png177072872071024912026-02-10T13:05:20.758Z"c9a3405c1f84505a545e02a017ef8844"1508220-meet-the-expert--breast-cancer-edition---esmo-2025.jpeg176070505661048212025-10-17T12:44:16.672Z"7d0fd603a937a76479237b3bbe0224f2"256726-oceanic-stroke-fase-iii-asundexiana-na-preveno-secundria-do-avc--o-que-representa-um-nnt-de-53-em-1-ano.png177161849091689312026-02-20T20:14:51.034Z"62c044bbf959db581226716d68afcfcd"24205-programa-estructurado-de-ejercicio-y-apoyo-al-estilo-de-vida-reduce-la-fatiga-y-mejora-la-calidad-de-vida-en-pacientes-con-cncer-de-prstata-tratados-con-terapia-de-privacin-andrognica.png178913537607412412026-09-11T14:02:56.190Z"ee07dacca372a83eb0cd8c2a4bf320e8"1693309-riscos-respiratórios-associados-ao-uso-contínuo-de-cigarros-eletrônicos.jpeg174869870485019112025-05-31T13:38:24.895Z"732d390fad29725c82a718fb37f2cd22"807909-ueg-week-2026--inibidor-oral-de-pde4-apresenta-resultados-iniciais-na-doena-de-crohn-fibroestenosante-295.png179233303566340312026-10-18T14:17:15.728Z"11cd73ea87ee6944e91a6fe7925208d0"3329799.png176408777036051412025-11-25T16:22:50.400Z"64c6ab0e7e63c34eeb1ca48eb5b6a420"234641-ano-do-lançamento-de-mounjaro-coverage.png178432244591955612026-07-17T21:07:25.992Z"edf6078b5ac90b06e07be3476f9d1c3e"101399414-mitos-sobre-amamentação-que-todo-profissional-de-saúde-deve-conhecer-(e-desconstruir)-.png175466258889981212025-08-08T14:16:28.937Z"6be5683e36a3856f19b48ff5ed38090d"8221101600o-efficacy-and-safety-of-ima203-a-prametargeted-tcell-receptor-tcr-therapy-in-previously-treated-patients-with-advanced-or-metastatic-uveal-melanoma-results-from-a-phase-i-clinical-trial.png176157328353509112025-10-27T13:54:43.584Z"f98263fb3992483eed7297b1c9949949"190438219-de-maio-dia-mundial-da-doença-inflamatória-intestinal---os-desafios-nutricionais-dos-pacientes.jpeg174861329704221012025-05-30T13:54:57.082Z"8d8bba1a0284deaee32dd2dbc2255c91"157653951st-international-clinical-research-summit-icrs.png175759872860724012025-09-11T13:52:08.668Z"10060cd355f3ea6a71dc905f5c29f8fa"4011852026-aha-acc-acute-pulmonary-embolism-guideline--the-new-a-through-e-classification-that-redefines-pe-management-1.png177343262608948912026-03-13T20:10:26.129Z"1441a7909c087dbbe7ce59881b9df8b9"152026-aha-acc-acute-pulmonary-embolism-guideline--the-new-a-through-e-classification-that-redefines-pe-management-2.png177343262693084712026-03-13T20:10:26.968Z"1441a7909c087dbbe7ce59881b9df8b9"152026-ahaacc-acute-pulmonary-embolism-guideline-the-new-athroughe-classification-that-redefines-pe-management.jpeg177343262844686012026-03-13T20:10:28.479Z"ef0726bb0eb706bea4b30cb696981b26"28045424th-world-congress-on-insulin-resistance,-diabetes---cardiovascular-disease--coverage.webp179137806729732812026-10-07T13:01:07.381Z"1f179757233d88ed0615b0ee20dc2413"7667624th-world-congress-on-insulin-resistance,-diabetes---cardiovascular-disease-hero-banner-en.webp179137913252970312026-10-07T13:18:52.594Z"a3b254cf977bd30ac478cc120b514581"23478024th-world-congress-on-insulin-resistance,-diabetes---cardiovascular-disease-hero-banner-mobile-en.webp179137913075015412026-10-07T13:18:50.816Z"1f179757233d88ed0615b0ee20dc2413"7667626-de-maio:-dia-nacional-de-combate-ao-glaucoma-.jpeg174827934446112712025-05-26T17:09:04.509Z"36b1acd1147e2ce85d7b70b7927178fa"206696278th-world-health-assembly-meets-in-may-to-discuss-challenges-and-establish-strategies-for-strengthening-global-health.jpeg174793607633498912025-05-22T17:47:56.373Z"67a92c2c80ee3e7fbefb888b40c36d2f"27249078º-assembleia-mundial-da-saúde-se-reúne-em-maio-para-discutir-os-desafios-e-estabelecer-estratégias-de-fortalecimento-da-saúde-global.jpeg174791966538082212025-05-22T13:14:25.431Z"67a92c2c80ee3e7fbefb888b40c36d2f"27249081-congresso-brasileiro-de-cardiologia--diretriz-brasileira-de-cardiogeriatria-2026-10-recomendaes-para-a-prtica-clnica-9584.png179154893375443712026-10-09T12:28:53.818Z"c884ae3606b4f1c87ed4d4dae55802b2"261453681-congresso-brasileiro-de-cardiologia--nova--diretriz-brasileira-de-insuficincia-cardaca-redefine-classificao-e-amplia-opes-teraputicas-5031.png179149454547568512026-10-08T21:22:25.570Z"300cd9a891e725d3152d38cac0a59dd9"255182181-congresso-brasileiro-de-cardiologia--nova-diretriz-de-valvopatias-2026-atualiza-critrios-para-cirurgia-e-tavi-4753.png179154791070210712026-10-09T12:11:50.765Z"00b6037f25a5cdd8a59942427779a0fe"264589781º-congresso-brasileiro-de-cardiologia-–-diretriz-brasileira-de-cardiogeriatria-2026--10-recomendações-para-a-prática-clínica-1.jpeg179154893136032512026-10-09T12:28:51.426Z"bea781b6cbca7cde0b79b9c92869f86a"8505181º-congresso-brasileiro-de-cardiologia-–-nova-diretriz-de-valvopatias-2026-atualiza-critérios-para-cirurgia-e-tavi-1.jpeg179154790805614012026-10-09T12:11:48.120Z"605c57770cecb8ea741a774d2f64eb24"172390915o-kras-g12d-inhibitor-hrs4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation-phase-i-study.png176157081125527412025-10-27T13:13:31.322Z"e8989ba75af7199a43ceab401cdcbd88"2575476918o-telisotuzumab-adizutecan-abbv400-temaba-in-patients-with-advanced-solid-tumors-harboring-met-amplification-metamp-results-from-a-phase-i-study.png176124929207471912025-10-23T19:54:52.132Z"59ca665ea68fb3e3aa2366476ee225b4"2004948Agenda TribeMD Bayer Feed.pdf177377289451483022026-03-17T18:41:34.554Z"36c1c2dbdff1378361a420ee90b8d505"421981AnalisisAGPen5pasos.pdf175269482247269822025-07-16T19:40:22.519Z"a31402004fd92ec070be6d2d4ec5ec47"1121463Apostila de Linux-1920.pdf179186002713846512026-10-13T02:53:47.223Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-4401.pdf179190134374822612026-10-13T14:22:23.821Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-516.pdf179186036260846112026-10-13T02:59:22.699Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-5161.pdf179176498959356712026-10-12T00:29:49.721Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-6021.pdf179185625757587712026-10-13T01:50:57.650Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-8954.pdf179186476922163712026-10-13T04:12:49.293Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-9254.pdf179186670697180912026-10-13T04:45:07.043Z"faa8fa677f474367d5364a953d91d40b"770784Apostila de Linux-9739.pdf179184767997001912026-10-12T23:28:00.057Z"faa8fa677f474367d5364a953d91d40b"770784Ascent03 - BARRIOS - gilead_ajustado_28.11.pdf176590403754715822025-12-16T16:53:57.593Z"cf0200533ac0f19a58d3848f9bf20e82"315333CASOS clinicos OBR.pdf179069354395728922026-09-29T14:52:24.023Z"a5b9063c2e3d4b5bca4c985523adbeb0"55956827ChatGPT-Image-30-de-mar.-de-2026-15_19_50.webp179216047949058512026-10-16T14:21:19.629Z"706651b50d3e3e0f50f765a24beab07d"136276ComparativoFreeStyleLibre2vsFreeStyleLibre.pdf175269489808012522025-07-16T19:41:38.178Z"18914519c4b3109ef1851ca504ca8973"1003614Desktop.png177309370167326022026-03-09T22:01:41.713Z"f3425137c36a752a0929ae02b3dbe23d"1302636E-book_ESC 2026_Completo.pdf178950754562030112026-09-15T21:25:45.749Z"ef231625f7acc0a7d6cd5b6a9c448ec8"5359575ExactituddelsistemaFreeStyleLibre2(MARD).pdf175269494279515122025-07-16T19:42:22.848Z"d61285e27f41bcea789a89b9a0e73bfd"1981032GATE Capa.jpg177687471014632922026-04-22T16:18:30.209Z"f4e2789f24e835d8c5818f7361280b23"48678KV-1.webp179320943149653112026-10-28T17:43:51.569Z"28666b9b493a00de2c337fd324c9e3a9"43728KV-Square-2.jpg179218253682291212026-10-16T20:28:56.951Z"a67683a33671c328a1785eeee73c48b4"272603MaterialresumenRWE2025finalll.pdf175269567421186522025-07-16T19:54:34.257Z"cab3921dff54e135b0c200399ead91e2"825747Mobile-acc.png177309373374134022026-03-09T22:02:13.780Z"85fe7aa32238846daf0c4d22a8d3c838"367938NocomplementarioFDA.pdf175269506145320422025-07-16T19:44:21.492Z"e585aa4372bc2bbb9c461e663e71e967"885697SABCS-Banner-Propor.png176288845210662712025-11-11T19:14:12.131Z"1681441676f15887789c872f2c1ea481"276759Tabela (1) (1).png175571925621829522025-08-20T19:47:36.256Z"2b1a099eb93d635bde4cdbd40c475dc1"3288022TribeNews_Site-2.png176591452137775022025-12-16T19:48:41.417Z"84c33c910cd3fa1bf7c1bb45de6cedb5"1809703TribeNews_Site.jpg176591460107622622025-12-16T19:50:01.116Z"b2133d897e6ecab24136c85c39941cab"663919_image.webp179320943339390712026-10-28T17:43:53.520Z"e26ee0f824a4d348f1575ceee678ea7e"50092a-asco-atualizou-sua-diretriz-sobre-terapia-sistêmica-para-pacientes-com-câncer-de-próstata-metastático-resistente-à-castração-(mcrpc).jpeg174861457155577612025-05-30T14:16:11.598Z"754e1c07d44fe98a76536bda6716acbc"15463899a-cafeina-vila-ou-aliada-dos-estudantes-de-medicina-863b712c3f8b47f4b0eafe6cab2b6b25.jpeg176945023531434322026-01-26T17:57:15.361Z"60f2ead818eb0999e87108c2870d2dd6"363994a-colonoscopia-de-vigilncia-a-cada-5-anos-no-aumenta-a-incidncia-de-cncer-colorretal-em-comparao-com-o-intervalo-de-3-anos-aps-adenomas-de-alto-risco-8533.png179122794794572312026-10-05T19:19:08.010Z"aa64d77017cd2228abb8203463d0945b"1216687a-colonoscopia-de-vigilncia-a-cada-5-anos-no-aumenta-a-incidncia-de-cncer-colorretal-em-comparao-com-o-intervalo-de-3-anos-aps-adenomas-de-alto-risco-9243.png179122794981440112026-10-05T19:19:09.878Z"aa64d77017cd2228abb8203463d0945b"1216687a-decisive-step-toward-democratizing-cancer-diagnosis-the-global-potential-of-an-accessible-aipowered-blood-test.png176003652870669912025-10-09T19:02:08.748Z"197670990ea34977e07df1a330a51757"2283915a-evolucao-dos-tratamentos-nefrologicos-na-pratica-clinica-moderno-3124.webp179156644983606912026-10-09T17:20:49.938Z"02a3c921d68b1b340d97a003a39d19d8"45442a-evoluo-da-dapagliflozina-impactos-no-cuidado-cardiometablico-e-renal.jpeg177273687694639412026-03-05T18:54:37.006Z"c24b854138f624d046b6b6c3c56a65aa"316277a-evolução-da-dapagliflozina--impactos-no-cuidado-cardiometabólico-e-renal-1.png177273687321146212026-03-05T18:54:33.276Z"3bfc4ef709895691388921f505784eea"58473a-evolução-da-dapagliflozina--impactos-no-cuidado-cardiometabólico-e-renal-2.png177273687439699712026-03-05T18:54:34.461Z"b3c3d4d60ace2599004da8667a36f73b"46950a-evolução-da-dapagliflozina--impactos-no-cuidado-cardiometabólico-e-renal-3.png177273687541178912026-03-05T18:54:35.472Z"7c7401856ecd0a9bba39c5101a06201a"41958a-fully-oral-strategy-for-acute-myeloid-leukemia-are-we-approaching-a-new-therapeutic-option-1114.png178596201461939212026-08-05T20:33:34.680Z"a648067af341381c7b1161fa7788e9fc"2035822a-fully-oral-strategy-for-acute-myeloid-leukemia-are-we-approaching-a-new-therapeutic-option-8926.png178596175639820412026-08-05T20:29:16.460Z"a648067af341381c7b1161fa7788e9fc"2035822a-importancia-da-saude-na-vida-moderna-166c9853f402403d863d916a27bc91ea.jpeg177263101332122022026-03-04T13:30:13.390Z"dccc15b29be4d13401f3d8004b882009"629231a-importância-da-cardiologia.jpeg177247538409672812026-03-02T18:16:24.166Z"70a6d597c6900a3a0448d49ffaa13710"326577a-integrao-entre-tomografia-e-patologia-pode-ajudar-a-prever-a-resposta-ao-bevacizumabe-no-cncer-colorretal-com-metstases-hepticas-7444.png178696882951084612026-08-17T12:13:49.582Z"bf0af600d0b296026e7a322b89b4ef22"1273796a-inteligncia-artificial-identifica-malignidades-hepticas-no-reconhecidas-na-rotina-o-que-melhora-a-segurana-diagnstica-930.png178828270883276512026-09-01T17:11:48.919Z"f8b622c8ff3b2c6b0d243b2bfa905f4e"2616599a-linha-de-frente-contra-o-câncer--a-evolução-e-a-humanização-da-oncologia.png178043046321484412026-06-02T20:01:03.285Z"ea951e1d0bb416b413c2b78c7e5fd1df"8184993a-new-collection-of-patientderived-models-expands-the-tools-available-for-studying-different-types-of-cancer-2610.png178696649353220312026-08-17T11:34:53.595Z"3adc0993001d095ed6c9282997a2dde1"1512542a-new-therapeutic-horizon-with-ipsc-derived-nk-cells-in-b-cell-lymphoma.jpeg175371873836761312025-07-28T16:05:38.409Z"2d4a2b737f6997a9aa43942c32812037"816306a-nomogram-predicts-urinary-tract-infection-risk-in-older-adults-with-type-2-diabetes.png176955213757481612026-01-27T22:15:37.618Z"b89e4322da91c8dbdd3fc38f2a6e7b62"6537072a-novel-bindingtorelease-strategy-releases-drugs-in-tumors-without-relying-on-cellular-internalization-2451.png178913485240651612026-09-11T13:54:12.477Z"4cf03d2a1e23138687e107654ac60e2a"2028451a-revolucao-da-oncologia-de-precisao-no-tratamento-do-cancer-1033.webp178958186204182512026-09-16T18:04:22.111Z"02a3c921d68b1b340d97a003a39d19d8"45442a-revolucao-da-oncologia-de-precisao-no-tratamento-do-cancer-1596.webp178958059674034412026-09-16T17:43:16.823Z"e26ee0f824a4d348f1575ceee678ea7e"50092a-revolucao-da-oncologia-de-precisao-no-tratamento-do-cancer-9506.webp178958205089043612026-09-16T18:07:30.959Z"02a3c921d68b1b340d97a003a39d19d8"45442a-revolucao-da-oncologia-de-precisao-no-tratamento-do-cancer.pdf178958205287021012026-09-16T18:07:32.938Z"73bcdb6a3e053cf33bb340df0e7864c4"904083a-revolucao-do-dna-circulante--como-a-biopsia-liquida-transforma-a-oncologia-8639.webp179025196456651712026-09-24T12:12:44.637Z"e26ee0f824a4d348f1575ceee678ea7e"50092a-revolucao-tricolor-alem-das-quatro-linhas-7ae479ede56b45e0b21f1682d5ff4fab.jpeg176935403519332322026-01-25T15:13:55.241Z"2c282af1c491796a6815cf5ec671025c"406520a-revolucao-tricolor-alem-das-quatro-linhas-82b29952649b423db3cfc3ce25c793ab.jpeg176935256297191422026-01-25T14:49:23.011Z"566e3affe78ce1bd63a2d97bea28fee7"571150a-rimegepant-demonstrates-efficacy-in-the-acute-treatment-of-migraine-in-a-systematic-review-and-metaanalysis-4728.png179088130530339212026-10-01T19:01:45.368Z"57ebe71a60508768e19382e2c2213c3e"1517655a-tribute-to-professor-eugene-braunwald-a-paragon-4052.png177703585376192412026-04-24T13:04:13.828Z"59a6c50aae11338fd09400e3abe3cd8d"1028306a-tribute-to-professor-eugene-braunwald-a-paragon-of-medical-scholarship-3368.177699534830825612026-04-24T01:49:08.361Z"13882ce27a235006f707add88a0d0eec"1030207a-year-in-review---cardiologia-2025.png175987058054998412025-10-07T20:56:20.644Z"a192e3ae1445f6c772356483a7ed6c1c"329581a-year-in-review-2-hero-banner-2382.png178345392296162912026-07-07T19:52:03.038Z"4f0a8a9eef466b231a9e110696898641"1208240a-year-in-review-2-hero-banner-mobile-2382.png178345392571700312026-07-07T19:52:05.787Z"4f0a8a9eef466b231a9e110696898641"1208240a-year-in-review-breast-cancer---destaques-em-cncer-de-mama-2025-.png176590738844447112025-12-16T17:49:48.491Z"06857e4dc0ceac22046763240c5cdbc9"3086885a-year-in-review-breast-cancer---destaques-em-câncer-de-mama-2025-hero-banner.jpeg177092409165095712026-02-12T19:21:31.740Z"4ac1e5670e4c783060a683c1bf779ffc"316452a-year-in-review-hero-banner-3261.png178293551415700312026-07-01T19:51:54.228Z"4f0a8a9eef466b231a9e110696898641"1208240a-year-in-review-hero-banner-8069.png178585026885794512026-08-04T13:31:08.930Z"38669279643b13a76ed60087cdbfe7c9"843673a-year-in-review-hero-banner-8089.png178293551690640012026-07-01T19:51:56.977Z"4f0a8a9eef466b231a9e110696898641"1208240a-year-in-review-hero-banner-mobile-3261.png178293551617352712026-07-01T19:51:56.244Z"4f0a8a9eef466b231a9e110696898641"1208240ablao-trmica-intersticial-a-laser-mostra-baixa-morbidade-e-controle-clnico-em-pacientes-selecionados-com-tumores-cerebrais-2491.png178818980121119812026-08-31T15:23:21.279Z"4a8e5a9625c3ec17458db3c65957dc65"3004493acalabrutinib-combined-with-br-improves-survival-in-treatment-naïve-mantle-cell-lymphoma.png175406564323690312025-08-01T16:27:23.279Z"d913864a1f738223bfe2552ec0e63a6d"489acc-2026--acc-2026--orbita-cto-la-angioplastia-reduce-la-carga-de-angina-y-mejora-la-calidad-de-vida-ms-all-del-efecto-placebo-en-la-oclusin-coronaria-crnica.jpeg177490291525842512026-03-30T20:35:15.299Z"cd1c658499853712a4cc8a17a1533070"252699acc-2026--all-rise-angiography-derived-fractional-flow-reserve-to-guide-pci.pdf177506109755773412026-04-01T16:31:37.602Z"7b87d52e2f17487299de9e398840acce"910751acc-2026--all-rise-reserva-de-flujo-fraccional-derivada-de-la-angiografa-para-guiar-la-intervencin-coronaria-percutnea-icp.jpeg177547891620391812026-04-06T12:35:16.251Z"9f54b0e65e9921d15c2ed2147874a24b"252127acc-2026--all-rise-reserva-de-flujo-fraccional-derivada-de-la-angiografa-para-guiar-la-intervencin-coronaria-percutnea-icp.pdf177547897389851612026-04-06T12:36:13.942Z"c4d26f5d45770553446c1641ee2a183d"910751acc-2026--all-rise-reserva-de-fluxo-fracionada-derivada-da-angiografia-para-guiar-a-interveno-coronria-percutnea-icp-5617.jpeg177497870108687812026-03-31T17:38:21.135Z"f3f824e45b777ee9f91e417288e9d052"253481acc-2026--all-rise-reserva-de-fluxo-fracionada-derivada-da-angiografia-para-guiar-a-interveno-coronria-percutnea-icp.pdf177506106098691512026-04-01T16:31:01.032Z"7b87d52e2f17487299de9e398840acce"910751acc-2026--champion-af-left-atrial-appendage-occlusion-or-anticoagulation-for-atrial-fibrillation.pdf177505645143484712026-04-01T15:14:11.539Z"a264197d653c161c7565e9081ae3f330"1369590acc-2026--champion-af-oclusin-de-la-orejuela-auricular-izquierda-o-anticoagulacin-en-fibrilacin-auricular.jpeg177547413481536512026-04-06T11:15:34.915Z"c89b0bc97f1837bf4f5deaf2e1e027cf"267611acc-2026--champion-af-oclusin-de-la-orejuela-auricular-izquierda-o-anticoagulacin-en-fibrilacin-auricular.pdf177547413767285012026-04-06T11:15:37.770Z"cd2fef1e36a4e9441faa968e5e804e9d"1369590acc-2026--champion-af-ocluso-do-apndice-atrial-esquerdo-ou-anticoagulao-para-fibrilao-atrial-1433.jpeg177481488721697312026-03-29T20:08:07.252Z"f96e1de0a497da3821a0302180b52efe"255951acc-2026--champion-af-ocluso-do-apndice-atrial-esquerdo-ou-anticoagulao-para-fibrilao-atrial.jpeg177547439669979312026-04-06T11:19:56.746Z"c89b0bc97f1837bf4f5deaf2e1e027cf"267611acc-2026--champion-af-ocluso-do-apndice-atrial-esquerdo-ou-anticoagulao-para-fibrilao-atrial.pdf177505722825303912026-04-01T15:27:08.353Z"a264197d653c161c7565e9081ae3f330"1369590acc-2026--chip-bcis3-descompresin-del-ventrculo-izquierdo-en-la-intervencin-coronaria-percutnea-de-alto-riesgo.pdf177547794487003712026-04-06T12:19:04.915Z"2650b9f8d18cc013e9da5ca3ff740629"1491910acc-2026--chip-bcis3-descompresin-del-ventrculo-izquierdo-en-la-intervencin-coronaria-percutnea-de-alto-riesgo.png177547792301407912026-04-06T12:18:43.063Z"4ff9c139035c0f067c319d8ab0ae0d16"2268313acc-2026--chip-bcis3-descompresso-do-ventrculo-esquerdo-em-interveno-coronria-percutnea-de-alto-risco-1080.png177491030802489612026-03-30T22:38:28.057Z"cffdf9d9012148d30a9b29e6c60eedce"2263230acc-2026--chip-bcis3-descompresso-do-ventrculo-esquerdo-em-interveno-coronria-percutnea-de-alto-risco.pdf177506090988934712026-04-01T16:28:29.928Z"b3bc8df7327c0213f86872e23377f25d"1491910acc-2026--chip-bcis3-left-ventricular-unloading-in-high-risk-percutaneous-coronary-intervention.pdf177506094161463212026-04-01T16:29:01.660Z"b3bc8df7327c0213f86872e23377f25d"1491910acc-2026--dig-rhd-digoxina-reduz-desfecho-composto-em-pacientes-com-doena-cardaca-reumtica-3346.jpeg177557587903579312026-04-07T15:31:19.074Z"f49747680d306469f00a663d17b5dfef"397311acc-2026--dig-rhd-la-digoxina-reduce-el-desenlace-compuesto-en-pacientes-con-cardiopata-reumtica.jpeg177557914644975712026-04-07T16:25:46.500Z"717c8e013bb500d4246d3e8ae290b5ad"394452acc-2026--dkcrush-viii-ivus-or-angiography-guidance-for-percutaneous-coronary-intervention-in-complex-coronary-bifurcation-lesions-.pdf177556843974431712026-04-07T13:27:19.855Z"ac48003a1f7cca4d41533e21b840c91f"1652726acc-2026--dkcrush-viii-orientacin-mediante-ivus-o-angiografa-para-la-intervencin-coronaria-percutnea-en-lesiones-coronarias-complejas-de-bifurcacin.pdf177556827263223012026-04-07T13:24:32.672Z"ac48003a1f7cca4d41533e21b840c91f"1652726acc-2026--dkcrush-viii-orientacin-mediante-ivus-o-angiografa-para-la-intervencin-coronaria-percutnea-en-lesiones-coronarias-complejas-de-bifurcacin.png177550002287492012026-04-06T18:27:02.915Z"5454f0508beaf7c60b7094c08a05b55f"2179872acc-2026--dkcrush-viii-orientao-por-ivus-ou-angiografia-para-interveno-coronria-percutnea-em-leses-complexas-de-bifurcao-coronria-4858.png177522346719838512026-04-03T13:37:47.244Z"0c86d785959a0322fa84575401e3c906"2179568acc-2026--dkcrush-viii-orientao-por-ivus-ou-angiografia-para-interveno-coronria-percutnea-em-leses-complexas-de-bifurcao-coronria.pdf177556837010370212026-04-07T13:26:10.149Z"ac48003a1f7cca4d41533e21b840c91f"1652726acc-2026--essence-timi-73b-efecto-de-la-inhibicin-de-apoc3-con-olezarsen-sobre-la-aterosclerosis-coronaria-estudio-de-imagen.png177557363127237012026-04-07T14:53:51.312Z"3fcb837d91a7a0bb8e019cc82289a7f6"1718292acc-2026--essence-timi-73b-efeito-da-inibio-de-apoc3-com-olezarsen-na-aterosclerose-coronariana-estudo-de-imagem-6139.png177557493845210712026-04-07T15:15:38.499Z"a76618978950197088db1e28790bd56a"1718357acc-2026--ez-pave-estratgia-de-ldl-55-mgdl-reduz-desfechos-cardiovasculares-em-pacientes-com-ascvd-em-comparao-a-70-mgdl-2405.jpeg177481106404976712026-03-29T19:04:24.084Z"b91c7ba51ce470dfc910ab9797cd68c1"323282acc-2026--ez-pave-metas-mais-baixas-de-ldl-se-associam-a-menor-risco-cardiovascular-na-preveno-secundria-341.jpeg177481155359160712026-03-29T19:12:33.623Z"b91c7ba51ce470dfc910ab9797cd68c1"323282acc-2026--ez-pave-objetivos-ms-bajos-de-ldl-se-asocian-con-un-menor-riesgo-cardiovascular-en-prevencin-secundaria.jpeg177547672158027512026-04-06T11:58:41.626Z"bb6bb5b3f458d52bff8e987fa69eb0e8"334559acc-2026--fast-iii-angiography-based-physiology-to-guide-coronary-revascularization.pdf177506125551076112026-04-01T16:34:15.556Z"767b1eb94b2e4e17c7e95c219bbb4cd1"1913119acc-2026--fast-iii-fast-iii-fisiologa-basada-en-angiografa-para-guiar-la-revascularizacin-coronaria.jpeg177548025967390412026-04-06T12:57:39.719Z"263a1620184692a9a26eef09235ce045"260904acc-2026--fast-iii-fisiologa-basada-en-angiografa-para-guiar-la-revascularizacin-coronaria.pdf177548029366105412026-04-06T12:58:13.698Z"5478d882a802f1925b8c53e8f27839d5"1913119acc-2026--fast-iii-fisiologia-baseada-em-angiografia-para-guiar-a-revascularizao-coronariana-5350.jpeg177491079598007112026-03-30T22:46:36.012Z"5fec8d1001350fe497c261b41042f3c5"262164acc-2026--fast-iii-fisiologia-baseada-em-angiografia-para-guiar-a-revascularizao-coronariana.pdf177506121963955612026-04-01T16:33:39.678Z"767b1eb94b2e4e17c7e95c219bbb4cd1"1913119acc-2026--hi-peitho-la-tromblisis-dirigida-por-catter-reduce-la-descompensacin-en-la-embolia-pulmonar-de-riesgo-intermedio.jpeg177481045549395112026-03-29T18:54:15.528Z"02400f19f99391ad3d1435fca95c19de"342467acc-2026--hi-peitho-tromblise-dirigida-por-cateter-reduz-descompensao-em-tep-de-risco-intermedirio-8397.jpeg177480927259789512026-03-29T18:34:32.632Z"8557311f720d2dea4d5f492353aaf7c6"338010acc-2026--hi-peitho-tromblise-dirigida-por-cateter-reduz-descompensao-em-tep-de-risco-intermedirio.jpeg177480977685262712026-03-29T18:42:56.944Z"02400f19f99391ad3d1435fca95c19de"342467acc-2026--impedance-hfpef-deteco-precoce-no-invasiva-do-fluido-pulmonar-reduz-morte-e-hospitalizao-7407.jpeg177497190617065012026-03-31T15:45:06.216Z"47b65c238bceaf3e61c41f9efdfc5deb"262587acc-2026--impedance-hfpef-deteco-precoce-no-invasiva-do-fluido-pulmonar-reduz-morte-e-hospitalizao.pdf177506139260743512026-04-01T16:36:32.653Z"2d4aca06b65d9fcc563b991bb8d6aac5"1046017acc-2026--impedance-hfpef-early-noninvasive-detection-of-lung-fluid-reduces-death-hospitalization.pdf177506148765024012026-04-01T16:38:07.697Z"2d4aca06b65d9fcc563b991bb8d6aac5"1046017acc-2026--impedance-hfpef-la-deteccin-precoz-no-invasiva-del-fluido-pulmonar-reduce-la-mortalidad-y-las-hospitalizaciones.jpeg177548130878442312026-04-06T13:15:08.823Z"b52523d0ea6ea56280ce084d74897dac"261037acc-2026--impedance-hfpef-la-deteccin-precoz-no-invasiva-del-fluido-pulmonar-reduce-la-mortalidad-y-las-hospitalizaciones.pdf177548132408389012026-04-06T13:15:24.121Z"3808d313940f0be5de4d1bb8e71370dc"1046017acc-2026--ivus-chip-ultrassonografia-intravascular-guiada-ou-angiografia-guiada-em-interveno-coronria-percutnea-icp-complexa-de-alto-risco-172.jpeg177507069680254112026-04-01T19:11:36.848Z"4fd2cbeae2685e86175053f6c7fe69b8"308671acc-2026--ivus-chip-ultrassonografia-intravascular-guiada-ou-angiografia-guiada-em-interveno-coronria-percutnea-icp-complexa-de-alto-risco.jpeg177548757538921512026-04-06T14:59:35.428Z"cfe106b8c1b7409f27e3efb35027ffab"305995acc-2026--kardinal-antisense-therapy-with-tonlamarsen-in-uncontrolled-hypertension.pdf177505983065323612026-04-01T16:10:30.699Z"06ad90baac9b1d7f945c054fd5efbc6e"347815acc-2026--kardinal-terapia-antisense-com-tonlamarsen-em-hipertenso-no-controlada-4787.jpeg177480708287706412026-03-29T17:58:02.913Z"f5e3422735c306d50bb1838c2f1b66e5"356202acc-2026--kardinal-terapia-antisense-com-tonlamarsen-em-hipertenso-no-controlada.pdf177505975670664412026-04-01T16:09:16.775Z"06ad90baac9b1d7f945c054fd5efbc6e"347815acc-2026--kardinal-terapia-antisentido-con-tonlamarsen-en-hipertensin-no-controlada.jpeg177547596950647412026-04-06T11:46:09.615Z"af3c530f4bddad5bb7626cafdf969491"370378acc-2026--kardinal-terapia-antisentido-con-tonlamarsen-en-hipertensin-no-controlada.pdf177547600691152312026-04-06T11:46:46.957Z"06ad90baac9b1d7f945c054fd5efbc6e"347815acc-2026--orbita-cto-angioplastia-reduz-carga-de-angina-e-melhora-qualidade-de-vida-alm-do-efeito-placebo-em-ocluso-coronariana-crnica-1390.jpeg177490956090312212026-03-30T22:26:00.936Z"3de9e913a2d0e6563737e48bb239f5c0"254385acc-2026--pro-tavi-adiamento-da-interveno-coronariana-percutnea-em-pacientes-submetidos-a-implante-transcateter-da-valva-artica-3212.jpeg177498428962331212026-03-31T19:11:29.668Z"681a754e52a3ae110cbf4cb558f4e861"262260acc-2026--pro-tavi-adiamento-da-interveno-coronariana-percutnea-em-pacientes-submetidos-a-implante-transcateter-da-valva-artica.pdf177506165535025812026-04-01T16:40:55.397Z"ff1113fb209fb6c642c5bbf197471dff"2874401acc-2026--pro-tavi-aplazamiento-de-la-intervencin-coronaria-percutnea-en-pacientes-sometidos-a-implante-transcatter-de-la-vlvula-artica.jpeg177548198352396012026-04-06T13:26:23.564Z"f2175a5452c82d53060ec3987192a9ec"262524acc-2026--pro-tavi-aplazamiento-de-la-intervencin-coronaria-percutnea-en-pacientes-sometidos-a-implante-transcatter-de-la-vlvula-artica.pdf177548210617056712026-04-06T13:28:26.209Z"ff1113fb209fb6c642c5bbf197471dff"2874401acc-2026--pro-tavi-deferral-of-percutaneous-coronary-intervention-in-patients-undergoing-transcatheter-aortic-valve-implantation.pdf177506169203751012026-04-01T16:41:32.152Z"ff1113fb209fb6c642c5bbf197471dff"2874401acc-2026--smart-decision-descontinuao-do-betabloqueador-aps-infarto-no-aumenta-eventos-em-pacientes-estveis-9050.png177507993905480212026-04-01T21:45:39.095Z"de8311e024f0c0e1c7e7f02003152fb2"2254767acc-2026--smart-decision-la-suspensin-del-betabloqueador-tras-infarto-no-aumenta-eventos-en-pacientes-estables.jpeg177507001542528512026-04-01T19:00:15.471Z"2fc2366ed65b75343378a35baf02b217"326488acc-2026--spirit-hf-ausencia-de-beneficio-de-la-espironolactona-en-pacientes-con-insuficiencia-cardaca-con-fraccin-de-eyeccin-preservada-o-levemente-reducida.jpeg177498428165979912026-03-31T19:11:21.705Z"90a1a849af8c8db9730470af8de0462d"225291acc-2026--spirit-hf-ausncia-de-benefcio-da-espironolactona-em-pacientes-com-ic-com-frao-de-ejeo-preservada-ou-levemente-reduzida-2006.jpeg177498364487654212026-03-31T19:00:44.921Z"865a340149e91937481c0a0157eed92a"231193acc-2026--spirit-hf-ausncia-de-benefcio-da-espironolactona-em-pacientes-com-ic-com-frao-de-ejeo-preservada-ou-levemente-reduzida-2519.jpeg177498361986307912026-03-31T19:00:19.903Z"865a340149e91937481c0a0157eed92a"231193acc-2026--stemi-door-to-unload---descompresso-do-ventrculo-esquerdo-em-pacientes-com-infarto-agudo-do-miocrdio-com-supradesnivelamento-do-segmento-st-iamcsst-anterior-sem-choque-3061.jpeg177480323758362812026-03-29T16:53:57.647Z"daa0fab59992626a86296480f025cb40"155624acc-2026--stemi-door-to-unload---descompresso-do-ventrculo-esquerdo-em-pacientes-com-infarto-agudo-do-miocrdio-com-supradesnivelamento-do-segmento-st-iamcsst-anterior-sem-choque.pdf177505130489422012026-04-01T13:48:25.001Z"759b006820e68a149a6fbf1eae5f8fad"2592280acc-2026--stemi-door-to-unload-left-ventricular-decompression-in-patients-with-anterior-stsegment-elevation-myocardial-infarction-stemi-without-cardiogenic-shock-.pdf177506055756860412026-04-01T16:22:37.607Z"f9b5998fd7ac9292e2a22beabf344e66"2592280acc-2026--stemi-doortounload-descompresin-del-ventrculo-izquierdo-en-pacientes-con-infarto-agudo-de-miocardio-con-elevacin-del-segmento-st-iamcest-anterior-sin-shock.jpeg177504553849842212026-04-01T12:12:18.538Z"9ff87dbc95c1b226506fac19ac3cd619"161826acc-2026--vesalius-cv-evolocumab-para-la-reduccin-del-primer-evento-cardiovascular-mayor-en-pacientes-con-diabetes-y-sin-aterosclerosis-significativa-conocida-.jpeg177481376549309812026-03-29T19:49:25.526Z"8619cf6328af21cc0f62160f4b45cba8"390375acc-2026--vesalius-cv-evolocumabe-para-reduo-do-primeiro-evento-cardiovascular-maior-em-pacientes-com-diabetes-e-sem-aterosclerose-significativa-conhecida-7530.jpeg177481329883022612026-03-29T19:41:38.863Z"3bf42aaa1859a831cd5eb57e3aa144f9"359077acc-2026-allrise-angiography-derived-fractional-flow-reserve-to-guide-pci-5789.177497028829047512026-03-31T15:18:08.336Z"d3318cfefc9d6281fdf7abde0379f4cb"252196acc-2026-championaf-left-atrial-appendage-occl-2229.jpeg177489065260416012026-03-30T17:10:52.642Z"896113c34a94eb4edccca4176bfb2a68"294966acc-2026-championaf-left-atrial-appendage-occlusion-or-anticoagulation-for-atrial-fibrillation-173.177481539746963312026-03-29T20:16:37.504Z"64c323f5a98f30c609d050ef04ecfd75"268534acc-2026-chipbcis3-left-ventricular-unloading-in-highrisk-percutaneous-coronary-intervention-5019.177498034206570312026-03-31T18:05:42.104Z"6b9bc94c35c89eb9099a2534636b2606"2268805acc-2026-digrhd-digoxin-reduces-composite-outcomes-in-patients-with-rheumatic-heart-disease-6159.177558186123683512026-04-07T17:11:01.282Z"3b7e48b59eb8af91380ae1ee84565410"395210acc-2026-dkcrush-viii-ivus-or-angiography-guidance-for-percutaneous-coronary-intervention-in-complex-coronary-bifurcation-lesions-1343.177522414760189912026-04-03T13:49:07.649Z"1e12d610ccf7482a3e57474f90d87078"2180043acc-2026-essencetimi-73b-effect-of-apoc3-inhibition-with-olezarsen-on-coronary-atherosclerosis-imaging-study-5672.177557810856027312026-04-07T16:08:28.600Z"a9fa334645431cacd3716dd3e6054563"1717618acc-2026-ezpave-lower-ldl-targets-are-associat-607.jpeg177489083200472812026-03-30T17:13:52.045Z"e3be1a4fe556ba7de795a9a8db45210d"294263acc-2026-ezpave-lower-ldl-targets-are-associat-8951.jpeg177489095640760512026-03-30T17:15:56.449Z"e3be1a4fe556ba7de795a9a8db45210d"294263acc-2026-ezpave-lower-ldl-targets-are-associated-with-reduced-cardiovascular-risk-in-secondary-prevention-8218.177481229652243012026-03-29T19:24:56.554Z"531fb6601e91393baad0d5b9e3120771"339255acc-2026-fast-iii-angiography-based-physiology-to-guide-coronary-revascularization-1625.177497108155335512026-03-31T15:31:21.600Z"291a10134a2258617572ad133ebade29"260949acc-2026-hero-banner-8207.png177446068381155412026-03-25T17:44:43.852Z"f3425137c36a752a0929ae02b3dbe23d"1302636acc-2026-hero-banner-9155.png177446181072190712026-03-25T18:03:30.829Z"f3425137c36a752a0929ae02b3dbe23d"1302636acc-2026-hero-banner-en.png177334228996577312026-03-12T19:04:50.066Z"f3425137c36a752a0929ae02b3dbe23d"1302636acc-2026-hero-banner-mobile-2435.png177453142680786812026-03-26T13:23:46.841Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-3380.png177453086284865912026-03-26T13:14:22.890Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-3477.png177453144400586512026-03-26T13:24:04.045Z"85fe7aa32238846daf0c4d22a8d3c838"367938acc-2026-hero-banner-mobile-625.png177453088955843012026-03-26T13:14:49.596Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-6627.png177453028631336212026-03-26T13:04:46.354Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-85.png177446084595592712026-03-25T17:47:25.997Z"85fe7aa32238846daf0c4d22a8d3c838"367938acc-2026-hero-banner-mobile-9155.png177446181964353012026-03-25T18:03:39.736Z"85fe7aa32238846daf0c4d22a8d3c838"367938acc-2026-hero-banner-mobile-9342.png177453113166155212026-03-26T13:18:51.702Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-9884.png177453034412068712026-03-26T13:05:44.160Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile-en.png177334278288816912026-03-12T19:13:02.929Z"65d431172288d52a98301c5d0fd711cc"313852acc-2026-hero-banner-mobile.png177484180900108212026-03-30T03:36:49.101Z"7a3fc90c40655acf10b9b47241fe6b5a"696740acc-2026-hero-banner.png177484180702500412026-03-30T03:36:47.123Z"7a3fc90c40655acf10b9b47241fe6b5a"696740acc-2026-hipeitho-catheterdirected-thrombolysis-reduces-decompensation-in-intermediaterisk-pulmonary-embolism-4463.177480993972334112026-03-29T18:45:39.757Z"8e15a9c99a8b2282d242198ccc25c621"342445acc-2026-impedancehfpef-early-noninvasive-detection-of-lung-fluid-reduces-death-hospitalization-9922.177498106111404612026-03-31T18:17:41.152Z"29b8e67af2b151904383f5911bd3cb0b"260951acc-2026-ivuschip-intravascular-ultrasoundguided-or-angiographyguided-complex-highrisk-pci-936.177506284440969012026-04-01T17:00:44.450Z"a5d73277a12df3139c544d8a2f1e3bb2"305649acc-2026-kardinal-antisense-therapy-with-tonlamarsen-in-uncontrolled-hypertension-7140.177480765076093512026-03-29T18:07:30.796Z"e30bd16d5247aa54484def04a34e9a89"367421acc-2026-orbitacto-angioplasty-reduces-angina-burden-and-improves-quality-of-life-beyond-placebo-in-chronic-coronary-occlusion-4468.177490332831314112026-03-30T20:42:08.352Z"05aaf2b6e33490542fe86fa40352e415"252354acc-2026-protavi-deferral-of-percutaneous-coronary-intervention-in-patients-undergoing-transcatheter-aortic-valve-implantation-4486.177498218481046612026-03-31T18:36:24.851Z"49a97243901821841aad4b3e3d178ae0"261670acc-2026-smartdecision-betablocker-discontinuation-after-myocardial-infarction-does-not-increase-events-in-stable-patients-7428.177506610618931012026-04-01T17:55:06.228Z"1e6e11160fd07c341fb7136f5f039982"325300acc-2026-spirithf-lack-of-benefit-of-spironolactone-in-patients-with-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction-2033.177497972753465812026-03-31T17:55:27.575Z"74c4ccf1b74b09e97ddf91d2ef80fea6"224413acc-2026-stemi-door-to-unload-left-ventricular-decompression-in-patients-with-anterior-stsegment-elevation-myocardial-infarction-stemi-without-cardiogenic-shock-5830.177480489511142212026-03-29T17:21:35.149Z"70fa45d8d3c6bee1d4a2d2d12402e43d"162090acc-2026-vesaliuscv-evolocumab-for-the-reducti-2511.jpeg177489098064813612026-03-30T17:16:20.687Z"29d407359b322f4b33c03e9c6b5251d9"1496517acc-2026-vesaliuscv-evolocumab-for-the-reducti-9911.jpeg177489062480460412026-03-30T17:10:24.844Z"29d407359b322f4b33c03e9c6b5251d9"1496517acc-2026-vesaliuscv-evolocumab-for-the-reduction-of-first-major-cardiovascular-events-in-patients-with-diabetes-and-without-known-significant-atherosclerosis-9502.177481429608517912026-03-29T19:58:16.117Z"01876cfd998c8c37ca926968331ed4ac"372282acc-2026.png177314847786751712026-03-10T13:14:37.969Z"1e22c9d0080e2234e716195e43655bb1"898836acc-2027-hero-banner-mobile.png177334193621354712026-03-12T18:58:56.251Z"8ef92e04d8a2d7b145b5d068ce35bb65"273618acc-2027-hero-banner.png177334193373038112026-03-12T18:58:53.768Z"938c89d73fe70e402539da39685e5b40"170892acc-2028-coverage.png177783571073251612026-05-03T19:15:10.805Z"cfa3d1497e48f0c8029097232b1ce73b"1774535acc-2028.png177764514181001712026-05-01T14:19:01.945Z"cfa3d1497e48f0c8029097232b1ce73b"1774535acc-2029-coverage.png177783590063591012026-05-03T19:18:20.707Z"cfa3d1497e48f0c8029097232b1ce73b"1774535acc-issues-consensus-on-medical-weight-management:-structured,-stepwise-approach-recommended..png175192400708534912025-07-07T21:33:27.132Z"bf3f6b5c23f0b51e16c06167329088fc"1328023acoramidis-and-cardiovascular-mortality:-42-month-results-from-attribute-cm-ole.png175690830088986512025-09-03T14:05:01.002Z"af4af7da6b1657ed92e4004591d5f9f4"1721860acticca-1-gemcitabina-e-cisplatina-mostram-benefcio-em-anlise-de-tempo-mdio-livre-de-doena-na-adjuvncia-dos-tumores-de-vias-biliares-7131.png179286329744864112026-10-24T17:34:57.512Z"9ad2819e93a20ba6ffcdc68f64da7f5b"1698075acticca-1-gemcitabina-y-cisplatino-muestran-beneficio-en-un-anlisis-del-tiempo-medio-libre-de-enfermedad-en-la-adyuvancia-del-cncer-de-vas-biliares.png179287273065873712026-10-24T20:12:10.723Z"6409367e215b8f33585f56e5a8e7d686"1700738acticca1-adjuvant-gemcitabine-and-cisplatin-show-benefit-in-restricted-mean-diseasefree-survival-analysis-in-biliary-tract-cancer-4290.png179287256520264312026-10-24T20:09:25.267Z"a0529bc8d302cf4da7252b3439a941f2"1700268actionable-molecular-alterations-are-common-in-rare-cancers-yet-few-patients-receive-precision-therapy-7910.png178551158306330012026-07-31T15:26:23.127Z"f4e539113fb0fe73d7bc434dc54b86f3"2079941actualizacin-de-la-informacin-de-prescripcin-de-fremanezumab-destaca-aspectos-de-seguridad.png179097726191708112026-10-02T21:41:01.987Z"0194bdf9ba39e3bb5991c1e274bde196"1904522ada-2025---benefício-tardio-da-intervenção-no-estilo-de-vida:-look-ahead.png175046694555850312025-06-21T00:49:05.602Z"e0f6ef5e1b0bfbf379be21573a0528ed"1306656ada-2025---novo-agonista-quádruplo-mostra-efeito-na-perda-de-peso-sem-perda-muscular..png175046906058514912025-06-21T01:24:20.625Z"23b808bff707f011ef10bd1b9d891fb2"458720ada-2025---orforglipron-em-dm2-inicial:-achieve-1.jpeg175053796134136112025-06-21T20:32:41.383Z"612ab1c97e7484b1d373a4e6e589d697"13824262ada-2025---perda-de-peso-sustentada-com-tirzepatida-em-pacientes-com-pré-diabetes:-análise-pós-hoc-do-surmount-1.png175046993581440012025-06-21T01:38:55.874Z"a554e063c0d3e89f2a9fdb91004ba659"2398278ada-2025---redução-sustentada-do-tecido-adiposo-epicárdico-após-4-anos-com-dapagliflozina-–-dapaheart.jpeg175047019005325512025-06-21T01:43:10.097Z"bebd44521c98e27925659131ae2c1fe9"93345ada-2025---semaglutida-7,2-mg-mostra-benefício-adicional-na-obesidade.jpeg175053700812632912025-06-21T20:16:48.167Z"bb11f6a91672bc9014203ad1bf3a4dcb"82228ada-2025---sglt2-e-glp-1-ras-na-redução-de-demência.png175045012384860112025-06-20T20:08:43.895Z"ab1029c322aa779d2100b377267b27ae"1168902ada-2025---tirzepatida-na-perda-de-peso:-benefício-consistente,-independente-da-velocidade-de-resposta.jpeg175055187548603112025-06-22T00:24:35.530Z"b7e2611150efa50f7285e080715749f8"535192ada-2025---tirzepatida-vs.-dulaglutida:-sinal-de-maior-benefício-cardiovascular.jpeg175055215301074412025-06-22T00:29:13.054Z"556f0afe7b372482af31390a2faaf9c2"601362ada-2025-–-cagrisema-no-manejo-da-obesidade:-redefine-1.jpeg175059956663218912025-06-22T13:39:26.698Z"340801643aeb84d09ac617f49a8ae498"85315ada-2025-–-finerenona-e-empagliflozina-na-drc-e-dm2:-confidence.jpeg175062033321916912025-06-22T19:25:33.261Z"f3d1c867173ea49d1ad69f21d0ca5829"13192335ada-2025-–-insulina-semanal-para-dm2-sem-insulina-prévia:-qwint-1.jpeg175063676973824512025-06-22T23:59:29.799Z"f5a4100a0437aacbf48764b33ac16f75"93500ada-2025-–-perda-de-peso-com-preservação-muscular:-believe.jpeg175069952939211812025-06-23T17:25:29.434Z"2a18d1c4e92f01b7f7d930c4263429aa"30481ada-2025-–-semaglutida-melhora-capacidade-funcional-na-doença-arterial-periférica-com-diabetes-tipo-2:-stride.jpeg175072679241275012025-06-24T00:59:52.478Z"fee10ce09ca530903158ad2d25c3e9d0"2570066ada-2025-–-semaglutida-oral-reduz-riscos-de-eventos-cv:-soul.png175071016252055012025-06-23T20:22:42.564Z"58dece976fe13a16c60db1396ab7ab9e"1455002ada-2025-–-semaglutida-reduz-risco-renal-e-cardiovascular-independente-do-peso.jpeg175063905304461612025-06-23T00:37:33.091Z"d3e59ace41e7b2b9d3e0f17366950cd2"5478205ada-2025-–-triplo-agonista-promissor-na-nash.jpeg175063835147075012025-06-23T00:25:51.524Z"40a7c6acbe54c82e66b430d1365c1804"80213ada-2026-access-trial-aleniglipron-oral-demonstra-reduo-significativa-de-peso-em-estudo-fase-2b-6783.png178071313344111912026-06-06T02:32:13.513Z"207f5207bca3a8601acaa859cd5c6e4a"1713401ada-2026-access-trial-shows-meaningful-weight-reduction-with-oral-aleniglipron-in-phase-2b-study-8960.178071322516021612026-06-06T02:33:45.251Z"18446711d55fddc3e27bf74e2e9a1a18"1713064ada-2026-achieve-5-orforglipron-melhora-o-controle-glicmico-e-promove-perda-de-peso-em-pacientes-com-diabetes-tipo-2-em-uso-de-insulina-basal-7577.png178086764292270812026-06-07T21:27:22.991Z"0a877df77ecbccf6668663f8ded29203"1258636ada-2026-achieve5-orforglipron-improves-glycemic-control-and-promotes-weight-loss-in-patients-with-type-2-diabetes-receiving-basal-insulin-1945.178086797808898512026-06-07T21:32:58.156Z"fd0c8b47f6204369d5603df8c859a630"1256633ada-2026-alk7-inhibition-enhances-tirzepatideinduced-weight-loss-while-preserving-lean-mass-in-an-experimental-obesity-model-7981.178078356164144712026-06-06T22:06:01.709Z"6e4e328428f3bbc1d869efdf1d78dd58"1830474ada-2026-cagrisema-demonstra-efeitos-sobre-apetite-comportamento-alimentar-e-atividade-cerebral-relacionada--alimentao-4999.png178071257001882412026-06-06T02:22:50.091Z"98e50eb295773e4aad867731e7c7e696"1386548ada-2026-cagrisema-demonstrates-effects-on-appetite-eating-behavior-and-foodrelated-brain-activity-5183.178071271898994612026-06-06T02:25:19.062Z"8f6530b92f222e3d7321d28e26561c18"1379950ada-2026-inibio-de-alk7-potencializa-os-efeitos-da-tirzepatida-e-preserva-massa-magra-em-modelo-experimental-de-obesidade-4995.png178078328381180812026-06-06T22:01:23.881Z"fc8a63929a05fd75c4497b40f80c712a"1838390ada-2026-inibio-de-alk7-potencializa-os-efeitos-da-tirzepatida-e-preserva-massa-magra-em-modelo-experimental-de-obesidade-654.png178078317223773312026-06-06T21:59:32.310Z"fc8a63929a05fd75c4497b40f80c712a"1838390ada-2026-olezarsen-reduces-triglycerides-and-pancreatitis-risk-in-patients-with-severe-hypertriglyceridemia-and-diabetes-9219.178078368752472512026-06-06T22:08:07.593Z"686416e92c9a9711bba1778cb9d79231"1638968ada-2026-olezarsen-reduz-triglicerdeos-e-risco-de-pancreatite-em-pacientes-com-hipertrigliceridemia-grave-e-diabetes-3099.png178078337048060512026-06-06T22:02:50.550Z"ed3f525f151234d2858dc39aa3af1f45"1636340ada-2026-synchronize-masld-survodutide-demonstra-reduo-significativa-de-gordura-heptica-e-peso-corporal-em-pacientes-com-masld-6537.png178086748102057312026-06-07T21:24:41.092Z"8997fa2196348e2a94f3924f072e4dc1"1722971ada-2026-synchronizemasld-survodutide-demonstrates-significant-reductions-in-liver-fat-and-body-weight-in-patients-with-masld-7463.178086788469816712026-06-07T21:31:24.768Z"0b5b2a199a3b3338f4a70bd0c8b3db71"1713777ada-2026-transcend-t2d-1-retatrutide-demonstra-redues-expressivas-de-hba1c-e-peso-corporal-como-monoterapia-no-diabetes-tipo-2-5660.png178086732669641412026-06-07T21:22:06.768Z"90835546196c495f1b54a5703a84a1a4"1478231ada-2026-transcendt2d1-retatrutide-demonstrates-robust-reductions-in-hba1c-and-body-weight-as-monotherapy-in-type-2-diabetes-6344.178086777536931912026-06-07T21:29:35.441Z"e4c9ef1abe3f6ebf0327f14b5abb3505"1475805adapt-af-des-la-monoterapia-con-acod-es-superior-a-la-terapia-combinada-en-pacientes-con-fibrilacin-auricular-despus-del-implante-de-stent-farmacoactivo-.png176270814891615012025-11-09T17:09:08.962Z"0b4a357521f79853ab35e077ca3e395c"1481681adapt-af-des-monoterapia-com-noac--superior--terapia-combinada-em-pacientes-com-fibrilao-atrial-aps-stent-farmacolgico.png176270424027523412025-11-09T16:04:00.327Z"d6b0619dc62fc1da11805fb43f2a6dae"1461727adapt-afdes-acod-monotherapy-superior-postdes-in-af.png176563157191216812025-12-13T13:12:51.970Z"d78845ffa0272ddfafb77620e058bc01"656311adapt-afdes-noac-monotherapy-is-superior-to-combination-therapy-in-patients-with-atrial-fibrillation-after-drugeluting-stent-implantation.png176270846842026812025-11-09T17:14:28.470Z"49cb76415a305a75603886462615faf2"1473539adapt-afdes-noac-monotherapy-superior-postdes-in-af.null176563380420821612025-12-13T13:50:04.322Z"71192e6f313d4478e530b790d86867b3"1481987adapt-afdes-noac-monotherapy-superior-postdes-in-af.png176563374967969112025-12-13T13:49:09.724Z"71192e6f313d4478e530b790d86867b3"1481987adapt-afdes-trial-anticoagulant-monotherapy-outperforms-dual-therapy-beyond-12-months-after-des-in-af-patients.png176295984672142212025-11-12T15:04:06.771Z"b4bda1e30dbd6aa7360d4f290111eb10"2657526adc-de-nueva-generacin-en-el-aacr-2026-payloads-duales-nuevos-blancos-y-combinaciones-que-cambian-la-prctica-clnica-.jpeg177645194423282612026-04-17T18:52:24.292Z"1b4725d1979145c10e518022e03a3388"240004adc4-nurses.png176165260920480712025-10-28T11:56:49.258Z"1b6923dbdefc378b559edfa6e05551d0"3532139adcs-de-nova-gerao-no-aacr-2026-payloads-duplos-novos-alvos-e-combinaes-que-mudam-a-prtica-clnica--7555.jpeg177645601594741412026-04-17T20:00:16.017Z"dda20a31656da01f30456371d64f5e5e"243636adcs-parp-cirurgia-o-novo-mapa-teraputico-est-sendo-desenhado-agora-3479.png177603972349822912026-04-13T00:22:03.585Z"02cd9e7249afd8aa0897fdcd376060f6"2222744adding-tucatinib-to-trastuzumab-deruxtecan-does-not-outperform-monotherapy-in-advanced-her2-breast-cancer-phase-2-trial-finds-5995.png178456598792681312026-07-20T16:46:27.994Z"66e5b593bce34ed008a8866db965d5a3"1936338adjuvant-chemotherapy-improves-survival-in-older-women-with-triplenegative-breast-cancer-study-finds-6061.177576900644932612026-04-09T21:10:06.508Z"ef27670845535f8d79d50af2801b1fc8"2189356adore-study:-ruxolitinib-+-siremadlin-30-mg-shows-efficacy-in-myelofibrosis..png175632570084728712025-08-27T20:15:00.887Z"9086d94d62b07be624a2afc6c0d342c2"1467852adrenal-androgen-profiling-reveals-a-novel-hormonal-signature-associated-with-endometriosis-1602.png178767772396626512026-08-25T17:08:44.038Z"9dbb79660386dfb2c67fbd4a67c67ac6"1186782adrisk-study-evaluates-adjuvant-pembrolizumab-combined-with-radiotherapy-and-cisplatin-in-locally-advanced-head-and-neck-cancer.png176080471946969612025-10-18T16:25:19.514Z"61e9025a25ee8aec9ad439be5b139e76"1895256advanced-hodgkin-lymphoma-can-nivolumab-modify-th-136.png179253208863663912026-10-20T21:34:48.711Z"8c8c8825121bef212e7232d791f0b845"2715161advanced-hodgkin-lymphoma-can-nivolumab-modify-th-4647.png179259203382326112026-10-21T14:13:53.896Z"8c8c8825121bef212e7232d791f0b845"2715161advanced-hodgkin-lymphoma-can-nivolumab-modify-the-prognostic-impact-of-ebv-and-histology-4148.png179253128542183812026-10-20T21:21:25.495Z"2e8d45be58435cb7771d0931f4d9df49"4261363advanced-nsclc-with-pdl1-50-antipdl1-monotherapy-or-chemoimmunotherapy-in-the-firstline-setting-6933.178154971800983612026-06-15T18:55:18.074Z"b94b246909d947770ec43ae20e7caddb"1963248advances-and-ongoing-challenges-in-rare-endocrine-disorders..png175519343206489712025-08-14T17:43:52.113Z"6506dc2faafb0a0adfbfe0b8e9046cea"1936433advances-in-the-management-of-metabolic-dysfunction–associated-steatotic-liver-disease-(masld)..png175519329392983612025-08-14T17:41:33.979Z"44acdb9ff13a5de2e684c18eb5165893"2361764advances-in-understanding-and-managing-long-qt-syndrome-genetics-risk-modifiers-and-evolving-therapies.jpeg176415956918128212025-11-26T12:19:29.222Z"49c7c755392a5f699f47c02881f0e53a"190881aeneas2-aumolertinib-plus-chemotherapy-prolongs-progressionfree-survival-in-advanced-egfrmutated-nsclc-3308.png178233212965651012026-06-24T20:15:29.732Z"cd2291e00523041c66c0eb5e6e398877"2039649aeneas2-aumolertinibe-associado--quimioterapia-prolonga-a-sobrevida-livre-de-progresso-no-cpnpc-avanado-com-mutao-de-egfr-9404.png178223922252281212026-06-23T18:27:02.586Z"339aef0866f7da6b03f7997a8dd069b6"2039059aficamten-vs-metoprolol-maplehcm-shows-superiority-of-myosin-inhibition-in-obstructive-hcm.png175880450445765212025-09-25T12:48:24.509Z"342886481ed938dd7ee17f55daf7610e"2677830age-40-years-alone-may-not-define-high-risk-in-idhmutant-lowergrade-gliomas-2278.png178766636221897712026-08-25T13:59:22.290Z"92e433274c8ff010b06dfb0e7cadb888"1946087age-40-years-alone-may-not-define-high-risk-in-idhmutant-lowergrade-gliomas-238.png178766660443764312026-08-25T14:03:24.498Z"92e433274c8ff010b06dfb0e7cadb888"1946087agenda-cientifica-curso-intensivo-de-reciclagem-em-clinica-medica.C7DC1XNC.pdf178786118815931512026-08-27T20:06:28.295Z"c023b4f2449448666386f1039dca7b2a"1082437agendas/agenda-cientifica.pdf178706342312574912026-08-18T14:30:23.284Z"73bcdb6a3e053cf33bb340df0e7864c4"904083agendas/hello-kirk.pdf178697077001621012026-08-17T12:46:10.088Z"1441a7909c087dbbe7ce59881b9df8b9"15agendas/hhhh.png178760138655949912026-08-24T19:56:26.621Z"06d6aaac121dc4f5e6eaa33b0f76f7d7"1470090agendas/kirk.pdf178697233517780612026-08-17T13:12:15.243Z"55f924af410dd775524d069ffe80dbdc"49672agendas/manual-retool.pdf178708235034722812026-08-18T19:45:50.417Z"e0e72109d623c0ff71599e8e1ff56268"4067948agendas/nome-teste.pdf178697466103601412026-08-17T13:51:01.108Z"c023b4f2449448666386f1039dca7b2a"1082437agendas/teste-charle-kirk.pdf178699661981127412026-08-17T19:56:59.887Z"73bcdb6a3e053cf33bb340df0e7864c4"904083agendas/teste-da-silva.pdf178697175716892812026-08-17T13:02:37.297Z"55f924af410dd775524d069ffe80dbdc"49672agendas/teste-de-imagem.pdf178708802373172712026-08-18T21:20:23.857Z"73bcdb6a3e053cf33bb340df0e7864c4"904083agendas/teste-imagem-2.jpg178708806928075812026-08-18T21:21:09.349Z"761d0b2826de04e9f20864abdedb7370"24497agendas/testea.pdf178697202646890212026-08-17T13:07:06.547Z"73bcdb6a3e053cf33bb340df0e7864c4"904083agomelatina-inovao-na-interface-entre-farmacologia-e-cronobiologia.png175771126482358512025-09-12T21:07:44.883Z"5ac03b84246fcc764c737eaa6e8a0ba6"2242703agomelatine-innovation-at-the-interface-of-pharmacology-and-chronobiology.png175777742931522712025-09-13T15:30:29.383Z"5ac03b84246fcc764c737eaa6e8a0ba6"2242703agonistas-de-glp-1-reduzem-risco-cardiovascular-em-t2d-precoce-comparados--insulina.jpeg175821983118153412025-09-18T18:23:51.223Z"b91e2d30b0c302c73088af9de68dba53"319418agonistas-de-glp-1-sob-nova-regulamentação:-anvisa-exige-retenção-de-receita-a-partir-de-junho.jpeg175009299186941812025-06-16T16:56:31.912Z"ee7f6b0d33c78a3e26733c5bf97711a0"8178689aha-2025.png176045060671476512025-10-14T14:03:26.761Z"9f724840a10c4655574a6d60d6a06cdb"626663aha-2026--do-nutriente-ao-padrão-—-10-mensagens-que-devem-mudar-a-forma-como-pensamos-a-alimentação-na-prática-clínica.png177609095831915612026-04-13T14:35:58.375Z"7390e889d72a9947a89e03454db30d88"1880490aha-2026-coverage.png179321470965547312026-10-28T19:11:49.785Z"1ce2c41f9f371ec44c8e598f7cd80198"325311aha-2026-do-nutriente-ao-padro--10-mensagens-que-devem-mudar-a-forma-como-pensamos-a-alimentao-na-prtica-clnica-1472.png177576438924815512026-04-09T19:53:09.315Z"5ebe974f6315924612b3390f97c047bb"2139438ai-improves-sensitivity-in-detecting-her2-low-and-her2-ultralow-in-advanced-breast-cancer.jpeg175493617727648612025-08-11T18:16:17.361Z"5bc0b7da8698c8ea36c61b3d42ecc1a2"10408858ai-prime-hero-banner.jpeg176606586367198912025-12-18T13:51:03.711Z"b2f6b1c1bfbc239f2ae0910922401628"835415aids-2026--el-rgimen-inyectable-cada-ocho-semanas-fue-superior-al-tratamiento-oral-en-adolescentes.png178536810844825112026-07-29T23:35:08.520Z"7456fa21ca321ca35b802e564e938b87"1595673aids-2026--el-rgimen-oral-semanal-fue-no-inferior-al-tratamiento-diario-en-islend-2.png178533876185429912026-07-29T15:26:01.926Z"5e55292dccee24820febd2a98cc8dae6"1667727aids-2026--hero-banner-3214.png178492684119649512026-07-24T21:00:41.277Z"2616104460a2ca1501b832b6d7cf0789"1325392aids-2026--hero-banner-mobile-3214.png178492684341829512026-07-24T21:00:43.481Z"a6198bc798a3a0410a925533a6094c23"313531aids-2026--islend-1-2026-estudio-de-fase-3-evala-un-rgimen-oral-semanal-con-islatravirlenacapavir-en-adultos-con-vih-1.png178536186156429912026-07-29T21:51:01.628Z"0c016b04b77852f4de224e1ef9fd099e"1846976aids-2026--islend-1-estudo-de-fase-3-avalia-regime-oral-semanal-com-islatravirlenacapavir-em-adultos-com-hiv-1-6121.png178536225902344712026-07-29T21:57:39.087Z"9bb799008fa4ad3b171b306dc97197d0"1845951aids-2026--lenacapavir-semestral-mantiene-una-baja-incidencia-del-vih-durante-la-extensin-abierta-de-purpose-2.png178543974703949412026-07-30T19:29:07.107Z"e66bbd63cbd7e7e902d5acdee04ce921"1933551aids-2026--lenacapavir-semestral-mantm-baixa-incidncia-de-hiv-na-extenso-aberta-do-purpose-2-5822.png178543945983481012026-07-30T19:24:19.898Z"3d7215ebb335da1d42562e3f1c5f631e"1932775aids-2026--novo-caso-de-remisso-do-hiv--relatado-aps-transplante-alognico-4776.png178534692293135012026-07-29T17:42:03.005Z"11e8b94ea728373ff4864896499dd88d"2014240aids-2026--opti-dor-compara-controle-virolgico-e-ganho-de-peso-no-tratamento-inicial-do-hiv-3583.png178551937038707212026-07-31T17:36:10.451Z"6978af43c39afc96c83d16dc838f037e"1780947aids-2026--opti-dor-compara-la-eficacia-virolgica-y-el-aumento-de-peso-en-el-tratamiento-inicial-del-vih.png178551982900839412026-07-31T17:43:49.071Z"33e2509f9c31c9139ed111dcc40cafb4"1781436aids-2026--perfil-de-clulas-nk--associado-ao-controle-viral-aps-interrupo-da-terapia-antirretroviral-4520.png178536454488199412026-07-29T22:35:44.946Z"3c7cdaa95f913fca4aa6245e3ed9838b"2358280aids-2026--perfil-de-clulas-nk--associado-ao-controle-viral-aps-interrupo-da-terapia-antirretroviral-8137.png178543773980664812026-07-30T18:55:39.878Z"3c7cdaa95f913fca4aa6245e3ed9838b"2358280aids-2026--perfil-de-clulas-nk-asociado-con-el-control-viral-despus-de-la-interrupcin-del-tratamiento-antirretroviral.png178543815773714012026-07-30T19:02:37.809Z"e6f7bc872bfcc63629552c184963a8be"2355887aids-2026--regime-injetvel-a-cada-oito-semanas-foi-superior-ao-tratamento-oral-em-adolescentes-4114.png178536784381386312026-07-29T23:30:43.886Z"0fae24988bd1aac256123759bce4399f"1598497aids-2026--regime-oral-semanal-foi-no-inferior-ao-tratamento-dirio-no-islend-2-3020.png178533851974535512026-07-29T15:21:59.817Z"2591a8b841bdd03fb104c0b714383c54"1667549aids-2026--se-informa-un-nuevo-caso-de-remisin-del-vih-tras-un-trasplante-alognico.png178534760798096512026-07-29T17:53:28.052Z"7b43d80853ca1e716ca08e3fac4c65e8"2015604aids-2026-aids-2026-islend1-2026-phase-3-study-evaluates-onceweekly-oral-islatravirlenacapavir-in-adults-with-hiv1-3055.png178536148661315612026-07-29T21:44:46.677Z"0c016b04b77852f4de224e1ef9fd099e"1846976aids-2026-comea-no-rio-de-janeiro-sob-o-tema-rethink-rebuild-rise--7886.png178517974377588512026-07-27T19:15:43.839Z"a51833b6b1fce542c0433da0058a1082"2093488aids-2026-comienza-en-ro-de-janeiro-bajo-el-lema-rethink-rebuild-rise-.png178517985935185812026-07-27T19:17:39.415Z"c97dce005b171f575cea6de774058637"2090671aids-2026-every8week-injectable-regimen-was-superior-to-oral-therapy-in-adolescents-3710.png178536835538838212026-07-29T23:39:15.460Z"155ebe22d84e1da4427e0cc13415e53c"1595701aids-2026-highlight-less-frequent-dosing-and-new-evidence-in-hiv-prevention-and-remission-8167.png178542629988040212026-07-30T15:44:59.945Z"a896c4fae8096a190a928d5098237572"1826585aids-2026-islend1-2026-phase-3-study-evaluates-onceweekly-oral-islatravirlenacapavir-in-adults-with-hiv1-6155.png178536551365193512026-07-29T22:51:53.714Z"0c016b04b77852f4de224e1ef9fd099e"1846976aids-2026-kicks-off-in-rio-de-janeiro-under-the-theme-rethink-rebuild-rise-2219.png178517997269211912026-07-27T19:19:32.763Z"a68825a4d9c6ba7a498067f28b1c73bd"2090662aids-2026-new-case-of-hiv-remission-reported-following-allogeneic-transplantation-4038.png178534723634392512026-07-29T17:47:16.417Z"27f88937810dacbc6e9696c131dea5dd"2015243aids-2026-nkcell-profile-associated-with-viral-control-after-antiretroviral-therapy-interruption-221.png178543804753089812026-07-30T19:00:47.602Z"9da475d2b727fbe18657ee74c333cdad"2355947aids-2026-onceweekly-oral-regimen-was-noninferior-to-daily-therapy-in-islend2-2048.png178533867153101812026-07-29T15:24:31.603Z"4f32de353a0caa84c76ffa023a7bb3ec"1667565aids-2026-optidor-compares-virologic-efficacy-and-weight-gain-in-initial-hiv-therapy-9208.png178551953160520912026-07-31T17:38:51.668Z"bac3b64dddf7870af26729c170d794f0"1781143aids-2026-twiceyearly-lenacapavir-maintains-low-hiv-incidence-during-the-purpose-2-openlabel-extension-9192.png178543954997137112026-07-30T19:25:50.035Z"e66bbd63cbd7e7e902d5acdee04ce921"1933551ainda-h-espao-para-os-glicosdeos-digitlicos-na-insuficincia-cardaca-resultados-de-uma-metanlise-publicada-no-jama-4489.png178216873240925412026-06-22T22:52:12.471Z"128a972df2950e7fc7b2811d9323b6f6"1790721ainda-há-espaço-para-os-glicosídeos-digitálicos-na-insuficiência-cardíaca--resultados-de-uma-metanálise-publicada-no-jama-1.png178216873042985012026-06-22T22:52:10.491Z"c38532af7aa630f804252916b1c58780"13227algoritmos-baseados-em-machine-learning-para-detecção-precoce-e-triagem-de-distúrbios-neurodegenerativos-e-neurocognitivos.jpeg174861388252334412025-05-30T14:04:42.564Z"1a9360bc8b4fef014a0263b95a4c9249"742364alguém-sabe-origem-da-foto-bob-esponja-agiota-v0-037qzidt2cjd1.webp179191313808673512026-10-13T17:38:58.223Z"e74ace88ca7ea5c8e8f05b08cc5852ee"12232aliana-internacional-prope-integrao-de-dados-de-mundo-real-para-transformar-a-pesquisa-e-os-resultados-no-tratamento-dos-linfomas-2107.png178964420082684112026-09-17T11:23:20.890Z"8c7afa4b4a9d5a02370e815933133a48"1154793altas-taxas-de-negatividade-de-drm-com-belantamabe-mafodotina-marcam-resultados-promissores-no-mieloma-mltiplo-recm-diagnosticado-4717.png178129882195186812026-06-12T21:13:42.017Z"c86d2abb1188b7b72e04a214995fd494"2241617alteraes-moleculares-so-frequentes-em-cnceres-raros-mas-poucos-pacientes-recebem-terapia-personalizada-6661.png178551133945129312026-07-31T15:22:19.522Z"b1418263b144a6e5f584050e2fb8c753"2078275alzheimer-em-estágio-avançado--sus-passa-a-ofertar-donepezila-para-quadros-graves.jpeg175286492946680012025-07-18T18:55:29.510Z"51a62e9ae4b2cb17a94366f42f7b0df0"6568605alzheimers-beyond-the-brain-a-review-reframes-ad-as-an-organbrain-immune-network.png176970266815958112026-01-29T16:04:28.207Z"f15e4af1035bc63df20ebd87c9ea8255"6783885amiloidose-al-o-diagnstico-ainda-demora-dois-anos--e-isso-mata-pacientes-2808.jpeg177574312526750012026-04-09T13:58:45.327Z"fffb07c9059e2b1be1da481365778c22"5397104amiloidose-attr-como-o-pcdt-orienta-o-diagnstico-e-o-tratamento.jpeg176969024066149712026-01-29T12:37:20.701Z"0d1023b739a463d2d47908accad5c544"174132amiloidose-do-subdiagnstico-ao-tratamento-precoce-que-muda-a-histria-da-doena.png177072856394101812026-02-10T13:02:43.986Z"502a825b8e66c510386e1ff4512bd123"1085934amiloidose-na-prtica-clnica-reconhecendo-red-flags-e-transformando-o-prognstico-7396.png179200426330021812026-10-14T18:57:43.373Z"400aef76726805344b3f6952ccd33d52"2282197amivantamabe-no-carcinoma-de-cabea-e-pescoo-resultados-do-origami-4-e-perspectivas-para-a-esmo-2026-3667.png179262338795650012026-10-21T22:56:28.017Z"3ab67d25fd415a561200967dde18d692"3005624amivantamabe-no-carcinoma-de-cabea-e-pescoo-resultados-do-origami-4-e-perspectivas-para-a-esmo-2026-8959.png179262332869568612026-10-21T22:55:28.756Z"3ab67d25fd415a561200967dde18d692"3005624amivantamablazertinib-improves-overall-survival-in-egfrmutated-advanced-nsclc.png175745489760416012025-09-09T21:54:57.645Z"8c96fa9260e906af0c91557270ce58b8"2641224ampliao-das-indicaes-peditricas-de-belimumabe-e-ocrelizumabe-representa-avano-no-tratamento-de-doenas-autoimunes-6676.png178483032798050212026-07-23T18:12:08.061Z"d279ec27b2c9679ae6a76e6d2ac16885"630076amplificação-de-fgfr1-define-subtipo-agressivo-de-câncer-colorretal.jpeg175647873108484212025-08-29T14:45:31.127Z"126532be6685e108d8e637b76215c1ef"15258540anbenitamab--hb1801-aumenta-la-respuesta-patolgica-completa-en-el-cncer-de-mama-her2-positivo.png178915583934731312026-09-11T19:43:59.418Z"97756c6ca2bea59edd1ac48da3e3c93a"1929195anbenitamab--hb1801-aumenta-resposta-patolgica-completa-no-cncer-de-mama-her2-positivo-2302.png178915563507470612026-09-11T19:40:35.144Z"431f1e939072d00aa20046034ebcef86"1934302anbenitamab--hb1801-aumenta-resposta-patolgica-completa-no-cncer-de-mama-her2-positivo-7997.png178915554819072212026-09-11T19:39:08.263Z"431f1e939072d00aa20046034ebcef86"1934302anbenitamab-hb1801-increases-pathological-complete-response-in-her2positive-breast-cancer-5700.png178915605134446812026-09-11T19:47:31.414Z"0c66410a7242a9cfb4a91766cb3fc9ad"1928589anemia-falciforme.jpeg178733378661544112026-08-21T17:36:26.685Z"9d240a13cbb0796945294e99fe57d18a"111033anito-cel-est-associado-a-maiores-chances-de-resposta-que-teclistamabe-e-talquetamabe-em-pacientes-com-mieloma-mltiplo-aps-4-linhas-de-tratamento-prvias-8326.png179036939153037612026-09-25T20:49:51.603Z"75e8eb2bd2d1b6bb66c40fa6c2b645f7"1007270anito-cel-se-asocia-con-mayores-probabilidades-relativas-de-respuesta-que-teclistamab-y-talquetamab-en-pacientes-con-mieloma-mltiple-tras-4-lneas-de-tratamiento-previas.png179037051578109212026-09-25T21:08:35.851Z"c5846ee5a9f982d2de84354311d4812c"1019209anitocel-is-associated-with-higher-odds-of-response-than-teclistamab-and-talquetamab-in-patients-with-multiple-myeloma-after-4-prior-lines-of-therapy-7144.png179037032233978912026-09-25T21:05:22.411Z"b2f75198b78106c8cf835e04978c5c7e"1020077anlise-crtica-da-eficcia-e-segurana-do-caplacizumabe-no-tratamento-da-prpura-trombocitopnica-trombtica-imune-uma-reviso-sistemtica-atualizada-e-meta-anlise.jpeg177248273637596212026-03-02T20:18:56.445Z"a4d8200c175e308f160da130a08932e7"7151787anlise-de-cinco-anos-do-estudo-polarix-eficcia-e-segurana-de-pola-r-chp-versus-r-chop-no-linfoma-difuso-de-grandes-clulas-b.jpeg177248232048557012026-03-02T20:12:00.555Z"c47d5579f24935bcb54c6d4dbcaf0d3c"13041007anlise-do-estudo-axsana-eubreast-3-estadiamento-axilar-menos-invasivo-aps-quimioterapia-neoadjuvante-.png176600433578790812025-12-17T20:45:35.833Z"1b87dc2799f41b5167b0a9ef3fc70631"1381746anlise-do-estudo-spport-mostra-impacto-transitrio-na-qualidade-de-vida-com-intensificao-da-radioterapia-de-resgate-no-cncer-de-prstata-1660.png178491543925990112026-07-24T17:50:39.324Z"800cd2abde290b0fb6a1d6707fa0908b"1973472anlogos-de-glp-1-podem-reduzir-a-progresso-para-doena-metasttica-o-que-o-abstract-3143-da-asco-2026-revela-7104.png178048927238169912026-06-03T12:21:12.446Z"d60bcc66335ee50086d05d9973ec712c"2800941ans-abre-consulta-pblica-sobre-proposta-de-incorporao-de-tepotinibe-para-pacientes-com-cpnpc-e-mutao-metex14-1261.png178659497919751812026-08-13T04:22:59.264Z"fa1b26c454f2f938202ba6899689b4f4"2263218ans-abre-consulta-pblica-sobre-proposta-de-incorporao-de-tepotinibe-para-pacientes-com-cpnpc-e-mutao-metex14-463.png178659497572043112026-08-13T04:22:55.788Z"fa1b26c454f2f938202ba6899689b4f4"2263218ans-avalia-inclusão-de-selpercatinibe-no-rol-para-tratamento-de-carcinoma-medular-de-tireoide-ret+.jpeg175009415069135912025-06-16T17:15:50.740Z"99d73444d603e295153fb9cb1b371d08"7948516antes-de-que-falle-la-memoria-un-estudio-latinoamericano-ampla-el-debate-sobre-la-prevencin-de-la-demencia-7405.png178604477345816012026-08-06T19:32:53.528Z"ee91ce0a27dec7aac419ac3c994d7b12"2238636antes-de-que-falle-la-memoria-un-estudio-latinoamericano-ampla-el-debate-sobre-la-prevencin-de-la-demencia.png178611339363587712026-08-07T14:36:33.761Z"ee91ce0a27dec7aac419ac3c994d7b12"2238636antes-que-a-memria-falhe-estudo-latino-americano-amplia-a-discusso-sobre-preveno-da-demncia-5510.png178604450880519912026-08-06T19:28:28.878Z"f21359c57dbd0d7d5b6c732d3e1d69ee"2239710anti-amyloid-therapies-show-modest-benefits-in-alzheimer's-disease-meta-analysis-reveals-limited-cognitive-improvements-with-safety-concerns.png175405735382682912025-08-01T14:09:13.881Z"086800b0cb019e38694cb786d9e6078b"2852355antiagregacin-en-2026-menos-es-ms-lo-que-el-cardilogo-debe-saber-sobre-la-nueva-declaracin-cientfica-del-acc.png178422281436318712026-07-16T17:26:54.432Z"eb36857cd3a562e59c3f6fc2c0624b5d"674071antiagregación-en-2026--¿menos-es-más--lo-que-el-cardiólogo-debe-saber-sobre-la-nueva-declaración-científica-del-acc-1.png178422280936566112026-07-16T17:26:49.435Z"01287b7e63ef54823fc57ac8a03fd715"180484antiagregación-en-2026--¿menos-es-más--lo-que-el-cardiólogo-debe-saber-sobre-la-nueva-declaración-científica-del-acc-2.png178422281150157812026-07-16T17:26:51.570Z"b9da0e7bec311b67228fd677c8be4e00"208066antiagregao-em-2026-menos--mais-o-que-o-cardiologista-precisa-saber-sobre-a-nova-declarao-cientfica-do-acc-7578.png178422280695497212026-07-16T17:26:47.024Z"2a714c4dada94d446cc104e4307bd2f3"684324antiagregação-em-2026--menos-é-mais--o-que-o-cardiologista-precisa-saber-sobre-a-nova-declaração-científica-do-acc-1.png178422280287034012026-07-16T17:26:42.938Z"d99637cbe4016488c40afa9003c1b58a"247135antiagregação-em-2026--menos-é-mais--o-que-o-cardiologista-precisa-saber-sobre-a-nova-declaração-científica-do-acc-2.png178422280489063212026-07-16T17:26:44.988Z"97c1f4f2d3c94b725de16b04f92d2dab"117142anticd300c-antibody-cl7-reduced-tumor-growth-and-improved-survival-in-a-murine-nsclc-model.png176736076542703112026-01-02T13:32:45.466Z"f3bc3ba629a9a8244170e068e8e355f5"6919221anticd300c-antibody-cl7-suppresses-nsclc-tumor-growth-by-remodeling-macrophagedriven-microenvironment.png176736090614922112026-01-02T13:35:06.189Z"f3bc3ba629a9a8244170e068e8e355f5"6919221anticoagulantes-orais-diretos-na-preveno-primria-e-secundria-de-eventos-trombticos-scientific-statement-acc-2026-2665.png178422916815805312026-07-16T19:12:48.228Z"8a69f0f1f47459efdb1494803c7e92f6"1339942anticoagulantes-orales-directos-en-la-prevencin-primaria-y-secundaria-de-eventos-trombticos-scientific-statement-del-acc-2026.png178422914729947612026-07-16T19:12:27.359Z"ef8ed9e0173477ac62bb0079442ce53b"1341066anticoagulao-isolada--mais-segura-que-terapia-dupla-em-pacientes-com-sndrome-coronariana-crnica.png176597669957222612025-12-17T13:04:59.709Z"bf2ddd353d618a03f3daf855d9b00b21"659864anticoagulação-em-pacientes-com-fibrilação-atrial-após-hemorragia-intracraniana--meta-análise-mostra-benefício-clínico-líquido-mas-devemos-ter-muita-atenção-ao-risco-de-recorrência.jpeg175404950060169512025-08-01T11:58:20.640Z"5069695fdd3c1e757eea5c67dd2a58bb"224897anticorpo-biespecfico-pd-l1-vegf-combinado--quimioterapia-reduz-risco-de-progresso-no-snc-em-47-em-pacientes-com-metstases-cerebrais-aps-falha-de-tki-8950.jpeg177508089458253912026-04-01T22:01:34.628Z"a5fd71414f2c2d1837be9adabc46d0a2"314734anticorpo-biespecfico-pd-l1vegf-combinado--quimioterapia-reduz-risco-de-progresso-no-snc-em-47-em-pacientes-com-metstases-cerebrais-aps-falha-de-tki-1112.jpeg177508084366708912026-04-01T22:00:43.713Z"a5fd71414f2c2d1837be9adabc46d0a2"314734anticorpo-monoclonal-contra-pacap-demonstra-potencial-na-preveno-da-enxaqueca-em-pacientes-com-falha-teraputica-prvia-2348.png179087885254353912026-10-01T18:20:52.608Z"66e55ee4850e19b9d8e25e8ee24b9a27"1728747anticorpo-monoclonal-contra-pacap-demonstra-potencial-na-preveno-da-enxaqueca-em-pacientes-com-falha-teraputica-prvia-5912.png179087886001025412026-10-01T18:21:00.074Z"66e55ee4850e19b9d8e25e8ee24b9a27"1728747anticorpo-monoclonal-contra-pacap-demonstra-potencial-na-preveno-da-enxaqueca-em-pacientes-com-falha-teraputica-prvia-811.png179087885242571412026-10-01T18:20:52.488Z"66e55ee4850e19b9d8e25e8ee24b9a27"1728747anticorpo-monoclonal-contra-pacap-demonstra-potencial-na-preveno-da-enxaqueca-em-pacientes-com-falha-teraputica-prvia-9124.png179087885377163412026-10-01T18:20:53.834Z"66e55ee4850e19b9d8e25e8ee24b9a27"1728747antiplatelet-therapy-in-2026--is-less-more--what-cardiologists-need-to-know-about-the-new-acc-scientific-statement-1.png178422279803565012026-07-16T17:26:38.106Z"1441a7909c087dbbe7ce59881b9df8b9"15antiplatelet-therapy-in-2026--is-less-more--what-cardiologists-need-to-know-about-the-new-acc-scientific-statement-2.png178422279929497312026-07-16T17:26:39.366Z"1441a7909c087dbbe7ce59881b9df8b9"15antiplatelet-therapy-in-2026-is-less-more-what-cardiologists-need-to-know-about-the-new-acc-scientific-statement-1730.png178422280138577912026-07-16T17:26:41.454Z"dd3f0964cafc1ef45020d315be03685f"672888anvisa-amplia-indicao-do-obinutuzumabe-para-lpus-eritematoso-sistmico-7834.png179209308393102312026-10-15T19:38:04.005Z"09f19b7fac19c306bd4bd31f9e9940cc"2374690anvisa-aprova-alfapegunigalsidase-para-terapia-de-reposio-enzimtica-de-longa-durao-na-doena-de-fabry-5280.jpeg179122567604196712026-10-05T18:41:16.113Z"96dba8e9d19aefe1e1d12e8616c09578"221156anvisa-aprova-axatilimabe-para-tratamento-da-doena-crnica-do-enxerto-contra-o-hospedeiro-5295.png179157379256372712026-10-09T19:23:12.632Z"f844bce4e8b4961ada3888ce4120381d"1837290anvisa-aprova-butantan-dv-primeira-vacina-100-nacional-contra-dengue-baseada-em-ensaio-de-fase-3-com-mais-de-16-mil-brasileiros.jpeg176425600937806912025-11-27T15:06:49.426Z"cc08af432430fc078578c5a726d92d19"196875anvisa-aprova-camizestranto-para-cncer-de-mama-avanado-hr-positivo-com-mutao-esr1-emergente-3142.png178999968745034712026-09-21T14:08:07.513Z"088acc39c82b8cb61c700636a8cef073"1869139anvisa-aprova-caneta-que-combina-insulina-icodeca-e-semaglutida-para-adultos-com-diabetes-mellitus-tipo-2-577.jpeg179061617837615212026-09-28T17:22:58.441Z"b1ffb761c44480a17bb4c2a392135678"157060anvisa-aprova-cemiplimabe-adjuvante-no-cec-cutneo-de-alto-risco.jpeg176781641461804012026-01-07T20:06:54.902Z"8777842110f26b9c9271976aceafca96"184658anvisa-aprova-cinco-novas-canetas-de-semaglutida-em-meio-ao-avano-do-diabetes-e-da-obesidade-no-brasil-357.png178534306213811912026-07-29T16:37:42.204Z"9fe22e0d2233233417ff6031f39a4ded"1817349anvisa-aprova-fruquintinibe-para-cncer-colorretal-metasttico-previamente-tratado--4201.png178821173035909512026-08-31T21:28:50.423Z"6747518cfb8919207ee185da822c052a"1844737anvisa-aprova-glofitamabe-em-combinao-com-gemox-para-pacientes-com-ldgcb-recidivante-ou-refratrio-inelegveis-ao-transplante-autlogo-2671.png178492230107373812026-07-24T19:45:01.145Z"ac513eef802f7ae26554637c4332088e"1886044anvisa-aprova-mirvetuximabe,-primeiro-adc-direcionado-ao-receptor-de-folato-alfa,-para-câncer-de-ovário-resistente-à-platina-.jpeg175692293132640812025-09-03T18:08:51.367Z"108805e18416b7e65c84792371246b04"1131054anvisa-aprova-mosunetuzumabe-subcutneo-para-tratamento-do-linfoma-folicular-recidivado-ou-refratrio-1414.png178852269691979512026-09-04T11:51:36.984Z"5eba5a2d870f8bdd88b94686be5fbcfa"1337087anvisa-aprova-nerandomilaste-primeira-nova-opo-em-uma-dcada-para-fibrose-pulmonar-idioptica-2087.png178490396394451512026-07-24T14:39:24.013Z"a3e8f1fde52c3e78cdfae1f031869366"2117672anvisa-aprova-nova-indicao-de-lenacapavir-e-amplia-estratgias-de-preveno-ao-hiv-1-no-brasil.png177073510980950212026-02-10T14:51:49.937Z"ab41d426e9f4ab15e35e66e3f226c199"4145911anvisa-aprova-nova-indicao-de-tratamento-para-cncer-de-pncreas-metasttico-no-brasil--9081.jpeg178844749115243712026-09-03T14:58:11.221Z"6c5c0a57c901c8afc49df15e3f56793f"357076anvisa-aprova-nova-indicao-de-tratamento-para-cncer-de-pncreas-metasttico-no-brasil-1601.png178835982353075812026-09-02T14:37:03.617Z"576723a1be4242d5fb071bb5f0f70522"2326297anvisa-aprova-nova-terapia-de-reposio-enzimtica-para-doena-de-fabry-3293.png179190582607349712026-10-13T15:37:06.148Z"fbb2a0bd9ba8a7068053c02f9bfdc5fc"3037398anvisa-aprova-novas-indicaes-para-tislelizumabe-em-cncer-de-pulmo-de-pequenas-clulas-e-carcinoma-nasofarngeo-3029.png178031887061969812026-06-01T13:01:10.695Z"e6ccf3822898d1d4bb240626d7bdb25c"2331319anvisa-aprova-novo-medicamento-para-adultos-com-nefropatia-primria-por-iga-em-risco-de-progresso-da-doena-3116.jpeg178828521018655912026-09-01T17:53:30.310Z"9508c4b084169e53d45d559283b0a319"251490anvisa-aprova-pembrolizumabe-no-cenrio-perioperatrio-do-cec-de-cabea-e-pescoo.jpeg175822971136289312025-09-18T21:08:31.403Z"ca3878b51ad21409a617e1fc4c8d1de5"4366802anvisa-aprova-sacituzumabe-govitecana-em-primeira-linha-para-cncer-de-mama-triplo-negativo-avanado-319.png178898833988269012026-09-09T21:12:19.945Z"ce37c37f0d3b0306f4d633c857091855"3043054anvisa-aprova-sugemalimabe-em-primeira-linha-para-cpnpc-metasttico-6158.png179319871364139712026-10-28T14:45:13.718Z"01578cc731602ff7ff9eb6038b03f601"3824926anvisa-aprova-telisotuzumabe-vedotina-para-nsclc-no-escamoso-com-alta-expresso-de-c-met-8138.jpeg179258837967014112026-10-21T13:12:59.745Z"5620cdad8f158bfd450c46792be1e698"299047anxiety-depression-and-obesity-an-interconnected-challenge-in-clinical-practice.png175778471195843112025-09-13T17:31:52.024Z"429bf8d71a787ffc4b17563639a4fcc6"2204383ap_cabecalho_1.webp179208472982565312026-10-15T17:18:49.957Z"ac4bc870141075d04ac387691a91f2c3"38242ap_cabecalho_2.webp179208473090024512026-10-15T17:18:51.034Z"079139f97b8d29f034b8219b01d4e14b"26312apoc3-inhibition-with-olezarsen-achieves-significant-and-durable-triglyceride-reduction-in-highrisk-patients.png175984821553145212025-10-07T14:43:35.592Z"af809629ce36c59361e10474eaa646b4"2357823apoio-empático-por-telefone-melhora-controle-glicêmico-em-pacientes-com-diabetes-tipo-2.jpeg174827563252284012025-05-26T16:07:12.568Z"8daaef363c13398a069955dfb5a08941"550298apoio-que-impulsiona-a-ciência--viabilização-da-pesquisa-clínica-no-brasil-.jpeg175707330724158212025-09-05T11:55:07.299Z"d5cc216ae0b160ebd90eea8d70d3c80d"203857apoptosis-linked-plasma-biomarkers-emerge-as-correlates-of-breathlessness-in-long-covid..png175329635950777512025-07-23T18:45:59.556Z"ede5e4d32dcc94e00dc271cade91c6f4"1667982aprendendo-sobre-a-principal-função-do-coração-no-corpo-humano.jpeg177548295163404812026-04-06T13:42:31.672Z"1420351d0286536fb2206d3e24ff58f4"338521aprendendo-sobre-oncologia.png177573400729577012026-04-09T11:26:47.370Z"5eedac2d78bdbde9746067487dd5a2a8"758641are-community-health-workers-costeffective-in-primary-health-care-a-global-systematic-review-of-50-economic-evaluations.png176970209820630012026-01-29T15:54:58.245Z"0f8b14ffd6e592f608f1e18d79c1f8ea"8256368artificial-intelligence-and-hospital-outbreak-prevention:-a-novel-approach-to-identify-vancomycin-resistant-enterococcus-carriers.jpeg175287365960547712025-07-18T21:20:59.671Z"10e4ef0f4a612b4c31cb3f8d394de80c"26669005artificial-intelligence-identifies-cardiovascular-and-neurological-risks-from-polysomnography-9250.png178967158648291912026-09-17T18:59:46.546Z"ed8a61ecbe0d1a6f68cdbe5ebebe0152"1793279artificial-intelligence-identifies-previously-unrecognized-liver-malignancies-in-routine-practice-improving-diagnostic-safety-206.png178828226959816212026-09-01T17:04:29.682Z"3e4a13d69043aff96a77988f496098d4"2610756artificial-intelligence-in-acute-myeloid-leukemia:-diagnostic,-prognostic,-and-therapeutic-perspectives.png175691887551747312025-09-03T17:01:15.560Z"4ffb693d4b7155540f6a3a89ee9b4220"2107417artificial-intelligence-in-clinical-practice:-ethical-dilemmas-and-responsible-implementation-pathways.jpeg175287348657320912025-07-18T21:18:06.637Z"64d830098a704d94570d23419bb63d40"1180741artificial-intelligence-in-computational-pathology-aacr-2026-dedicates-a-plenary-to-the-revolution-reaching-the-diagnostic-bench-.jpeg177686470527770712026-04-22T13:31:45.346Z"6b21025ef65644e09c73c157aa3b4a2f"383875artificial-intelligence-in-computational-pathology-aacr-2026-dedicates-a-plenary-to-the-revolution-reaching-the-diagnostic-bench-1945.177687444096639512026-04-22T16:14:01.028Z"6b21025ef65644e09c73c157aa3b4a2f"383875artificial-intelligence-in-computational-pathology-aacr-2026-dedicates-a-plenary-to-the-revolution-reaching-the-diagnostic-bench-438.177686557681788012026-04-22T13:46:16.887Z"6b21025ef65644e09c73c157aa3b4a2f"383875artificial-intelligence-in-computational-pathology-aacr-2026-dedicates-a-plenary-to-the-revolution-reaching-the-diagnostic-bench-77.177687626727602112026-04-22T16:44:27.338Z"6b21025ef65644e09c73c157aa3b4a2f"383875artificial-intelligence-may-enable-costeffective-population-screening-for-glaucoma.png175934343479646612025-10-01T18:30:34.904Z"b800bd1b34f28801b5c71f8117e1c476"2214076artificial-intelligence-transforms-prediction-of-diabetes-complications.jpeg175822000604716112025-09-18T18:26:46.090Z"96153a626408f75f292e1859d3f7bffa"332501artificial-pancreas-system-lowers-hba1c-by-08-and-increases-time-in-range-by-23-in-adults-with-t1d.jpeg175832243703929012025-09-19T22:53:57.100Z"148e392415d45c16222aa2b3acc686de"315749ascent-04:-nova-combinação-com-sacituzumab-govitecana-melhora-slp-no-tnbc-metastático-pd-l1-positivo.png175226313624028712025-07-11T19:45:36.300Z"3f970aea2866956e1ccae04e8a946ae4"1353236asco-2024.png177783547809876512026-05-03T19:11:18.243Z"cfa3d1497e48f0c8029097232b1ce73b"1774535asco-2025-hero-banner-mobile.png177393093292773812026-03-19T14:35:32.962Z"cfa3d1497e48f0c8029097232b1ce73b"1774535asco-2025-hero-banner.png177393092960410912026-03-19T14:35:29.642Z"7a3fc90c40655acf10b9b47241fe6b5a"696740asco-2026--atualização-de-30-meses-do-estudo-c-post-em-carcinoma-espinocelular-cutâneo-de-alto-risco.jpeg178163884089757512026-06-16T19:40:41.044Z"516dcb4633fb88be72a3c657b92da335"1012804asco-2026--atualização-de-30-meses-do-estudo-c-post-em-carcinoma-espinocelular-cutâneo-de-alto-risco.png178163934144619112026-06-16T19:49:01.593Z"4684364e67ba9473768b3caa1a8192c2"407875asco-2026--possvel-reduzir-a-extenso-da-cirurgia-axilar-no-cncer-de-mama-inicial-sem-comprometer-os-resultados-oncolgicos--2990.png178095010401433112026-06-08T20:21:44.079Z"b6bddd7553c3cdc035eb5e487a240b49"1914782asco-2026-30-month-update-on-the-c-post-study-in-high-risk-cutaneous-squamous-cell-carcinoma-8910.png178163936404959712026-06-16T19:49:24.119Z"1804326b64a5f8122072aea79e9c4408"4190535asco-2026-adc-anti-sez6-abbv-706-demonstra-taxa-de-resposta-de-82-como-monoterapia-em-segunda-linha-do-cppc-e-viabilidade-de-combinao-com-anti-pd-1-5721.png178028061293754212026-06-01T02:23:33.018Z"5f61fbff307e3c0a0ddd68b516596b21"2046811asco-2026-adcs-imunoterapia-perioperatria-e-novas-combinaes-devem-marcar-a-programao-deste-ano-2580.jpeg178006269614335212026-05-29T13:51:36.212Z"8e5fc98fa797005a97cdca5ca7f3d453"290833asco-2026-adcs-imunoterapia-perioperatria-e-novas-combinaes-devem-marcar-a-programao-deste-ano-2607.jpeg178006262416620612026-05-29T13:50:24.241Z"8e5fc98fa797005a97cdca5ca7f3d453"290833asco-2026-adcs-imunoterapia-perioperatria-e-novas-combinaes-devem-marcar-a-programao-deste-ano-7659.jpeg178005997776439212026-05-29T13:06:17.830Z"000a2abea0a8c30440568003f0080fa5"294418asco-2026-adcs-imunoterapia-perioperatria-e-novas-combinaes-devem-marcar-a-programao-deste-ano-7950.jpeg178008316100546412026-05-29T19:32:41.069Z"8e5fc98fa797005a97cdca5ca7f3d453"290833asco-2026-adjuvant-giredestrant-reduces-risk-of-metastatic-disease-by-42-in-premenopausal-and-24-in-postmenopausal-patients-with-erher2-breast-cancer-34.178026684189597112026-05-31T22:34:01.956Z"f33657a86a7832436889e154405f8c1e"1463540asco-2026-adjuvant-ribociclib-benefits-all-pam50-molecular-subtypes-in-the-largest-genomic-dataset-from-any-adjuvant-cdk46i-trial-5592.178026747413913512026-05-31T22:44:34.200Z"1c3c1aa008f1ac92457cb7834009a326"1670117asco-2026-aibased-pathology-classifier-predicts-enzalutamide-benefit-in-metastatic-hormonesensitive-prostate-cancer-validation-in-enzamet-9367.178026795068893012026-05-31T22:52:30.750Z"67e26ed33578fd8445dfdf4a1edbcde9"1568242asco-2026-anlise-final-do-keynote-522-confirma-benefcio-sustentado-de-pembrolizumabe-perioperatrio-no-tnbc-inicial-de-alto-risco-4329.png178028398056414012026-06-01T03:19:40.625Z"e6704d167f7d45e5c227946f3f4b729d"2113932asco-2026-antisez6-adc-abbv706-demonstrates-82-response-rate-as-monotherapy-in-secondline-sclc-and-feasibility-of-combination-with-antipd1-7254.178028063528486712026-06-01T02:23:55.368Z"affd71068f4a24d24147333e739963d7"2047261asco-2026-aracog-mostra-menor-declnio-cognitivo-com-darolutamida-versus-enzalutamida-em-cncer-de-prstata-avanado-9168.png178028465265036512026-06-01T03:30:52.720Z"f9abec02b582fcf24911843329d9bb56"2176812asco-2026-aracog-muestra-menor-deterioro-cognitivo-con-darolutamida-frente-a-enzalutamida-en-cncer-de-prstata-avanzado.png178028462322393412026-06-01T03:30:23.295Z"a88a0fe00a72222e39e6c8b568f354b3"2179012asco-2026-aracog-shows-less-cognitive-decline-with-darolutamide-versus-enzalutamide-in-advanced-prostate-cancer-5907.178028463750984312026-06-01T03:30:37.578Z"4ca30fdc675e05864c1ace229996765d"2178267asco-2026-assista-agora-aos-destaques-do-dia-1-do-asco-expert-daily-695.png178024839553437512026-05-31T17:26:35.596Z"bd6bb4bf3c1a462f0d5fdbe606ab56dc"2036546asco-2026-assista-agora-aos-destaques-do-dia-2-do-asco-expert-daily-5485.png178027198990297612026-05-31T23:59:49.972Z"2d87414ee39303fa4ea5e44abe2ba0cb"398123asco-2026-assista-agora-aos-destaques-do-dia-3-do-asco-expert-daily-9231.png178035787322239812026-06-01T23:51:13.285Z"0803709f5549187fa4391701d03f283d"3297492asco-2026-atualizao-de-30-meses-do-estudo-c-post-em-carcinoma-espinocelular-cutneo-de-alto-risco-4813.jpeg178162705682173712026-06-16T16:24:16.893Z"1a02ba7594afd4f6e7764576c6dbf807"457154asco-2026-avanos-relevantes-em-tumores-gastrointestinais-apontam-novos-caminhos-teraputicos-9062.jpeg178292791115025312026-07-01T17:45:11.212Z"c64cfa7bb435323df27dbce5cc85e4a5"228499asco-2026-clasificador-de-ia-en-patologa-predice-beneficio-de-enzalutamida-en-cncer-de-prstata-metastsico-hormonosensible--validacin-en-enzamet.png178026794405508912026-05-31T22:52:24.118Z"478eea9cb68ec334c6d8459a6d38e294"1568920asco-2026-classificador-de-ia-em-patologia-prediz-benefcio-de-enzalutamida-no-cncer-de-prstata-metasttico-hormnio-sensvel--validao-no-enzamet-42.png178026796063356412026-05-31T22:52:40.693Z"1d2eec33e100be9109585d5b44e79d62"1569250asco-2026-como-otimizar-os-resultados-da-cirrgia-no-cncer-de-prstata-localizado-de-alto-risco-5805.jpeg178187211652947012026-06-19T12:28:36.603Z"291c1c549ad84539fed50c669de9fff5"493183asco-2026-como-otimizar-os-resultados-no-cncer-de-prstata-localizado-de-alto-risco-3417.jpeg178154588647509912026-06-15T17:51:26.540Z"c4485fc763f93ee1be5bf34a2de3ac7e"491072asco-2026-daraxonrasib-demonstrates-unprecedented-survival-improvements-in-previously-treated-metastatic-pancreatic-adenocarcinoma-3282.178027239511934912026-06-01T00:06:35.183Z"c597c9d3e92d6aa486d448bb167c10ef"1640010asco-2026-daraxonrasib-demuestra-mejoras-sin-precedentes-en-la-supervivencia-de-pacientes-con-adenocarcinoma-pancretico-metastsico-previamente-tratado.png178027239041363012026-06-01T00:06:30.476Z"49b7e4c620a1d43a87c4c7e9bf20232a"1640518asco-2026-daraxonrasibe-demonstra-melhora-sem-precedentes-na-sobrevida-de-pacientes-com-adenocarcinoma-pancretico-metasttico-previamente-tratado-7920.png178027239924215112026-06-01T00:06:39.303Z"9cd62369f0ead5f4030a5aef89fbc9cd"1641007asco-2026-datopotamab-deruxtecan-demonstra-benefcio-consistente-em-sg-slp-pfs2-e-tempo-at-terapia-subsequente-no-cncer-de-mama-triplo-negativo-em-primeira-linha-5467.png178016304499027512026-05-30T17:44:05.060Z"8957eadce256b57b7af731af36326ecc"1601397asco-2026-datopotamab-deruxtecan-demonstrates-consistent-benefit-in-os-pfs-pfs2-and-time-to-subsequent-therapy-in-firstline-triplenegative-breast-cancer-1628.png178016304174172612026-05-30T17:44:01.802Z"8e1511f4bc935e4efc9625190c55d30f"1600964asco-2026-datopotamab-deruxtecan-demuestra-beneficio-consistente-en-sg-slp-slp2-y-tiempo-hasta-terapia-subsecuente-en-primera-lnea-del-cncer-de-mama-triple-negativo.png178016303843832712026-05-30T17:43:58.501Z"c8caad70be431fd1ed298753e4786101"1601884asco-2026-desescalonamento-guiado-por-fmiso-pet-mantm-desfechos-de-longo-prazo-em-cncer-de-orofaringe-hpv-associado-4172.png178028187491118912026-06-01T02:44:34.971Z"ce32cbd8a955c7ff1b054d4700692aa9"1641213asco-2026-el-adc-anti-sez6-abbv-706-demuestra-tasa-de-respuesta-del-82-como-monoterapia-en-segunda-lnea-del-cpcp-y-viabilidad-de-combinacin-con-anti-pd-1.png178028065802566312026-06-01T02:24:18.087Z"074d8148f90aab4e7ba9def111fba47b"2047534asco-2026-el-anlisis-final-de-keynote-522-confirma-beneficio-sostenido-con-pembrolizumab-perioperatorio-en-tnbc-temprano-de-alto-riesgo.png178028396812886012026-06-01T03:19:28.193Z"e02fc1bdd212f0d185c2782391790750"2121365asco-2026-el-estudio-galaxy-demuestra-que-la-cintica-de-ctdna-en-dos-timepoints-identifica-pacientes-con-cncer-colorrectal-que-se-benefician-de-quimioterapia-adyuvante.png178009495778040212026-05-29T22:49:17.851Z"ec4b7ddc587de4a162b235a7faac4a63"1493997asco-2026-el-estudio-optima-valida-la-omisin-de-quimioterapia-adyuvante-en-cncer-de-mama-reher2--con-alto-compromiso-ganglionar.png178009409613403312026-05-29T22:34:56.196Z"5412f1d9e3ced0aac942179b609f0e75"1537070asco-2026-el-modelo-de-cura-del-estudio-ruby-sugiere-que-el-54-de-las-pacientes-con-cncer-de-endometrio-dmmrmsi-h-avanzado-tratadas-con-dostarlimab--quimioterapia-pueden-estar-curadas.png178016159282934012026-05-30T17:19:52.891Z"8fc8bc92187da641b7bad26385766cb1"1438216asco-2026-enfortumab-vedotin--pembrolizumab-sostiene-supervivencia-global-mediana-de-336-meses-en-carcinoma-urotelial-avanzado-tras-35-aos-de-seguimiento.png178009592899830612026-05-29T23:05:29.061Z"1c5ef46f2d6729cc0474b50767b96017"1501738asco-2026-enfortumab-vedotin--pembrolizumab-sustenta-sobrevida-global-mediana-de-336-meses-no-carcinoma-urotelial-avanado-aps-35-anos-de-seguimento-9215.png178009522843760912026-05-29T22:53:48.509Z"95eca5c31c9be211268d3c26dacfc75b"1499787asco-2026-enfortumab-vedotin-plus-pembrolizumab-sustains-median-overall-survival-of-336-months-in-advanced-urothelial-carcinoma-at-35year-followup-9176.png178009585637965612026-05-29T23:04:16.442Z"7203167235697a4a26963cb3bb7b19c2"1501535asco-2026-estudo-galaxy-demonstra-que-cintica-de-ctdna-em-dois-timepoints-identifica-pacientes-com-cncer-colorretal-que-se-beneficiam-de-quimioterapia-adjuvante-2559.png178009482066375412026-05-29T22:47:00.733Z"8a9637d9439a81a0b24c8efae9df5d98"1494806asco-2026-estudo-optima-valida-omisso-de-quimioterapia-adjuvante-em-pacientes-com-cncer-de-mama-erher2--e-alto-comprometimento-nodal-3829.png178009387722400512026-05-29T22:31:17.286Z"473f248dc8de88ec08d3d2e9deee8b62"1537387asco-2026-fmiso-petguided-deescalation-maintains-longterm-outcomes-in-hpvassociated-oropharyngeal-cancer-1928.png178028186747084212026-06-01T02:44:27.531Z"954bee35ccc21f90a06c5bc765cd9bcd"1640342asco-2026-galaxy-study-demonstrates-that-twotimepoint-ctdna-kinetics-identifies-colorectal-cancer-patients-who-benefit-from-adjuvant-chemotherapy-7321.png178009490381820512026-05-29T22:48:23.888Z"1e3d8b6cdedc74bea86524cf765d1866"1493963asco-2026-giredestrant-adjuvante-reduz-risco-de-doena-metasttica-em-42-nas-pr-menopusicas-e-24-nas-ps-menopusicas-com-cncer-de-mama-erher2--5397.png178026682483168912026-05-31T22:33:44.893Z"831fad432bfe459a7966a52f113952d7"1464517asco-2026-giredestrant-adyuvante-reduce-el-riesgo-de-enfermedad-metastsica-en-42-en-premenopusicas-y-24-en-posmenopusicas-con-cncer-de-mama-reher2-.png178026686021513012026-05-31T22:34:20.275Z"5a2f10d2caef43728b81581c45ad1f3c"1463848asco-2026-hero-banner-3430.png177877942687576012026-05-14T17:23:46.939Z"0344d5a72e2389fc5a4537f7bafa5f5a"265725asco-2026-hero-banner-en.png177430151675801412026-03-23T21:31:56.871Z"d4a22bbdf966799117ed94a823477c18"249602asco-2026-hero-banner-mobile-3430.png177877942926918812026-05-14T17:23:49.330Z"72d1ef6cf80c9b86710e0a7d78aee24b"72725asco-2026-hero-banner-mobile-en.png177430151510482012026-03-23T21:31:55.270Z"a88b8a0941eaa057d993887a7e7b24b4"401696asco-2026-highlights-1-dia-4344.png177938968830904812026-05-21T18:54:48.377Z"49dd3f6462eb785c85e412c1e1a0db61"1273994asco-2026-highlights-1-dia-5493.png177938651048803312026-05-21T18:01:50.550Z"6e0cac609979c3eae61d9a1388bf5b18"474597asco-2026-highlights-2-dia-4949.png178008512314190512026-05-29T20:05:23.213Z"ea951e1d0bb416b413c2b78c7e5fd1df"8184993asco-2026-highlights-2-dia-5238.png177938667464397912026-05-21T18:04:34.709Z"e4e4d4ab90e764b4efdf8fc6319f3186"1751695asco-2026-highlights-2-dia-8359.png178008904481968712026-05-29T21:10:44.882Z"8f6ad13192d2e2624e07cf4bde832716"1890267asco-2026-highlights-2-dia-8985.png177938958353554912026-05-21T18:53:03.603Z"35afbacf3ea1d87830687a2318f6e809"1111367asco-2026-highlights-2-dia-9012.png178008532863898612026-05-29T20:08:48.703Z"ea951e1d0bb416b413c2b78c7e5fd1df"8184993asco-2026-highlights-3-dia-3152.png177938683393110912026-05-21T18:07:13.994Z"cc3ca9170b0acec16e9120665b5cb0d4"1449151asco-2026-highlights-3-dia-5834.jpeg178035670344948812026-06-01T23:31:43.512Z"c98c3349a51ac4de7c8cc3f3a1f3e499"199946asco-2026-highlights-3-dia-8521.png177938956112828512026-05-21T18:52:41.196Z"42fe3629b5840d77c09354ab8d3fcdc8"1368817asco-2026-highlights-4-dia-1021.png177938954027491712026-05-21T18:52:20.343Z"ccbd2310153ed07e33f03d705b106544"1823527asco-2026-highlights-4-dia-3142.jpeg178035745791825212026-06-01T23:44:17.980Z"d58183739b3a74cb73660de0df05c8dd"211932asco-2026-highlights-4-dia-6310.png177938696418111712026-05-21T18:09:24.251Z"85c8f763191cf2370a84e4ec17fbbb0d"1713623asco-2026-highlights-5-dia-3831.png177938951515667512026-05-21T18:51:55.225Z"fea13e18719806206b5052e46d34c7d6"1551988asco-2026-highlights-5-dia-7032.png178040757254646512026-06-02T13:39:32.609Z"b26dd00497d18fb6a24cd74781ea9d9d"1901094asco-2026-highlights-5-dia-7378.png177938710587016912026-05-21T18:11:45.940Z"cb474d3ca915c90c0b15aa4d826b790f"1581048asco-2026-imforte-sugere-ganho-em-sobrevida-ajustada-por-qualidade-com-lurbinectedina--atezolizumabe-na-manuteno-de-es-sclc-794.png178041304864364812026-06-02T15:10:48.707Z"a8eb58cddca4c8096230b50ce6d57015"2129646asco-2026-imforte-suggests-qualityadjusted-survival-gain-with-lurbinectedin-plus-atezolizumab-maintenance-in-essclc-9373.178041317365569712026-06-02T15:12:53.726Z"9430d3c2a751c2c248d98fbf3727c1d4"2130206asco-2026-imforte-sugiere-ganancia-en-supervivencia-ajustada-por-calidad-con-lurbinectedina-ms-atezolizumab-en-mantenimiento-de-es-sclc.png178041324524102812026-06-02T15:14:05.301Z"b7aec8ed867c43510e926421952b947f"2129846asco-2026-intraperitoneal-m701-prolongs-puncturefree-survival-in-malignant-ascites-from-advanced-epithelial-tumors-2098.png178028162986641012026-06-01T02:40:29.929Z"84ec5efb5b1dab34b93f6653d26080eb"1809634asco-2026-keynote-942-mantiene-el-beneficio-de-intismeran-autogene-ms-pembrolizumab-tras-5-aos-en-melanoma-resecado-de-alto-riesgo.png178041025112253412026-06-02T14:24:11.192Z"b54b312ac8be637f97dd580a4c1346f7"1880447asco-2026-keynote-942-mantm-benefcio-de-intismeran-autogene--pembrolizumabe-aps-5-anos-em-melanoma-ressecado-de-alto-risco-8605.png178032098148789812026-06-01T13:36:21.551Z"4b64ae99f2512c38608428e65e242acc"1880531asco-2026-keynote522-final-analysis-confirms-sustained-benefit-with-perioperative-pembrolizumab-in-highrisk-early-tnbc-2551.178028397585913512026-06-01T03:19:35.921Z"a8de949bc6b5c474bca82bac80ab5c63"2120706asco-2026-keynote942-maintains-benefit-with-intismeran-autogene-plus-pembrolizumab-after-5-years-in-highrisk-resected-melanoma-5123.178040998119421012026-06-02T14:19:41.264Z"d77e1f8a7f5e8e4a9c59a830846d4a0e"1879717asco-2026-la-desescalada-guiada-por-fmiso-pet-mantiene-desenlaces-a-largo-plazo-en-cncer-de-orofaringe-asociado-a-hpv.png178028186035539612026-06-01T02:44:20.419Z"d48d566e22ef5c79791ac33f850afc88"1640794asco-2026-lorlatinib-maintains-unreached-median-progressionfree-survival-after-7year-followup-in-alkpositive-nsclc-3867.png178009433077536512026-05-29T22:38:50.846Z"7ca17964180e802bbd2834010975ad81"1344852asco-2026-lorlatinib-mantiene-supervivencia-libre-de-progresin-mediana-no-alcanzada-tras-7-aos-de-seguimiento-en-cpcnp-alk-positivo.png178009443973105912026-05-29T22:40:39.801Z"1150ebef54404c3028ab8650a90f3de6"1344766asco-2026-lorlatinib-mantm-sobrevida-livre-de-progresso-mediana-no-alcanada-aps-7-anos-de-seguimento-no-cpnpc-alk-positivo-1528.png178009455720479612026-05-29T22:42:37.266Z"2bf474b9180be052a163335799a430fb"1345909asco-2026-m701-intraperitoneal-prolonga-la-supervivencia-libre-de-puncin-en-ascitis-maligna-asociada-a-tumores-epiteliales-avanzados.png178028162162320612026-06-01T02:40:21.687Z"f3916d4f482a6e32cd62db5d31230bf2"1810721asco-2026-m701-intraperitoneal-prolonga-sobrevida-livre-de-puno-em-ascite-maligna-associada-a-tumores-epiteliais-avanados-2759.png178028163738934012026-06-01T02:40:37.450Z"2e9d34ff6546775ec8d092866bac6190"1809618asco-2026-medicina-de-preciso-amplia-fronteiras-no-tratamento-do-cncer-de-pulmo--2983.png178096735410342612026-06-09T01:09:14.177Z"e1d6f553e3ba75d98402dcba338add84"2244213asco-2026-medicina-de-preciso-amplia-fronteiras-no-tratamento-do-cncer-de-pulmo--775.png178096795079679412026-06-09T01:19:10.860Z"e1d6f553e3ba75d98402dcba338add84"2244213asco-2026-medicina-de-preciso-amplia-fronteiras-no-tratamento-do-cncer-de-pulmo--9940.png178096717580468012026-06-09T01:06:15.870Z"e1d6f553e3ba75d98402dcba338add84"2244213asco-2026-modelo-de-cura-do-estudo-ruby-sugere-que-54-das-pacientes-com-cncer-de-endomtrio-dmmrmsi-h-avanado-tratadas-com-dostarlimab--quimioterapia-podem-estar-curadas-7784.png178016158041798412026-05-30T17:19:40.482Z"309ccc8a1e2b70dc04dd1ff11f8f5ec2"1436087asco-2026-novos-dados-ampliam-as-perspectivas-da-imunoterapia-em-tumores-slidos-9033.png178096931655204912026-06-09T01:41:56.616Z"877521a0688260c3c2dbff855b599c66"2396982asco-2026-novos-dados-refinam-estratgias-teraputicas-ao-longo-da-jornada-do-cncer-de-mama-5174.png178154720178449112026-06-15T18:13:21.853Z"6d3959e4b441b9a331937cda89dbb117"1885168asco-2026-nrg-gy018-mostra-benefcio-sustentado-de-sobrevida-com-pembrolizumabe--quimioterapia-no-cncer-de-endomtrio-avanado-ou-recorrente-504.png178028093464952812026-06-01T02:28:54.712Z"0f771c18e00d4d3054caa37518075552"2461989asco-2026-nrg-gy018-muestra-beneficio-sostenido-en-supervivencia-con-pembrolizumab-ms-quimioterapia-en-cncer-de-endometrio-avanzado-o-recurrente.png178028101203723112026-06-01T02:30:12.098Z"9a78a4e0168e388c23e72ea88c0a4874"2470362asco-2026-nrggy018-shows-sustained-survival-benefit-with-pembrolizumab-plus-chemotherapy-in-advanced-or-recurrent-endometrial-cancer-6788.png178028093726689712026-06-01T02:28:57.327Z"9c0137a35b82457260fbcf2afffab1c0"2470221asco-2026-optima-apoia-quimioterapia-guiada-por-prosigna-pam50-no-cncer-de-mama-inicial-erher2-de-alto-risco-clnico-7950.png178028338760577212026-06-01T03:09:47.674Z"34645d86a4418ee25ef5a69e8b06c5a4"1980953asco-2026-optima-respalda-decisiones-de-quimioterapia-guiadas-por-prosigna-pam50-en-cncer-de-mama-temprano-erher2-de-alto-riesgo-clnico.png178028335502972812026-06-01T03:09:15.101Z"c2e068a0a99a902aa83dc83af7246632"1981197asco-2026-optima-supports-prosignapam50guided-chemotherapy-decisions-in-high-clinical-risk-erher2-early-breast-cancer-8653.178028337006249112026-06-01T03:09:30.132Z"962ddd50079b232799929ef415baf66b"1981815asco-2026-optima-trial-validates-omission-of-adjuvant-chemotherapy-in-erher2-breast-cancer-with-high-nodal-burden-2426.png178009402060250912026-05-29T22:33:40.666Z"8fd99352fba26fb0a2577dbb719723af"1535886asco-2026-optitrop-lung05-mostra-ganho-de-pfs-com-sacituzumabe-tirumotecana--pembrolizumabe-em-nsclc-avanado-pd-l1-positivo-8770.png178028131268203112026-06-01T02:35:12.743Z"91981f8f998e6704e05bbcc3614b5160"2050335asco-2026-optitrop-lung05-muestra-beneficio-en-pfs-con-sacituzumab-tirumotecn-ms-pembrolizumab-en-nsclc-avanzado-pd-l1-positivo.png178028130137744712026-06-01T02:35:01.440Z"29495d7089f40b4a3a99b686c6e49ad4"2056314asco-2026-optitroplung05-shows-pfs-benefit-with-sacituzumab-tirumotecan-plus-pembrolizumab-in-pdl1positive-advanced-nsclc-3135.png178028130514100912026-06-01T02:35:05.203Z"4066f35869adeb3511dd76bada5131a5"2055555asco-2026-perspectivas-da-dra-mariana-scaranti-sobre-os-principais-avanos-em-cncer-de-endomtrio-e-ovrio-148.jpeg178292779763602612026-07-01T17:43:17.697Z"36b6ee296998b2dc8c952595d3ae3016"297766asco-2026-perspectivas-da-dra-mariana-scaranti-sobre-os-principais-avanos-em-cncer-de-endomtrio-e-ovrio-3358.jpeg178292762022238712026-07-01T17:40:20.286Z"36b6ee296998b2dc8c952595d3ae3016"297766asco-2026-perspectivas-da-dra-mariana-scaranti-sobre-os-principais-avanos-em-cncer-de-endomtrio-e-ovrio-5820.jpeg178292756829081312026-07-01T17:39:28.362Z"36b6ee296998b2dc8c952595d3ae3016"297766asco-2026-prepec-sugere-melhor-qualidade-de-vida-com-reconstruo-mamria-pr-peitoral-aps-mastectomia-3835.png178028434893604512026-06-01T03:25:48.996Z"2743b4127fbc1404aa4382d513d36a66"2195854asco-2026-prepec-suggests-better-quality-of-life-with-prepectoral-breast-reconstruction-after-mastectomy-5296.178028430845849412026-06-01T03:25:08.522Z"2486361401187246cc7ef023093df43b"2196133asco-2026-prepec-sugiere-mejor-calidad-de-vida-con-reconstruccin-mamaria-prepectoral-tras-mastectoma.png178028430460776712026-06-01T03:25:04.672Z"53ed977db28dc7d96a02882717c3a109"2197434asco-2026-principais-resultados-do-estudo-origami-4-em-carcinoma-escamoso-de-cabea-e-pescoo-7797.png178553176021653412026-07-31T21:02:40.288Z"cc862f425c9ffb815a7e8a1d1c809425"2907635asco-2026-principais-resultados-do-estudo-proteus-em-cncer-de-prstata-localizado-de-alto-risco-8319.png178042308038411312026-06-02T17:58:00.454Z"e2ee50ce469eadf0d30ddc4001b94fb4"2508376asco-2026-reduse-demonstra-no-inferioridade-de-denosumabe-a-cada-12-semanas-aps-fase-de-carregamento-em-metstases-sseas-510.png178041246847548412026-06-02T15:01:08.536Z"546eda63ad00e5a86dae9fa9299a87a8"2023120asco-2026-reduse-demonstrates-noninferiority-of-12weekly-denosumab-after-loading-in-patients-with-bone-metastases-9772.178041236262099512026-06-02T14:59:22.691Z"9511dc28b34e9c650914749ef84d2cb5"2022267asco-2026-reduse-demuestra-no-inferioridad-de-denosumab-cada-12-semanas-tras-fase-de-carga-en-metstasis-seas.png178041245653700212026-06-02T15:00:56.602Z"cfcf102009feed6ccef797e1bbe1143a"2022581asco-2026-ribociclib-adyuvante-beneficia-a-todos-los-subtipos-moleculares-pam50-en-el-mayor-dataset-genmico-de-cualquier-ensayo-con-cdk46i-adyuvante.png178026748848327712026-05-31T22:44:48.544Z"aa71ddaf3b10c52a75f7f8cc714cbbeb"1670670asco-2026-ribociclibe-adjuvante-beneficia-todos-os-subtipos-moleculares-pam50-no-maior-dataset-genmico-de-qualquer-ensaio-com-cdk46i-adjuvante-3509.png178026745628244712026-05-31T22:44:16.343Z"165220bd66ff79dd15c60b7896823855"1672249asco-2026-ruby-trial-cure-model-suggests-54-of-patients-with-dmmrmsih-advanced-endometrial-cancer-treated-with-dostarlimab-plus-chemotherapy-may-be-cured-5643.png178016158707739612026-05-30T17:19:47.137Z"111423daf0469f5d88e21f8eb4d2c687"1438215asco-2026-sacituzumab-govitecan-maintains-sustained-pfs2-benefit-in-firstline-metastatic-triplenegative-breast-cancer-despite-82-crossover-6919.png178016274652944212026-05-30T17:39:06.591Z"d3e1b46f952a718114439a9cded648ee"1441705asco-2026-sacituzumab-govitecan-mantiene-beneficio-sostenido-de-slp2-en-primera-lnea-del-cncer-de-mama-triple-negativo-metastsico-a-pesar-del-82-de-crossover.png178016274257359212026-05-30T17:39:02.636Z"00bea4d02f77c698a9ce8238c6b9cd60"1442501asco-2026-sacituzumab-govitecan-mantm-benefcio-sustentado-de-pfs2-em-primeira-linha-do-cncer-de-mama-triplo-negativo-metasttico-apesar-de-82-de-crossover-9135.png178016275421729012026-05-30T17:39:14.278Z"18d31a29e25458192cba58cb1b008a01"1442839asco-2026-tarlatamab-demonstra-eficcia-intracraniana-superior--quimioterapia-no-cncer-de-pulmo-de-pequenas-clulas-em-segunda-linha-6243.png178016334562682012026-05-30T17:49:05.698Z"c2da2ac496da3e871bf8e2f4c8841725"1722006asco-2026-tarlatamab-demonstrates-superior-intracranial-efficacy-versus-chemotherapy-in-secondline-small-cell-lung-cancer-8397.png178016334877687612026-05-30T17:49:08.846Z"264b20ee1a19a5e8c3859a5073c4aa15"1728481asco-2026-tarlatamab-demuestra-eficacia-intracraneal-superior-a-la-quimioterapia-en-segunda-lnea-del-cncer-de-pulmn-de-clulas-pequeas.png178016335221726312026-05-30T17:49:12.287Z"6d075608ef65c70b68228cbae597681d"1729356asco-2026-trastuzumab-rezetecan-prolongs-pfs-in-chemotherapyrefractory-her2positive-advanced-colorectal-cancer-5731.178041050965161612026-06-02T14:28:29.720Z"cbac661f318e7fe6199ced87477b3ce4"2083565asco-2026-trastuzumab-rezetecn-prolonga-la-pfs-en-cncer-colorrectal-avanzado-her2-positivo-refractario-a-quimioterapia.png178041056037682612026-06-02T14:29:20.446Z"7e719c4448d40d5237599da86453a8db"2083990asco-2026-trastuzumabe-rezetecana-prolonga-pfs-em-cncer-colorretal-avanado-her2-positivo-refratrio--quimioterapia-8369.png178041041034111412026-06-02T14:26:50.410Z"198edbf33558f51d41dca1745e5eff42"2083980asco-gi-2026-atualizaes-relevantes-em-cncer-colorretal-.jpeg176850920892463712026-01-15T20:33:28.963Z"6ccf60ce5221c61ac0f821c49867443d"324490asco-gi-2026-hero-banner-mobile.png177444982752014912026-03-25T14:43:47.560Z"a88b8a0941eaa057d993887a7e7b24b4"401696asco-gi-2026-hero-banner.png177444982530701412026-03-25T14:43:45.410Z"d4a22bbdf966799117ed94a823477c18"249602asco-gi-2026-novas-estratgias-em-imagem-e-qualidade-de-vida-no-cncer-colorretal.jpeg176850502586313412026-01-15T19:23:45.902Z"384b0f88c388f56c259c59bcce5b4aa6"218824asco-gi-2026-novidades-no-tratamento-do-hepatocarcinoma.jpeg176823991155643612026-01-12T17:45:11.671Z"7fa4d44c56d26da737cf39bc758e4e40"214894asco-gi-2026.png176487534643567112025-12-04T19:09:06.481Z"9f1ecc878782d74e1e87b914b85de247"512357asco-gi-principais-destaques-em-cncer-gstrico-e-esofagogstrico.jpeg176823932748571312026-01-12T17:35:27.617Z"68d8daf30396c8acd6d0056a60aad3f4"200992asco-gu---cncer-de-bexiga-ctdna-utdna-no-niagara-e-resultados-finais-do-t-dxd-no-destiny-pantumor02.png177229406788060912026-02-28T15:54:28.019Z"66f99ddec440c662ba92027955577f51"1129545asco-gu---cncer-de-bexiga-ctdnautdna-no-niagara-e-resultados-finais-do-t-dxd-no-destiny-pantumor02.png177187989207546912026-02-23T20:51:32.144Z"eb38bf21acaa4c00824382add30b844e"1127239asco-gu---câncer-de-bexiga--ctdna-utdna-no-niagara-e-resultados-finais-do-t-dxd-no-destiny-pantumor02-1.png177222568705124312026-02-27T20:54:47.131Z"af8353a80e60d29d9a7c3c0334c88fca"26123asco-gu---câncer-de-bexiga--ctdna-utdna-no-niagara-e-resultados-finais-do-t-dxd-no-destiny-pantumor02-2.png177222568820929912026-02-27T20:54:48.284Z"45810c9a41ed17c04dcd280ec0d4adc6"20117asco-gu---prstata-intensificao-precoce-psma-pet-e-combinaes-biomarcadas--os-estudos-que-merecem-ateno.png177229374706321612026-02-28T15:49:07.187Z"cd79e92b5cd53c722edba45f3199eb4f"1381054asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-1.png177222673861373212026-02-27T21:12:18.683Z"771c117683f26a7b95d3f15b454f7187"73210asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-2.png177222673970531712026-02-27T21:12:19.773Z"39bc09f9c3b3826ffeb7ff577eb8a1e7"60799asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-3.png177222674086212712026-02-27T21:12:20.930Z"23d3827b3215f72864da9506d58650ea"62860asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-4.png177222674226757212026-02-27T21:12:22.334Z"cb9e91a72c437930bc75cc6e6ce27f82"61512asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-5.png177222674348559112026-02-27T21:12:23.554Z"9794758655c3bc39e0efd9d288c48610"53882asco-gu---próstata--intensificação-precoce,-psma-pet-e-combinações-biomarcadas-—-os-estudos-que-merecem-atenção-6.png177222674505347012026-02-27T21:12:25.122Z"8268d94af8bb74808b5d4975dc4bbcf9"51128asco-gu--cncer-de-bexiga-ctdnautdna-no-niagara-e-resultados-finais-do-t-dxd-no-destiny-pantumor02.png177187983793609212026-02-23T20:50:38.006Z"eb38bf21acaa4c00824382add30b844e"1127239asco-gu-2026-combinao-de-enzalutamida-e-rdio-223-demonstra-ganho-em-sobrevida-global-no-mcrpc-e-novas-estratgias-com-t-cell-engagers-avanam-no-cenrio-refratrio-.jpeg177228398208392712026-02-28T13:06:22.152Z"081515397b136e6de6120bbb3d3fe533"229364asco-gu-2026-keynote-b15-ev-304-demonstra-benefcio-expressivo-com-enfortumabe-vedotina--pembrolizumabe-no-cncer-de-bexiga-msculo-invasivo-.jpeg177230908432579712026-02-28T20:04:44.425Z"a4db51720cbac6ac45cfe888e73b94fb"361526asco-gu-2026-keynote-b15-ev-304-demuestra-beneficio-significativo-con-enfortumab-vedotina--pembrolizumab-en-cncer-de-vejiga-msculo-invasivo-.jpeg177231043825940212026-02-28T20:27:18.328Z"21f5ee5f606738c77110d0884d169974"352002asco-gu-2026-keynote-b15ev-304-demuestra-beneficio-significativo-con-enfortumab-vedotina--pembrolizumab-en-cncer-de-vejiga-msculo-invasivo-.jpeg177231029829454012026-02-28T20:24:58.377Z"21f5ee5f606738c77110d0884d169974"352002asco-gu-2026-la-combinacin-de-enzalutamida-y-radio-223-demuestra-beneficio-en-supervivencia-global-en-mcrpc-y-nuevas-estrategias-con-t-cell-engagers-avanzan-en-el-escenario-refractario-.jpeg177228746085441412026-02-28T14:04:20.924Z"4fa75381392a58ad5f35becafe70c2d2"216779asco-gu-2026-litespark-011-e-litespark-022-reforam-o-papel-do-belzutifano-no-cncer-renal-avanado-e-adjuvante-.jpeg177231107254998512026-02-28T20:37:52.619Z"ac660e131e552b04a420bbdd92349259"287142asco-gu-2026-litespark-011-e-litespark-022-reforam-o-papel-do-belzutifano-no-cncer-renal-avanado-e-adjuvante-.png177317284689137712026-03-10T20:00:46.922Z"e1ec89024b8e08a3d24adebf3df1d77f"1359718asco-gu-2026-litespark-011-y-litespark-022-consolidan-el-papel-de-belzutifan-en-el-carcinoma-renal-avanzado-y-en-el-escenario-adyuvante-.jpeg177231078414064312026-02-28T20:33:04.209Z"e2756df84017a459c735b1e65d19f41d"268646asco-gu-2026.png176858202083355312026-01-16T16:47:00.939Z"a620fac6bb202f6bd0a76bd882ea2493"359172ascogu-2026.png176858168138718612026-01-16T16:41:21.442Z"a620fac6bb202f6bd0a76bd882ea2493"359172asco®-2025:-highlights-tumores-gastrointestinais-.png174957364533030712025-06-10T16:40:45.382Z"60d0446d985584a42b6967b5a26695dd"544509asco®-2025:-highlights-tumores-gastrointestinais.png174956396152308212025-06-10T13:59:21.577Z"60d0446d985584a42b6967b5a26695dd"544509asco®-2025:-o-que-muda-na-prática-clínica-em-tumores-gênito-urinários-.png174964604186637312025-06-11T12:47:21.980Z"60d0446d985584a42b6967b5a26695dd"544509asdasd.jpeg176892708326107722026-01-20T16:38:03.305Z"80ff27ab1b16c0579737ec338e72ad70"583626ash-2025---atualizao-do-cartitude-4-revela-benefcio-sustentado-do-cilta-cel-no-mieloma-mltiplo-.jpeg176514247416445912025-12-07T21:21:14.271Z"004d1bc7b97e5d00f9b6686d336f5fbb"243143ash-2025---manejo-dos-eventos-oculares-com-belantamabe-mafodotina-no-mieloma-mltiplo-refratrio-dados-dos-estudos-dreamm-7-e-dreamm-8.png176531777491360512025-12-09T22:02:54.964Z"612603113fee619f87a688619753139d"1276891ash-2025--bruin-trial-expande-evidncias-para-pirtobrutinibe-em-macroglobulinemia-de-waldenstrm.jpeg176513807222114512025-12-07T20:07:52.267Z"0408be9c790eff893cd4e9a44861abaf"205819ash-2025--cartitude-4-mostra-benefcio-duradouro-de-ciltacabtagene-autoleucel-em-mieloma-mltiplo-recidivadorefratrio-de-risco-padro-.jpeg176514091737032112025-12-07T20:55:17.478Z"d513e74e0bb45c688d23493a503d5491"252076ash-2025--cartitude-4-mostra-benefcio-duradouro-de-ciltacabtagene-autoleucel-em-mieloma-mltiplo-recidivadorefratrio-de-risco-padro.jpeg176514002997617012025-12-07T20:40:30.115Z"d513e74e0bb45c688d23493a503d5491"252076ash-2025--epcoritamabe-demonstra-respostas-profundas-e-altas-taxas-de-negativao-de-drm-em-primeira-linha-para-dlbcl-fragilizado-.jpeg176514128282513712025-12-07T21:01:22.873Z"8c57af3d03f5ec2227308178c53adbbe"316918ash-2025--regime-zana-atinge-897-de-resposta-completa-com-zanubrutinibe--rituximabe--metotrexato-em-altas-doses-no-pcnsl-recm-diagnosticado-.jpeg176514316190658512025-12-07T21:32:41.953Z"74cd0fcea1af0031ceb4c5dcd3e66356"325104ash-2025-advances-in-myelodysplastic-syndromes-mds.png176614354733245112025-12-19T11:25:47.372Z"0fc2372d34c0d48b1c07834c145923b0"964635ash-2025-avano-no-tratamento-de-primeira-linha-da-llc---resultados-do-estudo-cll17.jpeg176538650902544012025-12-10T17:08:29.073Z"83616462fc0162b45a2c5c7e25a28426"576033ash-2025-avanos-em-terapias-com-car-t-e-anticorpos-biespecficos-.png176608881462003712025-12-18T20:13:34.659Z"b0b5551df2b4f40c7a711e018f8ffc6c"1941946ash-2025-avanos-na-imunoterapia-redefinem-o-tratamento-do-mieloma-mltiplo-recidivado-refratrio-.png176608837647240712025-12-18T20:06:16.511Z"0f6890158bb928bc6a50c1d248c5d0d7"1105056ash-2025-avanos-no-controle-da-hematopoiese-clonal-com-inibidores-de-cdk4-6.jpeg176547366379648412025-12-11T17:21:03.843Z"02796b2247aeb1ec6e04aac43d71f240"221687ash-2025-benefcios-do-uso-precoce-do-cilta-cel-no-tratamento-do-mieloma-mltiplo.png176528691711989912025-12-09T13:28:37.169Z"83be49d968abda379585d4a3df2010c2"1558789ash-2025-breakthroughs-in-aml-treatment-and-transplant.png176623505911224112025-12-20T12:50:59.152Z"b0285d72b11728eabd299d3f0eaf7cad"364593ash-2025-breakthroughs-in-cll-treatment-targeted-therapies.png176609631017063012025-12-18T22:18:30.215Z"bfe1baec3edfb278ff93d55db8fc6185"2436170ash-2025-breakthroughs-in-lymphoma-fixedduration-therapy.png176614277391128412025-12-19T11:12:53.951Z"f3e5b4a6027a3242d3709985caf085de"2159772ash-2025-cartitude-4-mostra-sobrevida-livre-de-progresso-superior-a-80-em-30-meses-para-pacientes-com-risco-citogentico-convencional-tratados-com-cilta-cel-.jpeg177196267957090612026-02-24T19:51:19.695Z"92081a2d0c1acd36d9429abfa34b02d0"242242ash-2025-durao-do-tratamento-com-hipometilantes-impacta-resultados-em-smd-de-baixo-risco.jpeg176547813810318612025-12-11T18:35:38.160Z"790169d129d965a66e5d382ba3f6cba2"271169ash-2025-estudo-cristallo---evidncias-de-longo-prazo-reforam-a-eficcia-do-venetoclax--obinutuzumabe-no-tratamento-da-llc-.jpeg176530883784475412025-12-09T19:33:57.886Z"4e055c3934d95ecf56159c275ba12a97"267556ash-2025-evidncias-de-mundo-real-sobre-o-uso-de-elranatamabe-no-tratamento-do-mieloma-mltiplo.jpeg177222711786769812026-02-27T21:18:37.937Z"01b02a226c2217f9898fc4f044b73d06"418337ash-2025-gmmg-hd7-demonstra-que-isa-vrd-mantm-a-qualidade-de-vida-global-do-paciente-com-melhora-significativa-na-fadiga-dos-pacientes-com-mieloma-mltiplo-recm-diagnosticado-elegvel-ao-transplante-.jpeg176539620605529712025-12-10T19:50:06.100Z"e753eb15f3407fd1cb26364c3a8d1832"231455ash-2025-immunotherapy-in-relapsed-multiple-myeloma.png176623699672169612025-12-20T13:23:16.766Z"040dfa902d413961888f4d006bf7f7dc"1080421ash-2025-new-frontiers-in-cart-and-bispecific-antibodies.png176623292404916212025-12-20T12:15:24.096Z"bca1bd22aa95978c5fac857028f768ea"1965719ash-2025-nova-definio-de-alto-risco-funcional--apresentada-por-dr-luciano-costa-no-ash.jpeg177193892872117812026-02-24T13:15:28.784Z"56170be6fcf71981e2d776a38f45892b"250556ash-2025-novos-dados-consolidam-avanos-em-terapias-dirigidas-drm-e-inibidores-de-btk-no-tratamento-da-leucemia-linfoctica-crnica.png176597468869199812025-12-17T12:31:28.731Z"4ae299d194a7b29cae71cd4a19de8f14"2364002ash-2025-novos-estudos-redefinem-o-tratamento-da-leucemia-mieloide-aguda-da-induo-ao-transplante-.png176608859698982412025-12-18T20:09:57.029Z"4d24e576faf3660bfac4aaae82a1c4f1"390424ash-2025-pirtobrutinibe-versus-ibrutinibe-no-tratamento-da-llc-resultados-do-estudo-bruin-cll-313.jpeg176530920691421112025-12-09T19:40:06.964Z"e9885c8625dae41f2bf31910ddf32a47"263472ash-2025-terapia-car-t-mostra-resultados-promissores-na-amiloidose-al.png176530118104913112025-12-09T17:26:21.096Z"aa45ceeb918b18cf6d28bcdef71cfdcb"1783634ash-2025.png176303900207235512025-11-13T13:03:22.112Z"6dc16edfa21094f05df045fdf214db55"212508ash-highlights-2025-o-que-muda-na-prtica-clnica-do-hematologista mdulo-leucemia.png177222005817378912026-02-27T19:20:58.302Z"2b631c86dd7a8ff483e6c6a0ac5c6dcf"1234992ash-highlights-2025-o-que-muda-na-prtica-clnica-do-hematologista mdulo-linfoma.png177221676684866912026-02-27T18:26:06.974Z"3a6c848bc15761dc858a15c9a14ab446"142611ash-highlights-2025-o-que-muda-na-prtica-clnica-do-hematologista mdulo-mieloma-mltiplo.png177221671365799812026-02-27T18:25:13.797Z"673f9a8342e8def000630940aeae42a0"848834aspirin-alone-noninferior-to-rivaroxaban-then-aspirin-for-vte-prevention-after-hip-or-knee-arthroplasty-epcat-iii-shows-7713.png178457644543636512026-07-20T19:40:45.505Z"8fa798903cbd20ee45f07d6a3431e945"1594101aspirina-isolada--no-inferior--rivaroxabana-seguida-de-aspirina-na-preveno-de-tev-aps-artroplastia-de-quadril-ou-joelho-mostra-epcat-iii-7660.png178457624184478012026-07-20T19:37:21.911Z"172d0d32e76340dfe21f7d4f1b56fd80"1593678assinaturas-genmicas-novas-evidncias-podem-redefinir-a-indicao-de-quimioterapia-em-mulheres-jovens-4176.png178273193218003612026-06-29T11:18:52.243Z"3ed62b560adf52fad3d85aa5186799f3"2093131assinaturas-genmicas-novas-evidncias-podem-redefinir-a-indicao-de-quimioterapia-em-mulheres-jovens-51.png178273196439485912026-06-29T11:19:24.458Z"3ed62b560adf52fad3d85aa5186799f3"2093131assinaturas-genmicas-novas-evidncias-podem-redefinir-a-indicao-de-quimioterapia-em-mulheres-jovens-6521.png178273190194420512026-06-29T11:18:22.009Z"3ed62b560adf52fad3d85aa5186799f3"2093131assist-banner.png178759262600481312026-08-24T17:30:26.120Z"1bb50ee9a5a6de31169c3969237487b8"570599assist-hero-banner-4684.png177446291466224112026-03-25T18:21:54.701Z"5e8bf66c92362ffcd8d7110379692d01"20399assist-hero-banner-7694.webp177625845579976512026-04-15T13:07:35.868Z"b6052a951b292688f5e28bfb04e23d17"152262assist-hero-banner-mobile-4684.png177446291607867812026-03-25T18:21:56.122Z"8ef92e04d8a2d7b145b5d068ce35bb65"273618assist-hero-banner.png177317029844247212026-03-10T19:18:18.551Z"5e8bf66c92362ffcd8d7110379692d01"20399associao-de-tafasitamabe-e-lenalidomida-se-mostra-eficaz-e-segura-mesmo-em-pacientes-mais-idosos-com-linfoma-difuso-de-grandes-clulas-b-recidivado-refratrio--4016.png178152290210119512026-06-15T11:28:22.172Z"b3d930db2720c5eb06450637488b674a"2024822astrazeneca-hero-banner-mobile.png177393182862825012026-03-19T14:50:28.745Z"0935acaf673f2600ae64c0171b24432f"1851328astrazeneca-hero-banner.png177394131409223112026-03-19T17:28:34.205Z"0935acaf673f2600ae64c0171b24432f"1851328astrazeneca-no-asco-2026-hero-banner-6482.png178007580239405312026-05-29T17:30:02.464Z"2809b16671105cf2a17e00a69afe305c"565466astrazeneca-no-asco-2026-hero-banner-7480.png178007580239383312026-05-29T17:30:02.464Z"2809b16671105cf2a17e00a69afe305c"565466astrazeneca-no-asco-2026-hero-banner-mobile-7480.png178007580827521212026-05-29T17:30:08.418Z"2809b16671105cf2a17e00a69afe305c"565466astrum-006-estratgia-perioperatria-com-serplulimabe-prolonga-a-sobrevida-livre-de-eventos-no-cncer-gstrico-ou-da-juno-gastroesofgica-ressecvel-e-pd-l1-positivo-9148.png178223960148897412026-06-23T18:33:21.554Z"fd890e735e3bf65e12adce32c9d28d03"1992961astrum006-perioperative-serplulimab-strategy-imp-7258.png178231293782124412026-06-24T14:55:37.885Z"85e357c68dd60ccf1873958d20b7101c"1992520astrum006-perioperative-serplulimab-strategy-improves-eventfree-survival-in-resectable-pdl1positive-gastric-or-gej-cancer-1188.png178223962131142612026-06-23T18:33:41.374Z"85e357c68dd60ccf1873958d20b7101c"1992520atezolizumab-aumenta-la-respuesta-patolgica-pero-no-mejora-la-supervivencia-libre-de-eventos-en-el-cncer-de-mama-triple-negativo-precoz.png178915063458487212026-09-11T18:17:14.649Z"bd2570fd7de62b3f37646186ffd89f02"1985562atezolizumab-increases-pathological-response-but-does-not-improve-eventfree-survival-in-early-triplenegative-breast-cancer-3516.png178915079402825212026-09-11T18:19:54.099Z"62507838923425f5566e412789e77b3a"1982757atezolizumabe-aumenta-a-resposta-patolgica-mas-no-melhora-a-sobrevida-livre-de-eventos-no-cncer-de-mama-triplo-negativo-precoce--1715.png178915110153066612026-09-11T18:25:01.593Z"973bfc8f60557e598487067142d9c7f5"1988860atezolizumabe-aumenta-a-resposta-patolgica-mas-no-melhora-a-sobrevida-livre-de-eventos-no-cncer-de-mama-triplo-negativo-precoce--3977.png178915109145906312026-09-11T18:24:51.521Z"973bfc8f60557e598487067142d9c7f5"1988860atezolizumabe-aumenta-a-resposta-patolgica-mas-no-melhora-a-sobrevida-livre-de-eventos-no-cncer-de-mama-triplo-negativo-precoce--6244.png178915093779445812026-09-11T18:22:17.858Z"973bfc8f60557e598487067142d9c7f5"1988860atezolizumabe-aumenta-a-resposta-patolgica-mas-no-melhora-a-sobrevida-livre-de-eventos-no-cncer-de-mama-triplo-negativo-precoce--9487.png178915104008823812026-09-11T18:24:00.151Z"973bfc8f60557e598487067142d9c7f5"1988860atezolizumabe-aumenta-a-resposta-patolgica-mas-no-melhora-a-sobrevida-livre-de-eventos-no-cncer-de-mama-triplo-negativo-precoce--9883.png178915106303232112026-09-11T18:24:23.101Z"973bfc8f60557e598487067142d9c7f5"1988860atg-ptcy-ou-os-dois-juntos-em-dose-baixa-o-primeiro-fase-iii-randomizado-em-haplo-tcth-com-clulas-perifricas-traz-respostas-1635.jpeg177574272139089212026-04-09T13:52:01.450Z"0e897b1bcb703cf805028e39a4245d49"755003atirando-para-tudo-que--lado-entendendo-os-ajustes-de-multiplicidade--5092.png177644922235069212026-04-17T18:07:02.420Z"2a120b6a47a78ed21952684f8dea06c1"1461021atogepant-reduces-menstrual-migraine-days-in-a-phase-3-study-9959.png179087820458759912026-10-01T18:10:04.650Z"cd4d081ecfcbd829175261dd1eff900a"1618976atogepanto-reduce-los-das-de-migraa-menstrual-en-un-estudio-de-fase-3.png179087840795581112026-10-01T18:13:28.021Z"57c8d474472336eb9f87752db6f9d1cf"1620193atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-1921.png179087786341329212026-10-01T18:04:23.483Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-2505.png179087786944619612026-10-01T18:04:29.579Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-2892.png179087786942309612026-10-01T18:04:29.494Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-3266.png179087786500237012026-10-01T18:04:25.075Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-4087.png179087786934081612026-10-01T18:04:29.410Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-4905.png179087786849915112026-10-01T18:04:28.571Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-5144.png179087786418990312026-10-01T18:04:24.260Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-5340.png179087786524975212026-10-01T18:04:25.319Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-6500.png179087786467846112026-10-01T18:04:24.748Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-6775.png179087786326198412026-10-01T18:04:23.334Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-6944.png179087786920534212026-10-01T18:04:29.343Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-6961.png179087786637861012026-10-01T18:04:26.448Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-8189.png179087786348055712026-10-01T18:04:23.550Z"369e8369fc61a40cdb605810887c104a"1621707atogepanto-reduz-dias-de-enxaqueca-menstrual-em-estudo-de-fase-3-881.png179087786923832012026-10-01T18:04:29.308Z"369e8369fc61a40cdb605810887c104a"1621707atrial-fibrillation-in-latin-america--the-lacross-registry-exposes-a-regional-gap-in-patient-management-1.png178534436380461012026-07-29T16:59:23.867Z"1441a7909c087dbbe7ce59881b9df8b9"15atrial-fibrillation-in-latin-america-the-lacross-registry-exposes-a-regional-gap-in-patient-management-5240.png178534436659700412026-07-29T16:59:26.660Z"a6ea6781ae65ca7cfb14a56db24324b1"1865603ats:-a-bússola-da-saúde-baseada-em-evidências-.jpeg174827783777340012025-05-26T16:43:57.815Z"df29e324add035c7a051c97e5e7d67aa"1938657attain-1-orforglipron-oral-diario-logr-prdida-de-peso-dependiente-de-dosis-a-72-semanas-en-adultos-con-obesidad-sin-diabetes.png176857931364886112026-01-16T16:01:53.694Z"039db7cc41c0865a32e52258ef518ca7"6946204attain1-oncedaily-oral-orforglipron-produced-dosedependent-weight-loss-over-72-weeks-in-adults-with-obesity-without-diabetes.png176857893454790312026-01-16T15:55:34.595Z"039db7cc41c0865a32e52258ef518ca7"6946204atualizaes-do-asco-gi-2026-avanos-no-tratamento-perioperatrio-do-cncer-hepatobiliar-e-pancretico.jpeg176799215052911412026-01-09T20:55:50.568Z"234e42fc2e2df2d553404fbd66801997"220100atualizaes-do-sabcs-2025-avanos-e-desafios-dos-adcs-anti-trop-2-no-cncer-de-mama.png176615188872317312025-12-19T13:44:48.761Z"7a34726007ea87464e5d46fc5f603237"609325atualizaes-em-cncer-de-mama-metasttico-e-rastreamento-baseado-em-risco-no-sabcs-2025.png176608180687476112025-12-18T18:16:46.914Z"7b11116b5f7343d4231425dcfd53cafa"1736667atualizaes-no-tratamento-dos-gliomas-idh-mutados-o-caso-de-uma-paciente-jovem-8478.jpeg177972982538602512026-05-25T17:23:45.456Z"59e7199933851c170e80750048c8acff"391514atualizao-da-informao-de-prescrio-do-fremanezumabe-destaca-aspectos-de-segurana-6440.png179097660024758112026-10-02T21:30:00.317Z"d92e7309eaaa9397371dbcb4ac8562e9"1903755atualizao-de-5-anos-do-destiny-breast03-confirma-benefcio-durvel-do-t-dxd-no-cncer-de-mama-her2-metasttico.png177323204205598812026-03-11T12:27:22.173Z"dd750cf5c660b4283a05ac6927cdebec"1263513atualizao-do-estudo-bruin-no-ash-2025-destaca-segurana-e-eficcia-do-pirtobrutinibe-no-linfoma-de-clulas-do-manto-9077.jpeg177852283599622212026-05-11T18:07:16.068Z"a789b1b1e39651868da7451a22fa15fa"595297atualizao-do-serena-6-refora-benefcio-do-switch-precoce-guiado-por-ctdna-em-cncer-de-mama-hr-positivo-her2-negativo.png176582839785972012025-12-15T19:53:17.920Z"5901d7b11c98b44a3cefe0399a1510e2"2235011aua-2027-coverage.png178223878951361312026-06-23T18:19:49.579Z"dc8aaf9c63b3c1f7a500afef27564af6"2473145aumento-de-casos-vsr-em-idosos-alerta-para-prevenção-e-desafia-especialistas.png175312318188203112025-07-21T18:39:41.925Z"7ab3d99e7b40e2bc646f56ee2a6255bb"1639069aumolertinibe-em-alta-dose-mostra-benefício-de-sobrevida-prolongada-em-pacientes-com-câncer-de-pulmão-com-metástases-cerebrais-e-variante-egfr:-resultados-do-estudo-achieve.png175138287355951012025-07-01T15:14:33.617Z"8179799851854fb90f084708b55e5d53"675382aumolertinibe-reduz-risco-de-recorrncia-em-cncer-de-pulmo-egfr-mutado-nos-estgios-ii-a-iiib-aponta-estudo-de-fase-3.jpeg177091803339932712026-02-12T17:40:33.438Z"908fbb6ac09150ba3500113d89100770"2850620autocoleta-aumenta-participação-no-rastreamento-do-câncer-do-colo-do-útero.jpeg175163916250347712025-07-04T14:26:02.563Z"175eca22dd286dafd2ed35592deab061"9152869autoimmune-mechanisms-may-underlie-a-subset-of-gestational-diabetes-and-predict-future-type-1-diabetes.png176070482663722812025-10-17T12:40:26.676Z"b89082be82239533f31ea97b17e5dfdc"2463593automated-aid-systems-improve-time-in-range-and-reduce-training-burden-in-pediatric-t1d.jpeg175832230995902412025-09-19T22:51:50.006Z"ebc25c5b71ff9654ccf709b118dd7b6e"268628avaliao-cardiovascular-em-atletas-masters-principais-recomendaes-das-atuais-diretrizes-553.png177757308690842012026-04-30T18:18:06.981Z"dc8aaf9c63b3c1f7a500afef27564af6"2473145avaliao-da-eficcia-e-segurana-do-hrs-5965-em-pacientes-com-hemoglobinria-paroxstica-noturna-hpn-no-tratados-previamente-com-inibidores-do-complemento.jpeg177248115070072712026-03-02T19:52:30.762Z"f88005ec421f7e4a614e2fd12c395cd9"1524731avaliao-geritrica-pode-aprimorar-a-seleo-de-pacientes-para-terapias-intensivas-no-mieloma-mltiplo-9293.png179019196455343312026-09-23T19:32:44.640Z"0a8b07c60f3b02ad37d2bbb2dfae9132"1299021avanos-e-desafios-no-tratamento-dos-linfomas-destaques-do-hemo-2025.png176357496447737312025-11-19T17:56:04.517Z"e1395607c5e81b030649021ba10dd419"2087408avanos-em-dislipidemia-e-novas-terapias-para-reduo-de-triglicerdeos-e-ldl.png176288083772346312025-11-11T17:07:17.765Z"da5e7baaa260270dc369ab31d6383d1c"1776027avanos-em-sndromes-mielodisplsicas-e-leucemias-agudas-novas-perspectivas-no-hemo-2025.png176244515491613512025-11-06T16:05:54.961Z"46a3d6683dfd5aadc1b77b27b2b0f80f"1168034avanos-no-cncer-de-pulmo-novos-alvos-teraputicos-imunoterapia-e-estratgias-emergentes-em-destaque-no-elcc-2094.jpeg177559181660547812026-04-07T19:56:56.643Z"8a9688df82f364d3fe91431cfdfd4e52"251520avanos-no-cncer-de-vias-biliares-dados-de-vida-real-e-terapias-alvo-em-destaque-no-asco-gi.jpeg176833507807999812026-01-13T20:11:18.121Z"2c437793d6a9ed6c9c56c3db22bafb48"238297avanos-no-tratamento-clnico-e-cirrgico-da-endometriose-uma-abordagem-integrada-3620.jpeg178757808662089312026-08-24T13:28:06.683Z"f7378556c4f65d0b6f77383f7abcbf87"31926avanos-no-tratamento-da-llc-resultados-do-estudo-flair-no-ash-2025.jpeg176530848377309312025-12-09T19:28:03.819Z"2f6b43386a04e6220c549328cfc0a78a"356273avanos-no-tratamento-da-mielofibrose-primria-novas-perspectivas-com-momelotinibe-ojjaara.png176314328450054512025-11-14T18:01:24.612Z"2e506b0cc89b5a89a80c99972257cd6e"2823481avanos-no-tratamento-de-cncer-de-pulmo-egfr-mutado-estudo-paloma-2-refora-benefcios-da-administrao-subcutnea-de-amivantamabe.jpeg175770605142826812025-09-12T19:40:51.529Z"4cb603ff97ad34eff894135b3cf26e35"334738avanos-no-tratamento-do-linfoma-difuso-de-grandes-clulas-b-evidncias-do-estudo-polarix-e-aplicao-clnica.png176236897711011512025-11-05T18:56:17.263Z"61c7d98d1e61f3acd6da763b3fe63e57"1870538avanos-no-tratamento-do-linfoma-do-manto-resultados-do-estudo-triangle.jpeg176132853885986712025-10-24T17:55:38.920Z"ae938fc2a57736407a269c7c96659cf2"262141avanos-no-tratamento-do-mieloma-mltiplo-o-papel-da-lenalidomida.jpeg176122766479436612025-10-23T13:54:24.962Z"178693c311deb0d7a3166ec5fdc6e2c8"302500avanos-no-tratamento-e-preveno-do-cncer-colorretal-destaques-no-asco-gi-2026.jpeg176822908651178012026-01-12T14:44:46.613Z"37a8955e9ae7ec8195fbc2b1cbc02d3e"141617avanos-no-tratamento-perioperatrio-do-cncer-de-esfago-e-estmago-perspectivas-dos-estudos-apresentados-no-asco-gi-2026.jpeg176791330468744012026-01-08T23:01:44.751Z"36fc24293e8f9af87e3f8235fb48e190"284807avanço-no-tratamento-da-atrofia-muscular-espinhal-(ame):-sus-incorpora-nova-terapia-gênica-para-bebês-com-ame-tipo-1.jpeg174827905619046912025-05-26T17:04:16.235Z"23b24fd21fc50415cf673281623a09ca"825635avanço-no-tratamento:-sus-expande-uso-da-donepezila-para-alzheimer-em-estágio-grave-.jpeg174922905710405412025-06-06T16:57:37.148Z"69f48f0459041fa26d8c0b71fa40319e"7162199avanços-na-imunização:-vacina-contra-chikungunya-é-aprovada-no-brasil-.jpeg175009281194371112025-06-16T16:53:31.985Z"d6b8e03b06c6585e963cefcf66292428"12180180axicabtageno-ciloleucel-no-dlbcl-recidivado/refratário:-o-impacto-da-linha-de-tratamento-e-dos-biomarcadores-.png175148493368744512025-07-02T19:35:33.791Z"a3e8d3efadb231c72b84b08fc8a5c90c"1169640axsana-study-deescalating-axillary-surgery-in-breast-cancer.png176610250855043812025-12-19T00:01:48.588Z"3f406e343c36fd6f05ca60c716f6341a"1373996az---programa-faz-bem-hero-banner.png176608328617403112025-12-18T18:41:26.220Z"3869cb0a033f5232fdeef1c039f2b522"930201az---spotlight-hero-banner-2411.png178043251319718412026-06-02T20:35:13.261Z"2809b16671105cf2a17e00a69afe305c"565466az---spotlight-hero-banner-5097.png178043354295232612026-06-02T20:52:23.021Z"a761383138d8ada2c5b0b076dd17d85a"623329az---spotlight-hero-banner-6872.png178043344685790912026-06-02T20:50:46.928Z"a761383138d8ada2c5b0b076dd17d85a"623329az---spotlight-hero-banner-6873.png178043363484138712026-06-02T20:53:54.910Z"fcd5ec7e7ed7efd4cdfe4f630b7a0569"684767az---spotlight-hero-banner-7723.png178043346811861912026-06-02T20:51:08.179Z"a761383138d8ada2c5b0b076dd17d85a"623329az---spotlight-hero-banner-mobile-2411.png178043251519780212026-06-02T20:35:15.262Z"2809b16671105cf2a17e00a69afe305c"565466az-faz-bem-hero-banner.png176945140092265312026-01-26T18:16:40.969Z"c18161d83c52b65a6245414120d76a8c"1254121azur-1-dostarlimab-muestra-respuestas-completas-sostenidas-en-cncer-de-recto-localmente-avanzado-dmmrmsi-h.png179296345799708112026-10-25T21:24:18.062Z"de9d03979b54a64535d4d9ae9f434cd4"2256539azur-1-dostarlimabe-demonstra-respostas-completas-sustentadas-no-cncer-de-reto-localmente-avanado-dmmrmsi-h-9313.png179294263372577012026-10-25T15:37:13.800Z"f65adfe0843b82577d8a8085658322d6"2256154azur1-dostarlimab-shows-sustained-complete-responses-in-dmmrmsih-locally-advanced-rectal-cancer-5483.png179296618734317512026-10-25T22:09:47.408Z"03eecabcf3eb1706845a2da1f8a30eaf"2257648balancing-cure-and-cardiotoxicity-in-adult-hodgkin-lymphoma-2025-jacc-cardiooncology-review.png175934563076440112025-10-01T19:07:10.803Z"7b5781608d2fcdb324edb1e4a6e74e53"1669003banner-ash-01.png177222170933116812026-02-27T19:48:29.396Z"68e95d2fd01cbc0e08a8f58f95c88669"1210771banner-ash-02.png177222173873871422026-02-27T19:48:58.807Z"6730248e11f467823cfdade29929c47a"215247banner-ash-03.png177222173902416122026-02-27T19:48:59.091Z"d17aa912e2295b01fbe6e0586c65421e"1155310banner-hero---medicina---cardiologia-hero-banner.jpeg178846335318662512026-09-03T19:22:33.259Z"af4d32159ccf7dc0378c4e659b9f236b"14988banner-hero-espanhol-hero-banner.jpeg176822958627568812026-01-12T14:53:06.320Z"133ab0a3b4c821372ecd7735fb1e68e9"261044banner-hero-ingles-hero-banner-en.jpeg176822791671551012026-01-12T14:25:16.760Z"133ab0a3b4c821372ecd7735fb1e68e9"261044banner-teste-hero-banner.jpeg176772066109327412026-01-06T17:31:01.134Z"133ab0a3b4c821372ecd7735fb1e68e9"261044banner-teste-hero-banner.png176416000484050512025-11-26T12:26:44.985Z"64c6ab0e7e63c34eeb1ca48eb5b6a420"23464banner.jpg176910301567663822026-01-22T17:30:15.717Z"d658f0ab31b6db8b571e0d2723a2e03f"116580bap-brain-bevacizumab--pemetrexedplatino-mejora-el-control-intracraneal-en-nsclc-no-escamoso-con-metstasis-cerebrales-en-primera-lnea.png176883692399744112026-01-19T15:35:24.036Z"f79be54fab45f7780bfe0ff082530920"7949208bap-brain-bevacizumab-plus-pemetrexedplatinum-improves-intracranial-control-in-untreated-nonsquamous-nsclc-with-brain-metastases.png176883692794286012026-01-19T15:35:27.986Z"f79be54fab45f7780bfe0ff082530920"7949208baseline-lipi-identifies-a-poorprognosis-subgroup-in-pdl1lownegative-nsclc-treated-with-firstline-chemoimmunotherapy.png176883604168030112026-01-19T15:20:41.725Z"192b044a015852a8931ec90b51372013"6716035baxdrostat-promotes-a-significant-and-clinically-meaningful-reduction-in-blood-pressure-in-patients-with-resistant-hypertension.jpeg176279636018764712025-11-10T17:39:20.230Z"213a2b0ab86ab88e4ae59d3d1f1a7763"194509baxdrostat-promove-reduo-expressiva-e-clinicamente-significativa-da-presso-arterial-em-pacientes-com-hipertenso-resistente.jpeg176279479615018012025-11-10T17:13:16.199Z"73eb71fb23b664ee33fe9000b00df833"207474baxhtn-baxdrostat-lowers-systolic-bp-in-uncontrolledresistant-hypertension-at-12-weeks.png175923058111014912025-09-30T11:09:41.165Z"d52987be0ca3a5ccb6f195582e44b6ce"2193031before-memory-fails-latin-american-study-broadens-the-conversation-on-dementia-prevention-4230.png178604467010129612026-08-06T19:31:10.175Z"a2e63951be8ff6ae9617e160006efebf"2238471before-memory-fails-latin-american-study-broadens-the-conversation-on-dementia-prevention-6285.png178611328538153012026-08-07T14:34:45.453Z"a2e63951be8ff6ae9617e160006efebf"2238471belantamab-mafodotin-asociado-con-una-mayor-tasa-de-negatividad-sostenida-de-enfermedad-residual-medible-en-el-mieloma-mltiple.png179036061193004012026-09-25T18:23:32.000Z"27e4ff8ef125f034f8892672e3482bba"1470983belantamab-mafodotin-associated-with-a-higher-rate-of-sustained-measurable-residual-disease-negativity-in-multiple-myeloma-4774.png179036995292001412026-09-25T20:59:12.984Z"a31d13864cbb7b2ea56b6b5ecd34b7cd"796180belantamab-mafodotin-associated-with-a-higher-rate-of-sustained-measurable-residual-disease-negativity-in-multiple-myeloma-783.png179036028856387012026-09-25T18:18:08.637Z"9061db1091f7e6d3c3126baa2e0c9234"1471309belantamabe-mafodotina-associado-a-maior-taxa-de-negatividade-sustentada-de-doena-residual-mensurvel-no-mieloma-mltiplo-1267.png179036013973198312026-09-25T18:15:39.799Z"76146b926ec465a3860e979e7557a696"1471708belantamabe-mafodotina-associado-a-maior-taxa-de-negatividade-sustentada-de-doena-residual-mensurvel-no-mieloma-mltiplo-1627.png179036014182934612026-09-25T18:15:41.894Z"76146b926ec465a3860e979e7557a696"1471708belantamabe-mafodotina-em-combinao-com-vd-ou-pd--aprovado-no-brasil-e-amplia-opes-teraputicas-para-pacientes-com-mieloma-mltiplo-4463.jpeg177938094451736612026-05-21T16:29:04.587Z"0f3f5e4cc68f92f98e3ff757399067f2"190413belantamabe-mafodotina-nova-opo-teraputica-no-mieloma-mltiplo-no-brasil--1753.png177937503750046312026-05-21T14:50:37.577Z"6bc7e198b30b7b201ed896e80d7d71e9"1706159belantamabe-mafodotina-novo-avano-no-tratamento-do-mieloma-mltiplo-no-brasil.png176409894103395912025-11-25T19:29:01.071Z"d9c8fe050c08fdb051981aaffb9d6083"2558927belzutifan-en-feocromocitomaparaganglioma-avanzado-litespark-015-fase-2-informa-respuestas-duraderas.png176848970720461212026-01-15T15:08:27.244Z"aebef9640baa25a4f37f5a65a734a130"6349241belzutifan-in-advanced-pheochromocytomaparaganglioma-phase-2-litespark015-reports-durable-responses.png176848957628431312026-01-15T15:06:16.324Z"aebef9640baa25a4f37f5a65a734a130"6349241benefcio-de-sobrevida-com-osimertinibe-adjuvante-permanece-aps-oito-anos-no-adaura-9349.png178940858952007512026-09-14T17:56:29.583Z"6a5603cf758af566c8f4f04edf50707e"1644017benefit-48month-analysis-shows-numerically-higher-pfs-with-isatuximabvrd-in-newly-diagnosed-multiple-myeloma-2671.png179027487996781912026-09-24T18:34:40.031Z"c805aca4908a3fe015fc101c1b406df2"1027376benefit-anlise-em-48-meses-mostra-slp-numericamente-maior-com-isatuximabe-vrd-em-mieloma-mltiplo-recm-diagnosticado-4569.png179027407740815512026-09-24T18:21:17.473Z"bbe99710bf7bdbaf6153754bf72bfdeb"1017712benefit-el-anlisis-a-48-meses-muestra-una-slp-numricamente-mayor-con-isatuximab-vrd-en-mieloma-mltiple-de-nuevo-diagnstico.png179027509651624412026-09-24T18:38:16.648Z"dbbd778d05417285e15e59240bc49575"1026332benign-prostatic-hyperplasia-a-clinical-overview.jpeg175872471012025312025-09-24T14:38:30.170Z"4ce0cfbbd7eca038f13cb5e66118963b"474557betablocker-therapy-after-myocardial-infarction-in-patients-with-preserved-ejection-fraction.jpeg176303931620756412025-11-13T13:08:36.251Z"9da635914f57fe8cce5ad16fcb74a894"127136betablockers-after-myocardial-infarction-without-reduced-ejection-fraction-no-benefit-in-reboot-trial.png175880523338301512025-09-25T13:00:33.438Z"5e964a330e54b5fb4a78efe4f36a96b7"2613297betablockers-in-hfpef-prescription-should-consider-clinical-phenotype-and-comorbidities-2942.png177983896308690512026-05-26T23:42:43.155Z"1bba83c984dd071e663b79e68699a320"1805692betabloqueadores-na-icfep-prescrio-deve-considerar-fentipo-clnico-e-comorbidades-5807.png177983892277735012026-05-26T23:42:02.845Z"9afe6672612186d4b3a664175cd4801b"1804709bevacizumab-plus-erlotinib-shows-significant-activity-in-hereditary-and-sporadic-papillary-renal-cell-carcinoma.jpeg175137089247324512025-07-01T11:54:52.531Z"5d54c0199a39c373a75c6c975ddb19a9"5507983bevacizumabe-e-erlotinibe-no-tratamento-do-carcinoma-papilar-renal-hereditário-e-esporádico.jpeg175138272063251812025-07-01T15:12:00.702Z"0d8e07daa46dd41bf9b006a22bf278db"2844482beyond-bmi-novel-adiposity-indices-predict-mortality-in-early-cardiovascularkidneymetabolic-syndrome.png176039128387336812025-10-13T21:34:43.921Z"ebffbe7ac44084e49adc48341a4bc134"2378755beyond-thrombosis:-pulmonary-hypertension-and-heart-failure-in-myeloproliferative-neoplasms.png175691826506161712025-09-03T16:51:05.105Z"0aa6a45419daa54cb1ed6b1a89c62852"1671044bidirectional-interaction-between-heart-failure-and-cancer:-new-insights-in-cardio-oncology..png175632867566472512025-08-27T21:04:35.703Z"e37a7be00d486d2ee619d1857c7cbab2"1824556big-data-analytics e-machine-learning-na-hematologia:-aplicações-transformadoras-e-principais-desafios.jpeg174923441426278512025-06-06T18:26:54.309Z"657ab3f1bb55537972ef285683c93da1"894776biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research-.jpeg177366575804812312026-03-16T12:55:58.079Z"dac3c02753253aae66d20b4e2fe27dcc"613599biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research-6033.jpeg177366613336113912026-03-16T13:02:13.407Z"dac3c02753253aae66d20b4e2fe27dcc"613599biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research-null.jpeg177366608062112612026-03-16T13:01:20.730Z"dac3c02753253aae66d20b4e2fe27dcc"613599biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research.jpeg177351699608710612026-03-14T19:36:36.129Z"1940fbe6ceb26745d29c085ac2db2411"950169biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research.null177342741737266712026-03-13T18:43:37.404Z"dac3c02753253aae66d20b4e2fe27dcc"613599biological-age-not-chronological-age-should-be-a-minimum-standard-in-agerelated-disease-research.png177066655785259612026-02-09T19:49:17.899Z"bbbfe0dcabb1b30e7eed065bc30f97ec"7611143biologics-lower-cardiovascular-risk-in-patients-with-psoriasis.jpeg175287308060335912025-07-18T21:11:20.667Z"01d3250098f5350809ed0f79854f176a"429127biológicos-reduzem-o-risco-cardiovascular-em-pacientes-com-psoríase.jpeg174923336026840612025-06-06T18:09:20.309Z"fb6ff2e0f49a641e755be3bddb01b697"1145925biomarcadores-sanguneos-podem-complementar-avaliao-de-doena-residual-mensurvel-no-mieloma-mltiplo-9368.png179027874785218612026-09-24T19:39:07.918Z"051f3421ef1a8531ed0a3e4ff15439dd"1214548biossensor-brasileiro-para-metstase-do-cncer-de-boca-avana-para-validao-multicntrica-com-quase-800-amostras-1329.png178221832163151912026-06-23T12:38:41.700Z"7804eec89fccddbd1c816f6aa606196c"8107965biossensor-brasileiro-para-metstase-do-cncer-de-boca-avana-para-validao-multicntrica-com-quase-800-amostras-5389.png178221834588007012026-06-23T12:39:05.948Z"7804eec89fccddbd1c816f6aa606196c"8107965bispecficos-t-cell-engagers-en-el-aacr-2026-nuevas-fronteras-en-linfomas-mieloma-y-la-era-del-doble-bloqueo-.jpeg177645356217157612026-04-17T19:19:22.240Z"37c84e582b2bfc6456b79144a51ecea5"246149bispecficos-t-cell-engagers-no-aacr-2026-novas-fronteiras-em-linfomas-mieloma-e-a-era-do-duplo-bloqueio--6710.jpeg177645664838838912026-04-17T20:10:48.458Z"ca2cc7d7d541914e008b08b97edef3e1"248713blablublué-1.png175468027956013912025-08-08T19:11:19.603Z"8dcd35410b4a9bc47248e51d9e734b23"1506404blinatumomab-en-la-lla-peditrica-cuando-menos-quimioterapia-significa-mayor-eficacia.png179157328273684712026-10-09T19:14:42.808Z"6756cbb8df9b2359f757045036155d4e"2158485blinatumomab-in-pediatric-all-when-less-chemotherapy-means-greater-efficacy-3547.png179157290984967612026-10-09T19:08:29.922Z"f0d875e2abfc299dcd256acef5dd0445"2154692blinatumomabe-na-lla-b-peditrica-recm-diagnosticada-da-adio--substituio-seletiva-da-quimioterapia-1146.png179097381464626712026-10-02T20:43:34.711Z"0537b0b07e5da02672bdb067778b4157"2025711blinatumomabe-na-lla-b-peditrica-recm-diagnosticada-da-adio--substituio-seletiva-da-quimioterapia-1147.png179097381751730612026-10-02T20:43:37.580Z"0537b0b07e5da02672bdb067778b4157"2025711blinatumomabe-na-lla-b-peditrica-recm-diagnosticada-da-adio--substituio-seletiva-da-quimioterapia-1728.png179097381648381612026-10-02T20:43:36.546Z"0537b0b07e5da02672bdb067778b4157"2025711blinatumomabe-na-lla-b-peditrica-recm-diagnosticada-da-adio--substituio-seletiva-da-quimioterapia-3673.png179097381790867712026-10-02T20:43:37.972Z"0537b0b07e5da02672bdb067778b4157"2025711blinatumomabe-na-lla-b-peditrica-recm-diagnosticada-da-adio--substituio-seletiva-da-quimioterapia-8383.png179097381769106112026-10-02T20:43:37.755Z"0537b0b07e5da02672bdb067778b4157"2025711blinatumomabe-na-lla-peditrica-quando-menos-quimioterapia-significa-maior-eficcia-3729.png179157209081076312026-10-09T18:54:50.880Z"438029e2626a201275b944d5275e9a41"2139861blood-cancer-new-insights-for-us-healthcare-pros.jpeg175803560395966612025-09-16T15:13:24.055Z"eb2a93172f704ae7ad1e572a86954feb"413134bloodbased-biomarkers-may-complement-measurable-residual-disease-assessment-in-multiple-myeloma-1144.png179027890099695212026-09-24T19:41:41.066Z"77f5f55649fea460f4d87099a2fdf372"1215083bloodbased-biomarkers-may-complement-measurable-residual-disease-assessment-in-multiple-myeloma-2014.png179027888044383812026-09-24T19:41:20.515Z"77f5f55649fea460f4d87099a2fdf372"1215083bloodbased-biomarkers-may-complement-measurable-residual-disease-assessment-in-multiple-myeloma-841.png179027905965993012026-09-24T19:44:19.730Z"77f5f55649fea460f4d87099a2fdf372"1215083bone-marrow-microenvironment-emerges-as-a-new-therapeutic-target-in-acute-myeloid-leukemia-5166.png178786159542613612026-08-27T20:13:15.493Z"5dae090cd8910ac9991ed6f9bfc8fc85"1400128bora-discutir-um-caso-cncer-gstrico-avanado-decises-teraputicas-na-prtica-clnica-244.jpeg179123218108753912026-10-05T20:29:41.163Z"481ec492a7da64a3b5fd279506bd649d"478635bora-discutir-um-caso-cncer-gstrico-avanado-decises-teraputicas-na-prtica-clnica-9965.jpeg179123218140957812026-10-05T20:29:41.480Z"481ec492a7da64a3b5fd279506bd649d"478635bora-discutir-um-caso-hero-banner-1512.webp178916793400514012026-09-11T23:05:34.075Z"6750900085af25ff61ec226064387e9c"36908bora-discutir-um-caso-hero-banner-mobile-1512.webp178916793546896512026-09-11T23:05:35.540Z"9fffcf7404e8f308e8306c13f1b6e47d"16896brasil-aprova-imunoterapia-subcutânea--atezolizumabe-sc-traz-inovação-na-experiência-do-tratamento-oncológico.png175370531587759312025-07-28T12:21:55.917Z"a4f92a99c092506249fc84879fad321e"2268157brasil-atinge-recorde-de-transplantes-e-anuncia-avanços-que-podem-impactar-práticas-clínicas-e-hospitalares.jpeg175071117717729212025-06-23T20:39:37.222Z"117cb2b83aef31edc851c37f6ebab3b7"18258764brasil-publica-protocolo-inédito-para-diagnóstico-e-tratamento-da-brucelose-humana-no-sus-.jpeg175009548829564612025-06-16T17:38:08.344Z"895b5a8961cfac90c70c74c252f21bd4"224152breaking-the-adenosine-barrier:-ent1-inhibition-as-a-novel-strategy-to-restore-anti-cancer-t-cell-function.png175371994685392812025-07-28T16:25:46.896Z"cbf614129ecc9b7a6cf4b1e8b9d59d2d"2885311breakwater-refora-importncia-da-terapia-alvo-no-cncer-colorretal-metasttico-com-mutao-braf-v600e-8654.png179123056157068712026-10-05T20:02:41.637Z"8fd65aa77a0d784e1c6fb6d04bd511a3"2504186breakwater:-nova-combinação-terapêutica-melhora-sobrevida-no-câncer-colorretal-metastático-com-mutação-braf-v600e.jpeg175136993856371212025-07-01T11:38:58.628Z"b8e43c6681a104e0934de18b380a88e1"10029502breakwater:-novel-therapeutic-combination-improves-survival-in-braf-v600e-mutant-metastatic-colorectal-cancer.jpeg175137074627191912025-07-01T11:52:26.313Z"b8e43c6681a104e0934de18b380a88e1"10029502brekiya-fda-approves-dihydroergotamine-autoinjector-for-the-acute-treatment-of-migraine-and-cluster-headache-1584.png179096991066056912026-10-02T19:38:30.725Z"34b72773c95677353238bd3a4cadbdee"1524665brekiya-fda-aprova-autoinjetor-de-di-hidroergotamina-para-tratamento-agudo-da-enxaqueca-e-cefaleia-em-salvas-9316.png179096968116313812026-10-02T19:34:41.229Z"1a807e5770aad5e253d56e5a86975d23"1524663brekiya-la-fda-aprueba-un-autoinyector-de-dihidroergotamina-para-el-tratamiento-agudo-de-la-migraa-y-la-cefalea-en-racimos.png179097024645961212026-10-02T19:44:06.525Z"e74bea4d9c800b81ac3fb8bd082c8a4b"1524891bridging-the-gap:-real-world-brca-testing-and-parp-inhibitor-utilization-in-metastatic-breast-cancer.png175371984326997912025-07-28T16:24:03.313Z"1bffc112c56849a80fbf7a0f360a309d"2603031broncoscopia-com-navegação-é-tão-eficaz-quanto-biópsia-transtorácica-no-diagnóstico-de-nódulos-pulmonares,-com-menos-complicações.jpeg175008419945080512025-06-16T14:29:59.493Z"51db2b9024ce2822d88db8e3c920f4d0"2784145bruin-cll-321-pirtobrutinibe-consolida-se-como-terapia-de-2-linha-na-llc-ps-inibidor-covalente-da-btk.jpeg176591533661419712025-12-16T20:02:16.653Z"0006eee42eec3e73da8c5bb3858f91fe"232619cabecalho_1.webp179207332079044512026-10-15T14:08:40.938Z"cebe732c6b8420aff242387a4dcf252b"6084cabecalho_2.webp179207332193024012026-10-15T14:08:42.077Z"9f9b63ef256ce89fd5baee6fdca5fe5c"5464cafena-e-corao-por-que-o-novo-statement-da-aha--leitura-obrigatria-no-contexto-atual-9488.png178708123725114412026-08-18T19:27:17.313Z"6fcd233d03f59194744748db93c9da3e"1288245cafena-y-corazn-por-qu-el-nuevo-documento-cientfico-de-la-aha-es-una-lectura-imprescindible-en-el-contexto-actual.png178708086783127312026-08-18T19:21:07.894Z"8810b3e76ccfecd3abf79507a0892f26"1289511cafeína-e-coração--por-que-o-novo-statement-da-aha-é-leitura-obrigatória-no-contexto-atual.-1.png178708123478793812026-08-18T19:27:14.853Z"a21b1854080629a238b6243440b5ddee"319306cafeína-y-corazón--por-qué-el-nuevo-documento-científico-de-la-aha-es-una-lectura-imprescindible-en-el-contexto-actual-1.png178708086568873512026-08-18T19:21:05.750Z"e59c0977b98e9f9527669661c6b7199e"764578caffeine-and-the-heart--why-the-new-aha-scientific-statement-is-essential-reading-today-1-162443.png178708108593807412026-08-18T19:24:46.002Z"1441a7909c087dbbe7ce59881b9df8b9"15caffeine-and-the-heart--why-the-new-aha-scientific-statement-is-essential-reading-today-1.png178708051409411712026-08-18T19:15:14.160Z"1441a7909c087dbbe7ce59881b9df8b9"15caffeine-and-the-heart-why-the-new-aha-scientific-statement-is-essential-reading-today-1255.png178708051857242012026-08-18T19:15:18.634Z"42a334c5ae0bf9173f7bbe5e5f69321b"1288632cagrisema-achieves->20%-weight-loss-in-adults-with-obesity..jpeg175197671470175412025-07-08T12:11:54.764Z"d372f546d129470b86e0b026b2a6b0da"1011288cagrisema-promove-perda-de-peso-inédita-em-pacientes-com-sobrepeso-e-obesidade-1-17444.png175589544961039312025-08-22T20:44:09.654Z"4bcf417a56db1a5e669d5882f019adf3"775751cagrisema-promove-perda-de-peso-inédita-em-pacientes-com-sobrepeso-e-obesidade.png175589539860273312025-08-22T20:43:18.644Z"8595f057bb49a85adab0f7bd8197612a"493655camoral-study-confirms-survival-benefit-with-perioperative-camrelizumab-in-locally-advanced-head-and-neck-cancer.png176080544038349012025-10-18T16:37:20.427Z"3653866655ca3460b7968750545528f4"1163371campanha-nacional-alerta-para-falhas-na-prescrição-de-antibióticos-em-hospitais.jpeg175580211219976312025-08-21T18:48:32.249Z"87d50d80ca52872938112f3f40cdfd46"9169344camrelizumabe-associado--quimioterapia-demonstra-benefcio-de-sobrevida-em-5-anos-no-carcinoma-nasofarngeo-recorrente-ou-metasttico.jpeg176971032556881112026-01-29T18:12:05.614Z"4080543be322f630e1727641c1577b91"6199085cancer-risk-factors--what-you-can-control-hero-banner-en.png178396270608150212026-07-13T17:11:46.152Z"02099ea679e8b51002c2fc3b49a9caf2"1250785cancer-risk-factors--what-you-can-control-hero-banner-mobile-en.webp178396270416031212026-07-13T17:11:44.234Z"ed1b015ade6b462980ce6b101e8d726a"21168capacitación-médica-en-cáncer-urotelial-her2-positivo:-diagnóstico-y-tratamiento-personalizado.jpeg174800758711677412025-05-23T13:39:47.216Z"880ec920054addf153fe522932203348"327955capecitabina-adjuvante-melhora-sobrevida-em-câncer-de-mama-triplo-negativo-com-doença-residual-após-quimioterapia-neoadjuvante.jpeg175683594509456012025-09-02T17:59:05.175Z"f1041d4504e25c483dfbd975617589e3"7324000capecitabina-adjuvante-melhora-sobrevida-em-câncer-de-mama-triplo-negativo-com-doença-residual-após-quimioterapia-neoadjuvantejpeg175683580988784812025-09-02T17:56:49.931Z"f1041d4504e25c483dfbd975617589e3"7324000capilaroscopia-mostra-potencial-para-identificar-neuropatia-associada-aos-taxanos-4716.png178601969479718612026-08-06T12:34:54.867Z"8df890415f3e080ff8c1832a9f5da11f"1662995capilaroscopia-mostra-potencial-para-identificar-neuropatia-associada-aos-taxanos-7102.png178601969265222712026-08-06T12:34:52.724Z"8df890415f3e080ff8c1832a9f5da11f"1662995capillaroscopy-shows-potential-to-identify-taxaneassociated-neuropathy-8702.png178601999006300612026-08-06T12:39:50.136Z"8df890415f3e080ff8c1832a9f5da11f"1662995capsaicin-and-nicotine-reduce-parkinsonsrelated-olfactory-dysfunction-by-targeting-neuroinflammation.png176064830280366212025-10-16T20:58:22.913Z"b8af976842ed70d9e7157f5bc895d8d7"1694222car-nk-alognico-no-lpus-refratrio-67-de-remisso-completa-sem-icans-sem-dech--o-que-o-primeiro-estudo-em-humanos-publicado-no-lancet-revelou-2545.jpeg177574582821367112026-04-09T14:43:48.272Z"4fa3656e392c9f2d7b1e2a852b864301"1163399car-t-em-tumores-slidos-o-aacr-2026-marca-a-virada--novos-designs-primeiros-dados-clnicos-e-a-era-do-car-t-in-vivo--2539.jpeg177662425087982712026-04-19T18:44:10.941Z"0c4ce43fa03986de225a799b43bcf866"325313car-t-em-tumores-slidos-o-aacr-2026-marca-a-virada--novos-designs-primeiros-dados-clnicos-e-a-era-do-car-t-in-vivo--431.jpeg177662423822884912026-04-19T18:43:58.312Z"0c4ce43fa03986de225a799b43bcf866"325313car-t-em-tumores-slidos-o-aacr-2026-marca-a-virada--novos-designs-primeiros-dados-clnicos-e-a-era-do-car-t-in-vivo--8618.jpeg177662426691870512026-04-19T18:44:26.978Z"0c4ce43fa03986de225a799b43bcf866"325313car-t-en-tumores-slidos-el-aacr-2026-marca-el-punto-de-inflexin--nuevos-diseos-primeros-datos-clnicos-y-la-era-del-car-t-in-vivo-.jpeg177685762288736212026-04-22T11:33:42.949Z"a2cf0ac8e8dc6d8667bdf5e8617c23fa"324465car-t-estudo-mostra-que-pacientes-podem-apresentar-carga-de-sintomas-maior-do-que-a-reconhecida-pelos-mdicos-9130.png178852771410548712026-09-04T13:15:14.177Z"c188d3f866ac4a170d09f4f1d25cb8c8"1204242car-t-no-linfoma-folicular-respostas-duradouras-e-segurana-a-longo-prazo-com-liso-cel-9108.png179319916393198112026-10-28T14:52:44.018Z"88c89f7530024def7860769e79649b60"2092155car-t-no-mieloma-mltiplo-avanos-uso-precoce-e-transformao-na-jornada-do-paciente.jpeg176478177934312712025-12-03T17:09:39.381Z"7714fc743b550e4fc503d9de51584c1f"392830car-t-therapy-achieves-complete-response-in-hairy-cell-leukemia-anti-cd22-car-t-shows-promise-for-rare-b-cell-malignancy.png175371887650803812025-07-28T16:07:56.566Z"7a143b3870f783ee94668860e5cc57d6"3071086car-t-un-estudio-muestra-que-los-pacientes-pueden-presentar-una-carga-de-sntomas-mayor-que-la-reconocida-por-los-mdicos.png178852818977810012026-09-04T13:23:09.841Z"2ac108738d3eb2a3d396f40626d2f62e"1206869car-tcell-therapy-in-follicular-lymphoma-durable-responses-and-longterm-safety-with-lisocel-5911.png179319940362537712026-10-28T14:56:43.690Z"2dfdf72a8ff1f17aa25f280c52632659"2105486carcinoma-espinocelular-de-cabea-e-pescoo-resultados-do-estudo-trilynx.jpeg175770657980998912025-09-12T19:49:39.853Z"272cc595e362044509284cf026650c84"2034645carcinoma-hepatocelular-avanado-como-personalizar-a-escolha-da-imunoterapia-na-prtica-clnica--4856.jpeg178820862506331312026-08-31T20:37:05.138Z"60276f8cb7a6dbf13ccd4143ea4f6858"341517carcinoma-hepatocelular-elegvel-para-embolizao-atualizaes-sobre-combinaes-com-tace-4301.jpeg178405121515967012026-07-14T17:46:55.231Z"92cb0263214646dddc83709cfb49b1c1"432300cardiac-conduction-system-regeneration:-a-key-to-preventing-post-infarction-arrhythmias..png175405666946933212025-08-01T13:57:49.511Z"372ac72c1e36cee1d2006f123c71d518"2355216cardiac-troponin-as-a-key-biomarker-in-light-chain-and-transthyretin-amyloidosis.png175880607428926312025-09-25T13:14:34.333Z"1f7ab889dd33ee0a946a9af0965865b9"2435502cardio-update.png177256572986914912026-03-03T19:22:09.938Z"9855ca701b1c9d596e575001b5bd88d8"717761cardiotoxicidad-de-las-nuevas-terapias-anti-her2-un-metaanlisis-refuerza-su-perfil-de-seguridad-cardiovascular.png178491732270020512026-07-24T18:22:02.830Z"c5a0b008cb1e2fa40978818032e8f602"1762516cardiotoxicidade-das-novas-terapias-anti-her2-metanlise-refora-perfil-de-segurana-cardiovascular-4779.png178483661600951912026-07-23T19:56:56.073Z"ab2f06102fba397e1f1636112aeef58c"1762163cardiotoxicity-of-newer-antiher2-therapies-metaanalysis-reinforces-their-cardiovascular-safety-profile-3420.png178489372814327912026-07-24T11:48:48.263Z"db2a088410dbeeaa4f308d1372f7ecf4"1762377cardiovascular-assessment-in-masters-athletes-6465.null177869490892813012026-05-13T17:55:08.999Z"c9fba0e90630ac20a762575f6b650cb0"2729701cardiovascular-assessment-in-masters-athletes-key-recommendations-from-current-guidelines-1387.png177945361266772912026-05-22T12:40:12.737Z"981671127803848e722671a3f7edcd58"1367166cardiovascular-assessment-in-masters-athletes-key-recommendations-from-current-guidelines-3919.177757561949124812026-04-30T19:00:19.551Z"cd3449fd048dce96daf3216b7b4b08e3"2473937cardiovascular-assessment-in-masters-athletes-key-recommendations-from-current-guidelines-3943.png177945359527875912026-05-22T12:39:55.342Z"981671127803848e722671a3f7edcd58"1367166cardiovascular-assessment-in-masters-athletes-key-recommendations-from-current-guidelines-555-7141.png177945362433889512026-05-22T12:40:24.401Z"981671127803848e722671a3f7edcd58"1367166cardiovascular-disease-increases-risk-of-cancer-insights-from-a-cohort-of-27-million-individuals.png175745761185358412025-09-09T22:40:11.910Z"3116bfb0093392a1b9369a7b170ec356"2084859cardiovascular-risk-associated-with-pregabalin-use-in-older-adults-with-chronic-pain.jpeg175502354204033212025-08-12T18:32:22.082Z"283e7ffa28c3a6e16f4d7868c09641b9"115058cardiovascular-risk-in-classical-hodgkin-lymphoma-survivors:-impact-of-genetic-and-treatment-factors..png175511151466200812025-08-13T18:58:34.703Z"23f0abbac35be07e75e62943a09a8339"2045964cardiovascular-risk-scores-and-cardiovascular-health-metrics-as-predictors-of-cancer:-evidence-from-a-scoping-review..png175691812947019412025-09-03T16:48:49.575Z"67e9843859d539c5a7233084779785a5"1571044cardiovascular-toxicity-in-cancer-survivors:-persistent-risks-and-emerging-strategies..png175519386993129412025-08-14T17:51:09.980Z"f0dffb84d0a9c876b1aa6ba475e6bf3d"1631786cart-in-solid-tumors-aacr-2026-marks-the-turning-point-novel-architectures-firstinhuman-data-and-the-dawn-of-in-vivo-cart-5171.177685966980980012026-04-22T12:07:49.874Z"ae9bd2842bf71ce81c92bbe8fa39cc82"320498cart-study-shows-that-patients-may-experience-a-greater-symptom-burden-than-that-recognized-by-physicians-6660.png178852793904441412026-09-04T13:18:59.108Z"70416e9f8e31c6bb6694e5be23dbf8cd"1206328cart-therapy-in-brazil-national-registry-shows-expansion-of-activity-between-2020-and-2025-2951.png178845709479930212026-09-03T17:38:14.869Z"5fd6c51b5a2cf8a20f95b37d8b173cb5"1797867cart-therapy-through-patients-and-caregivers-eyes-lessons-from-lived-experience.png175986151649000212025-10-07T18:25:16.542Z"fbcb8d72f19b83b35ff865ca563e51f7"2600521cartitude-4-mostra-benefcio-duradouro-de-ciltacabtagene-autoleucel-em-mieloma-mltiplo-recidivado-refratrio-de-risco-padro.jpeg176521561199657712025-12-08T17:40:12.076Z"d513e74e0bb45c688d23493a503d5491"252076cartitude-4-mostra-benefcio-duradouro-de-ciltacabtagene-autoleucel-em-mieloma-mltiplo-recidivadorefratrio-de-risco-padro.jpeg176521437488095012025-12-08T17:19:34.921Z"d513e74e0bb45c688d23493a503d5491"252076case-report-reveals-immune-restoration-and-tumor-regression-through-correction-of-defective-t-cell-receptor-signaling..png175493653683598312025-08-11T18:22:16.878Z"98c1516815302cdbc9d9356216033975"1362510cbosm-2025:-diretrizes-atualizadas-para-o-manejo-farmacológico-da-obesidade.jpeg174863622559331612025-05-30T20:17:05.685Z"865e258b503d41fa26bebd6c28997815"311254cd276-b7h3-adaptercar-tcells-show-antitumor-activity-in-small-cell-lung-cancer-and-reduce-cd276driven-fratricide.png176762046900394412026-01-05T13:41:09.051Z"7c737e3ad6b56fef114026cbc745c648"5989626cdk4-6-no-endomtrio-abemaciclibe--letrozol-entrega-controle-de-doena-sem-quimioterapia--3038.jpeg177618793729941212026-04-14T17:32:17.368Z"3eceb51aa1d5a285a94f42aae4cdf03e"238489cdk46-en-endometrio-abemaciclib--letrozol-ofrece-control-de-enfermedad-sin-quimioterapia-.jpeg177619120508204412026-04-14T18:26:45.216Z"be364ea0499048c0162de566216e31c0"235128cdk46-in-endometrial-cancer-abemaciclib-letrozole-delivers-disease-control-without-chemotherapy-2707.177619195186807212026-04-14T18:39:11.937Z"9cefb6b9b44fbaaa2e78f8b1dd6dbce3"235055cemitrio-de-molculas-por-que-a-inovao-farmacutica--cara-e-por-que-a-qualidade-do-ifa-muda-tudo.jpeg175762156880048612025-09-11T20:12:48.844Z"f7fc20f1b1a8c144761ada9b14c3f19e"194376cenrio-atual-do-uso-de-anticorpos-biespecficos-e-terapia-car-t-no-tratamento-de-linfomas-no-hodgkin.jpeg175762116834078512025-09-11T20:06:08.393Z"281dfca36d02c5afc78aafb7bb88c3d1"315056cerebral-embolic-protection-during-tavi:-clinical-evidence-does-not-support-routine-use..png175253199774016812025-07-14T22:26:37.778Z"8b2d28cb92a0d63435d13865d1b4e315"1446790certificadoo-cirurgia.png175760990508884422025-09-11T16:58:25.129Z"f14a2b254b3fe4bfa287020479d6f5eb"333651cetuximab-asociado-a-mfolfoxiri-prolonga-la-slp-en-un-subgrupo-molecularmente-seleccionado-de-cncer-colorrectal-metastsico.png178897429773754212026-09-09T17:18:17.804Z"c8fed54f671fa8530c9e5d533ee8d2e5"2015284cetuximab-plus-mfolfoxiri-prolongs-pfs-in-a-molecularly-selected-subgroup-of-metastatic-colorectal-cancer-8693.png178897400368574912026-09-09T17:13:23.750Z"df6d5102abd6740c48a303d80ad9bff2"2013795cetuximabe-associado-ao-mfolfoxiri-prolonga-pfs-em-subgrupo-molecularmente-selecionado-de-cncer-colorretal-metasttico-9885.png178897412459268412026-09-09T17:15:24.655Z"bd756f00b477e9060723624fbb961e40"2019908cevostamab-combinado-a-pomalidomida-e-dexametasona-mostra-respostas-profundas-em-pacientes-com-mieloma-mltiplo-recidivadorefratrio-bcma-nave-8116.png179019265897326612026-09-23T19:44:19.035Z"b30afdf4e7b28317cf65427d5cd759dc"825522cevostamab-ms-pomalidomida-y-dexametasona-muestra-respuestas-profundas-en-pacientes-con-mieloma-mltiple-en-recadarefractario-bcma-nave.png179019391557148712026-09-23T20:05:15.704Z"6334a01950980d2672b493ad0a43246f"833764cevostamab-plus-pomalidomide-and-dexamethasone-shows-deep-responses-in-patients-with-bcmanave-relapsedrefractory-multiple-myeloma-6871.png179019539986854412026-09-23T20:29:59.932Z"575659058a7d5496b473862b11284bbd"834022cgrptargeted-therapies-gain-ground-as-a-firstline-option-for-migraine-prevention-3652.png179131206898654212026-10-06T18:41:09.055Z"be73620c76d4b93041adab9719c38cad"1829632chagas-disease-in-the-ablation-suite-findings-from-a-brazilian-retrospective-cohort-1153.png178534486732896112026-07-29T17:07:47.402Z"cb778f7a61f0b9cc75db4083c0d0875e"2156971checkmate-743-biomarcadores-e-car-t-uma-nova-era-para-o-mesotelioma.png176588795541143612025-12-16T12:25:55.451Z"8c91fe1719f5a0afd86d4bd43a9ff90a"890018chemotherapy-plus-atezolizumab-improves-disease-control-in-metastatic-colorectal-cancer-7190.png178586201008638012026-08-04T16:46:50.157Z"df676620d212438c1e3c69c645073316"2509280cilta-cel-em-mieloma-mltiplo-recidivado-resultados-do-cartitude-4-em-pacientes-de-risco-padro.png176608764194769812025-12-18T19:54:01.987Z"e38d62b8efc3341fc3c0db1bfbc88380"1143460cilta-cel-no-mieloma-mltiplo-refratrio--lenalidomida-anlise-atualizada-do-estudo-de-fase-3-cartitude-4-com-incluso-de-dados-de-sobrevida-global.jpeg177248165313338512026-03-02T20:00:53.204Z"e8068d6d79c8040821743c15f06faa67"1720635ciltacel-in-relapsed-multiple-myeloma-cartitude4-results-in-standardrisk-patients.png176625566522788712025-12-20T18:34:25.269Z"266e7dce480aaa8310d2fb9d0d24cb87"1212031ciprofloxacin-alone-proves-as-effective-as-injectable-combination-therapy-for-bubonic-plague..png175502376359174012025-08-12T18:36:03.645Z"4ea2c51a6820587be08d1cd90eec5bce"1411792circulating-tumor-dna-enables-earlier-detection-of-colorectal-cancer-recurrence-9241.png178577990757040012026-08-03T17:58:27.641Z"9993e927dc3405b005c33b40a72beb64"2262379cirurgia-axilar-em-pacientes-com-cncer-de-mama-e-macrometstases-em-linfonodos-sentinela-resultados-secundrios-do-estudo-insema-.png176600381441759512025-12-17T20:36:54.469Z"533a9fd2e6e73d98d6c6d243647f05c3"1522082cirurgia-cardíaca-pediátrica-com-orientação-remota-marca-avanço-do-sus-na-região-norte.jpeg175071138662273912025-06-23T20:43:06.668Z"4a23c9b31a7c2df18d38170976f9e19c"10489038cisplatina-semanal-no-ps-operatrio-do-cncer-de-cabea-e-pescoo-o-que-o-seguimento-prolongado-do-jcog1008-acrescenta-2263.png178303024216118412026-07-02T22:10:42.229Z"6be82a182c9afebe38a71af520928b15"1560525cisplatina-semanal-no-ps-operatrio-do-cncer-de-cabea-e-pescoo-o-que-o-seguimento-prolongado-do-jcog1008-acrescenta-3.png178303019070444612026-07-02T22:09:50.770Z"6be82a182c9afebe38a71af520928b15"1560525cisplatino-semanal-en-el-tratamiento-posoperatorio-del-cncer-de-cabeza-y-cuello-qu-aporta-el-seguimiento-prolongado-de-jcog1008.png178303049603160812026-07-02T22:14:56.097Z"ad18f9ae307e93443d34d7bc8e0d5458"1562812cistectomia-radical-no-cncer-de-bexiga-insights-prticos-para-a-tomada-de-deciso.jpeg176615451250997612025-12-19T14:28:32.549Z"8ba813df0a931593d3475f0a72113cd9"78456clarity-gastric01-sonesitatug-vedotin-mejora-la-sg-en-carcinoma-gastroesofgico-avanzado-cldn182-positivo-previamente-tratado.png179296366470094312026-10-25T21:27:44.763Z"09a9e770ea8e83dd931aca559d2a2bbc"2001148clarity-gastric01-sonesitatug-vedotin-melhora-sg-no-carcinoma-gastroesofgico-avanado-cldn182-positivo-previamente-tratado-1244.png179295250832926312026-10-25T18:21:48.394Z"de9254cda17b9c75e2d094e1f2e35d9a"1996110claritygastric01-sonesitatug-vedotin-improves-os-in-previously-treated-cldn182positive-advanced-gastroesophageal-cancer-1796.png179296653824555012026-10-25T22:15:38.311Z"05a836744ac71bc4dd8389cc45db18a2"2003638clear-trial-hypertonic-saline-and-carbocisteine-do-not-reduce-exacerbations-in-noncf-bronchiectasis.png175924761653471612025-09-30T15:53:36.575Z"8bdc51be6e419bd9c3281dbe6a7a2000"2143404clesrovimab-reduces-rsv-infections-and-hospitalizations-in-healthy-infants.png175915978705580912025-09-29T15:29:47.105Z"4bf5b1f6c8b192aa167bfa69c89952e1"1164252clesrovimabe-reduz-infeces-e-hospitalizaes-por-vsr-em-lactentes-saudveis.png175882944455369412025-09-25T19:44:04.606Z"4bf5b1f6c8b192aa167bfa69c89952e1"1164252clinical-decision-support-and-pharmacist-outreach-improve-adherence-to-antihypertensives-but-not-overall-cardiometabolic-control.jpeg175310123468384712025-07-21T12:33:54.745Z"ec0d956e1d9e8942688ba744a98558df"486839clinical-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-in-sickle-cell-disease-and-transfusiondependent-betathalassemia.png175745520137109212025-09-09T22:00:01.430Z"4030a9d6b93e135d3b138a7bf9bba375"2573126clinician-engagement-as-a-pillar-for-cardiovascular-device-safety..png175511057009517912025-08-13T18:42:50.135Z"c84d48417d204dd4b62928a7e0e6ba9d"2701644closure-af-cierre-de-la-orejuela-auricular-izquierda-en-pacientes-con-fibrilacin-auricular-y-alto-riesgo-de-ictus-y-sangrado.png176270873095619212025-11-09T17:18:51.002Z"c89d2703d2cd43aa36c9db6dce31bf3e"1968840closure-af-ocluso-do-apndice-atrial-esquerdo-em-pacientes-com-fibrilao-atrial-e-alto-risco-de-avc-e-sangramento.png176270748215498812025-11-09T16:58:02.197Z"3cd57ee192c13a802b914e640edad300"1926318closureaf-left-atrial-appendage-closure-in-patients-with-atrial-fibrillation-and-high-risk-of-stroke-and-bleeding.png176270893154204412025-11-09T17:22:11.588Z"21d4964bfadd7b1900ffbcf7a5d2c090"1968942cncer-colorretal-dmmrmsi-h-da-caracterizao-molecular--escolha-da-imunoterapia-4561.jpeg178855576166298512026-09-04T21:02:41.726Z"7c83f09e7bd40167d3023d38f53e7d0a"345270cncer-de-mama-triplo-negativo-estdio-i-rumo--personalizao-8580.png177816925968713812026-05-07T15:54:19.750Z"d847b3954304d6d55e651d6a767c9609"1951896cncer-de-mama-triplo-negativo-inicial-o-seguimento-de-longo-prazo-consolida-o-benefcio-da-imunoterapia---7492.png178250484645323212026-06-26T20:14:06.559Z"f1b31ec6ed39a226a19ba0bdd66a561b"1965070cncer-de-pulmo--asco-2026--5136.jpeg178026401711512712026-05-31T21:46:57.179Z"a42ce0fe1ac4e2780bc6f03aab17e2f5"254307cncer-de-pulmo--asco-2026--6175.jpeg178292359146835012026-07-01T16:33:11.533Z"19bd7086a335ddbb0a6b6fddfea6817d"265749cncer-de-pulmo-a-terapia-alvo-est-mudando-a-prtica-clnica---quiz-6551.png177634610745172912026-04-16T13:28:27.521Z"c38d917ea5a7048ac8af50ba4b6cafae"878655cncer-de-pulmo-com-alterao-met-importncia-da-testagem-e-das-terapias-alvo-9491.png178717030484074512026-08-19T20:11:44.939Z"c1773c1ef6c8226cb1f762204276e12b"2936175cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica---quiz-6056.png177626370818217012026-04-15T14:35:08.252Z"c38d917ea5a7048ac8af50ba4b6cafae"878655cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica---quiz-7920.png177634297368781712026-04-16T12:36:13.750Z"c38d917ea5a7048ac8af50ba4b6cafae"878655cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica-3198.png177618343223370412026-04-14T16:17:12.313Z"70429127102f3223a71aabd9a1254ed4"380112cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica-4247.png177625628859336212026-04-15T12:31:28.660Z"70429127102f3223a71aabd9a1254ed4"380112cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica-5528.png177618167640484612026-04-14T15:47:56.465Z"c38d917ea5a7048ac8af50ba4b6cafae"878655cncer-de-pulmo-como-a-terapia-alvo-est-mudando-a-prtica-clnica-6248.png177625425439204212026-04-15T11:57:34.456Z"70429127102f3223a71aabd9a1254ed4"380112cncer-de-pulmo-como-a-terapia-alvo-est-mudando-essa-prtica-clnica-1211.png177619472289007412026-04-14T19:25:22.958Z"70429127102f3223a71aabd9a1254ed4"380112cncer-de-pulmo-como-a-terapia-alvo-est-mudando-na-prtica-clnica-9360.png177619299363760812026-04-14T18:56:33.701Z"70429127102f3223a71aabd9a1254ed4"380112cncer-de-pulmo-de-pequenas-clulas-estudo-chins-avalia-alternativa--radioterapia-convencional.png175770256580426512025-09-12T18:42:45.862Z"c152baef26d27c0c868d9f8b63e20a79"317958cncer-de-pulmo-preveno-rastreamento-e-acesso-no-sus-4488.png179253241053562712026-10-20T21:40:10.600Z"446ecc7f1535d99372d3769fb985119a"2015305cncer-de-pulmo-preveno-rastreamento-e-acesso-no-sus-5092.png179253253284595212026-10-20T21:42:12.910Z"446ecc7f1535d99372d3769fb985119a"2015305cobertura-completa-—-gp-de-são-paulo-f1-2026-coverage.webp177799459849861512026-05-05T15:23:18.560Z"8e96ed9ab31ec787cdd6c5ec4aab0a5b"50968cobertura-esc-congress-2026--insuficiência-cardíaca-coverage.webp179122097733261612026-10-05T17:22:57.399Z"706651b50d3e3e0f50f765a24beab07d"136276code-of-ethics-and-conduct-tribemd.pdf177576335021876612026-04-09T19:35:50.261Z"d136a972b67bc07175f2ab6dd10af784"1712466codigo-de-etica-e-conduta-tribe.pdf177576321089097612026-04-09T19:33:30.933Z"301c56c8c034ecffd954f238f9340913"1878679codigo-de-etica-y-conducta-tribemd.pdf177576329890215712026-04-09T19:34:58.942Z"4e4d70ccdd2349b1c8ce9c0291908e6d"1760603colonoscopy-surveillance-every-5-years-does-not-increase-colorectal-cancer-incidence-compared-with-a-3year-interval-after-highrisk-adenoma-removal-6657.png179122680279053712026-10-05T19:00:02.859Z"aa64d77017cd2228abb8203463d0945b"1216687com-quase-uma-dcada-de-seguimento-estudo-cll14-confirma-benefcio-duradouro-de-venetoclax-obinutuzumabe-na-llc-em-primeira-linha-7757.png178127522774419512026-06-12T14:40:27.820Z"29b601ade9cd4c4bf8e9d34281e91a39"2213359combate-à-malária-ganha-fôlego-com-novas-tecnologias-e-cooperação-internacional.png174861383690850612025-05-30T14:03:56.953Z"ba4bce5f0bcb8268504dc64044326439"342896combinao-de-biespecfico-pd-l1vegf-a-e-adc-anti-b7-h3-apresenta-atividade-inicial-no-sclc-7505.png178949504557077812026-09-15T17:57:25.645Z"b52a27b63441867b9fe231883f592ed5"1810715combinao-de-enzalutamida-e-rdio-223-aumenta-sobrevida-em-cncer-de-prstata-avanado-aponta-estudo-peace-3.jpeg177213600434470712026-02-26T20:00:04.416Z"2cc534ef4e47b23e5708cee455f9999d"181838combinao-de-osimertinibe-e-quimioterapia-em-primeira-linha-mostra-benefcio-em-sobrevida-global-no-cncer-de-pulmo-egfr-mutado.jpeg177023198804727212026-02-04T19:06:28.096Z"ba7155fdeddefd726ec588f7edf2a651"9944401combinao-de-sacituzumabe-tirumotecano-e-pembrolizumabe-mostram-benefcio-em-estudo-de-fase-iii-em-cpnpc-com-pd-l1-negativo-6032.png178483096275040812026-07-23T18:22:42.833Z"0e741760201f2dc7dc762c727bc1edd6"616950combinao-de-teclistamabe-e-talquetamabe-mostra-resultados-promissores-no-tratamento-do-mieloma-mltiplo-recidivado-refratrio-3976.png178518060736046112026-07-27T19:30:07.432Z"a61349153283ab16f6dee9deae3692b6"2267740combination-immunotherapy-in-hcc-clinical-benchmarks-mechanistic-synergy-and-the-biomarker-gap.png176771037044266212026-01-06T14:39:30.495Z"7f720c2fc1e59ceecdd1b3b66b40b878"6102768combination-of-enzalutamide-and-radium223-improves-survival-in-advanced-prostate-cancer-peace3-study-shows-.jpeg177366649286550812026-03-16T13:08:12.892Z"0b8f6bf02d4c1d45818a268187678b02"792876combination-of-enzalutamide-and-radium223-improves-survival-in-advanced-prostate-cancer-peace3-study-shows-3078.jpeg177366736547159312026-03-16T13:22:45.512Z"0b8f6bf02d4c1d45818a268187678b02"792876combination-of-enzalutamide-and-radium223-improves-survival-in-advanced-prostate-cancer-peace3-study-shows.jpeg177212945679099512026-02-26T18:10:56.854Z"9fd9cc5ed6c8852151cb82a01eafd42e"167980combination-of-enzalutamide-and-radium223-improves-survival-in-advanced-prostate-cancer-peace3-study-shows.null177342614273256112026-03-13T18:22:22.774Z"0b8f6bf02d4c1d45818a268187678b02"792876combination-of-finerenone-and-empagliflozin-enhances-albuminuria-reduction-in-ckd-with-type-2-diabetes..png175276427401066512025-07-17T14:57:54.059Z"2442ff7c4bcb341ab74b89eeecd643c9"2567885combinação-de-sintilimabe-e-axitinibe-mostra-resultados-promissores-em-carcinoma-renal-raro-e-agressivo.jpeg175528681388508312025-08-15T19:40:13.925Z"70a6d597c6900a3a0448d49ffaa13710"326577comisso-europeia-aprova-camizestrant-em-combinao-com-inibidor-de-cdk4-6-para-cncer-de-mama-avanado-er-positivo-com-mutao-em-esr1-7625.png178483192463665612026-07-23T18:38:44.700Z"b453091c9ed207f81ac4c13aea9e7676"1600864como-a-inteligncia-artificial-se-tornou-aliada-revolucionria-no-diagnstico-do-cncer-de-mama-3540.png178760607026206512026-08-24T21:14:30.332Z"0e199f4c6270074eddf5ad4da8cf9fc1"3033403como-a-terapia-alvo-est-mudando-a-prtica-clnica-5405.png177619152409092612026-04-14T18:32:04.154Z"70429127102f3223a71aabd9a1254ed4"380112como-abordar-a-hipercolesterolemia-no-cotidiano-do-consultório?.png175077469307262312025-06-24T14:18:13.167Z"adc06c4fb81d86cf957c7758f2beb9fc"371452comorbidades-importam-no-car-t--mas-no-da-forma-que-voc-imagina-1933.jpeg177574078260640612026-04-09T13:19:42.665Z"4fa91ceadd4314335e97a355c394c5bf"1634114comparative-efficacy-of-ciltacabtagene-autoleucel-versus-standardofcare-treatments-for-patients-with-previously-treated-relapsed-or-refractory-multiple-myeloma.png175745740395902512025-09-09T22:36:43.999Z"9346fd0a619730acf5745dbdae91da1f"3481468complete-revascularization-reduces-cardiovascular-mortality-in-patients-with-acute-myocardial-infarction-and-multivessel-coronary-disease.jpeg176312808586982112025-11-14T13:48:06.002Z"7300cfb1b24b1faca579523e5a475fc6"161698comprehensive-clinical-management-of-attr-cm-8847.jpg178604361509683012026-08-06T19:13:35.170Z"6ad7a99d50e619a8a49cb022777b8a23"278127comprehensive-clinical-management-of-attr-cm-hero-banner-en.webp178612711296065212026-08-07T18:25:13.030Z"cce4d8750ab95ba874ad304adbe5b33c"144214comprehensive-clinical-management-of-attr-cm-hero-banner-mobile-en.webp178612711131041012026-08-07T18:25:11.382Z"dcd8a7ce223e38b12b6498dbc124352f"79412congresso-ada-2025-|-cagrisema-e-a-nova-fronteira-terapêutica-no-controle-metabólico.png175276509214682512025-07-17T15:11:32.195Z"f9650fb7775a8aefeed66e7c1894adf5"1750910congresso-ada-2025-|-diabetes-tipo-2-e-comprometimento-cognitivo:-dados-por-subgrupos-clínicos.png175252533335461112025-07-14T20:35:33.462Z"1c565a9c7f796cab3e5c80832b1549af"754594congresso-ada-2025-|-estudo-demonstra-alta-acurácia-de-cgm-em-tempo-real-em-pacientes-com-diabetes-e-insuficiência-renal-no-cenário-intra-hospitalar.png175104823795100812025-06-27T18:17:17.992Z"f390a07f917f2ef2eee6e65fa7667699"960371congresso-ada-2025-|-neuropatia-periférica-diabética-como-novo-alvo-para-prevenção-de-demência-e-doença-cerebrovascular-em-pacientes-com-dm2.jpeg175104796935779712025-06-27T18:12:49.411Z"8f0eaec39200fa4898bf6f7e71e919eb"6531768congresso-ada-2025-|-novas-combinações-hormonais-no-tratamento-da-obesidade,-com-ou-sem-dm2.png175258503005720412025-07-15T13:10:30.147Z"891f9c0fd827f15868bd7461d6639ee6"2564480congresso-ada-2025-|-novas-fronteiras-no-tratamento-da-obesidade:-agonistas-múltiplos-demonstram-remodelação-adiposa-e-preservação-muscular.jpeg175104810266311912025-06-27T18:15:02.701Z"f4ee017923dfa79feb340fdbbaa913de"1420751congresso-ada-2025-|-orfoglipron--um-novo-agonista-de-glp-1-oral-com-potencial-promissor-no-tratamento-do-dm2-.png175269099021813512025-07-16T18:36:30.259Z"e1a40b9e5386fe96ed488c3c59016b95"897997congresso-ada-2025-|-stop-diabetes:-diagnóstico-precoce-e-intervenção-intensiva-.png175226759470132112025-07-11T20:59:54.742Z"38078d01597a5cea57eb263cc6445a8f"728155congresso-ada-2025-|-stop-diabetes:-diagnóstico-precoce-e-intervenção-intensiva.png175226725187066512025-07-11T20:54:11.985Z"38078d01597a5cea57eb263cc6445a8f"728155congresso-ada-2025-|-terapia-combinada-de-bimagrumabe-e-semaglutida-na-perda-de-peso-com-preservação-de-massa-magra.png175286713901595712025-07-18T19:32:19.056Z"0102d339243fa00c8c4b3e3bbcd7173f"1440914congresso-ada-2025-|-uso-de-monitoramento-contínuo-de-glicose-reduz-complicações-agudas-e-estresse-em-pacientes-com-dm2.jpeg175104833129678112025-06-27T18:18:51.354Z"ac0bad107ba1e30e1129a81b6d6c1666"27639904congresso-brasileiro-de-genética-hero-banner.png177794885549170112026-05-05T02:40:55.575Z"941f9dfbd1ca90c7bc63e503217fe3bf"506928congresso-de-câncer-de-mama-gramado-coverage.jpeg178602196888790012026-08-06T13:12:48.956Z"42cbcc559c6ff21ac2a90ef291f02227"131265congresso-eha-e-icml-2025:-novos-avanços-em-linfoma-folicular-e-linfoma-difuso-de-grandes-células-b.jpeg175147916337120812025-07-02T17:59:23.415Z"7c955644d17603eb76be1d2a7081d278"513510conheça-o-tribemd-assist--hero-banner-2353.webp178829285542714612026-09-01T20:00:55.498Z"b8b9c9a4f14c1a953d9ce447051171bd"79744conheça-o-tribemd-assist--hero-banner-4689.webp178828876202907012026-09-01T18:52:42.093Z"c00703f800ff9b71d4c861ad878f2ca2"81234conheça-o-tribemd-assist--hero-banner-8097.webp178828928366191512026-09-01T19:01:23.725Z"c00703f800ff9b71d4c861ad878f2ca2"81234conheça-o-tribemd-assist--hero-banner-mobile-4689.webp178828876335653012026-09-01T18:52:43.424Z"28b3241e3a6e5c6a9b4b88e121f41aab"32338conheça-o-tribemd-assist--hero-banner-mobile-8097.webp178828928481475812026-09-01T19:01:24.876Z"28b3241e3a6e5c6a9b4b88e121f41aab"32338conitec-abre-consulta-pblica-sobre-pcdts-de-dez-tipos-de-cncer-1615.png178709282989954812026-08-18T22:40:29.961Z"5a107b10b8d9b902542c8201b688f5bb"1414490conitec-abre-consulta-pública-sobre-incorporação-do-wegovy®-ao-sus-para-tratamento-da-obesidade.jpeg175007836800761112025-06-16T12:52:48.079Z"e02d1d98f4dcda40830221c997d3260b"6585650conitec-approves-innovative-strategies-against-respiratory-syncytial-virus-(rsv):-dual-protection-enters-brazil's-public-health-system.jpeg174964865014096912025-06-11T13:30:50.257Z"e68fe75928ff0191deda73f9f9332f32"3046223conitec:-guardiã-da-eficiência-e-segurança-tecnológica-no-sus.jpeg174863595891140912025-05-30T20:12:39.011Z"38f7bb61829159f5069843138b783d0f"1032322consenso-brasileiro-prope-abordagem-individualizada-para-reposio-de-vitamina-b12-5352.png179027383916514012026-09-24T18:17:19.237Z"b22c02095059e445fe79dce7f6fea4c4"1542308consenso-del-imwg-establece-recomendaciones-para-el-uso-seguro-de-anticuerpos-biespecficos-en-mieloma-mltiple.png178544340824525412026-07-30T20:30:08.317Z"1fcb909366f6193dd01554e1f8fb9cd8"9872859consenso-do-imwg-estabelece-recomendaes-para-o-uso-seguro-de-anticorpos-biespecficos-no-mieloma-mltiplo-7266.png178544291598830012026-07-30T20:21:56.059Z"13b0374fa2dae4e8c81e17e22eb14339"1837591consenso-internacional-define-el-papel-de-los-biomarcadores-en-el-manejo-clnico-del-cncer-de-vejiga.png178647310779989412026-08-11T18:31:47.867Z"38c71459ce348c878128b0249a1c3774"1852732consenso-internacional-define-o-papel-dos-biomarcadores-na-prtica-clnica-do-cncer-de-bexiga-3994.png178647043821787212026-08-11T17:47:18.281Z"38c71459ce348c878128b0249a1c3774"1852732consenso-internacional-define-o-papel-dos-biomarcadores-na-prtica-clnica-do-cncer-de-bexiga-8703.png178647046371724812026-08-11T17:47:43.779Z"38c71459ce348c878128b0249a1c3774"1852732consenso-internacional-sobre-cdigo-sepse-define-40-recomendaes-para-reconhecimento-e-manejo-da-sepse-754.png178726334625407412026-08-20T22:02:26.316Z"283496d3dcaa6a32b844d0643e4bdf10"1996091consenso-internacional-sobre-cdigo-sepsis-establece-40-recomendaciones-para-el-reconocimiento-y-manejo-de-la-sepsis.png178726345502624812026-08-20T22:04:15.088Z"03def2e2a759807fa2ecdb8790098ec3"1996011conservative-oxygen-therapy-in-unresponsive-patients-after-cardiac-arrest-results-of-the-logical-trial-3803.178216939054528412026-06-22T23:03:10.617Z"e342e551eb07be0581e25750ce6712f2"1975558